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Summary
Proteins are the basic building blocks and functional units in all living organisms. 
Moreover, differences between species can frequently be explained with 
differences in their protein complements. Importantly, proteins are often 
composed of segments, i.e. domains that have a certain level of evolutionary, 
structural and/or functional independence. The majority of proteins in nature 
contain two or more domains, and an individual domain can often occur in 
combinations with different domain partners.
In the first part of my thesis, I traced the history of animal gene families 
and the proteins these genes encode. By this means, I was able to infer events 
where changes in protein domain architectures took place. This showed that 
both insertions and deletions of single copy domains preferentially occur at 
protein termini, but also that changes are more likely to occur after gene 
duplication than organism speciation. Finally, domains that were most 
frequently gained were the ones that are related to an increase in organismal 
complexity, thus underlining the important role of domain shuffling in animal 
evolution.
In the second part of my thesis, I focused on a set of high confidence 
domain gain events and investigated the evidence for molecular mechanisms 
that caused these domain gains. In agreement with observations from the first 
part - that changes preferentially occur at the termini - I have found that the 
strongest contribution to gains of novel domains in proteins comes from gene 
fusion through the joining of exons from adjacent genes into a novel gene unit. 
Two other mechanisms that have been suggested to play a major role in the 
evolution of animal proteins, retroposition and middle insertions through 
intronic recombination, have a smaller role in comparison to gene fusions. Since 
the majority of these domain gains are again observed after gene duplication, 
this suggests a powerful mechanism for neofunctionalization after gene 
duplication.
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Finally, in the last part of my thesis, I address a mechanism that increases 
the number and variety of proteins in an organism – alternative splicing. In 
particular, I investigate the functional consequences of tissue-specific alternative 
splicing events. I found that tissue-specific splicing tends to affect exons that 
encode protein regions without defined secondary or tertiary structure. 
Importantly, it is known that these disordered regions frequently play a role in 
protein interactions. In agreement with this, I observed significant enrichment of 
tissue-specifically encoded protein segments in disordered binding peptides and 
posttranslationally modified sites. A possible result of the finely regulated 
alternative splicing of these segments is a tissue-specific rewiring of protein 
network. In conclusion, both alternative splicing and domain shuffling can 
increase proteome diversity. However, a protein with a new function can often 
directly or indirectly shape the functions of other proteins in its environment.  
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1Chapter 1
Introduction
Proteins are crucial functional elements of living organisms, involved in virtually 
every process within cells. Often, proteins with similar functions – which belong 
to the same or to different organisms - are evolutionary related. A well-described 
example for this is a family of oxygen-carrying globins in vertebrates. The major 
steps in the evolution of this family involved duplication of an ancestral oxygen-
binding protein, divergence of the copies into myo- and haemoglobin, and 
another duplication and divergence of ancestral haemoglobin into alpha and beta 
subunits (H Lodish, 2000). These and other proteins from the same globin family 
are all involved in oxygen transport but have evolved subtle differences of 
function, which make them suited to specific roles in the physiology of oxygen 
transport. Since the evolution of novel protein functions is essential for better 
adaptation to different environments, explanation of this process has been a 
central problem of evolutionary studies. 
Arrangement of protein structure is explained with several levels of 
organization and changes that disrupt any of these levels can have an affect on 
the overall protein function. The four levels of protein organization are: primary 
structure, which is defined by the amino acid sequence; secondary structure, 
defined as a regularly repeating local structure stabilized by hydrogen bonds –
its most common types being alpha helix, beta sheets and turns; tertiary 
structure, or the overall shape of a protein, which is stabilized by non-local 
2interactions – hydrophobic attractions, electrostatic interactions, hydrogen and 
disulfide bonds, as well as by post-translational modifications; and quaternary 
structure, which is the structure formed by several individual protein molecules, 
all functioning as a part of the same protein complex. Final protein structure and 
function can depend on the action of other proteins in the cell, in particular when 
the protein depends on chaperones for folding, peptidases for activation, or 
specific enzymes for posttranslational modifications. However, the majority of 
changes in proteins are the result of mutations in the gene sequences that 
encode proteins. These include both – mutations that result in changes of single 
amino acids, but also mutations that result in larger scale changes, such as 
deletion, duplication or insertion of a longer stretch of amino acids. 
It is important to note that many genes in higher eukaryotes do not code 
for one protein only. Rather, thanks to alternative splicing, they can produce 
several protein products. A radical example for this is neural protein Dscam that 
can have more than 38,000 isoforms in Drosophila (Wojtowicz et al., 2004). This 
has important implications for the studies of gene evolution, as well as studies on 
a single gene level, since, in order to appreciate the full repertoir of gene 
function, it is necessarry to take into account all protein isoforms of the gene. For 
example, alternative inclusion of a single exon can have severe consequences for 
the overall function of the produced isoform. 
In this introduction, I will first give an overview of the ongoing work that 
aims to describe functional elements in proteins and group the related elements 
together. I will then describe the general aspects of protein evolution and discuss 
the previous efforts for its systematic study. Finally, I will discuss the role of 
alternative splicing in creating different protein products of a same gene,
31.1 Characterization of functional elements in proteins
Different functional elements in proteins frequently have specific characteristics 
that distinguish them from other protein regions. Hence, systematic knowledge 
about a class of protein segments that share a similar function enables the 
recognition of these elements in uncharacterized protein sequences and 
ultimately a better understanding of protein function and regulation. In this 
section, I will discuss different types of protein functional elements, as well as 
commonly used approaches to identify these in protein sequences. Organization 
of functional elements in proteins defines protein architecture, and a focus of 
this thesis is on the changes in proteins that are the result of a gain or loss of 
these elements between protein homologues or different isoforms of the same
gene.
1.1.1 Protein domains
By the standard definition, protein domains are described as basic structural, 
evolutionary and functional units of proteins (Holm and Sander, 1994). 
According to this, an individual domain is an independent folding unit in a 
polypeptide chain; a segment of amino acid sequence, which corresponds to a 
domain, is inherited and conserved in differing surrounding contexts; and 
distinct biological function is assigned to the domain coding segment of a protein 
sequence. However, dependence on structural and functional evidence restricts 
these well-defined domain assignments to only a handful of proteins. Therefore, 
a complementary domain definition, based on the sequence homology, is widely 
used in domain annotation. 
Homology between protein regions can be identified by using pairwise 
sequence comparison methods, such as BLAST (Altschul et al., 1990). However, 
not all residues in a protein domain/family are equally well conserved. Methods 
that use sequence profiles were shown to be more sensitive for domain 
detection. These approaches rely on a multiple alignment of known members of 
a domain family, from which the frequency of site-specific residues are 
4calculated. Profile hidden Markov models (HMMs) (Eddy, 1998) formalise the 
more simple position specific scoring matrices (Gribskov et al., 1987), which can 
be used for this, into probabilistic models and allow insertions and deletion 
states in the models (Figure 1.1). Application of profile HMMs for domain 
detection has been shown to be very successful and has had a high impact on the 
understanding of newly sequenced genes and genomes (Bateman et al., 2002).
Figure 1.1: Diagram of profile hidden Markov model. States shown as 
squares or diamonds emit symbols, while those shown as circles do not. Each 
match state Mi corresponds to a column in a multiple alignment which emits 
over a distribution of amino acids. Insert states Ii allow for the segments of query 
sequence not present in the protein family and delete states allow for deletions 
of conserved residues in the protein family from the query sequence. The 
transition to the J state allows for multiple hits of the model to a single query 
sequence. The N and C states are analogous to insert states but occur before and 
after the model hit, respectively. The B and E state mark start and end of a hit to 
the query, while S and T are the overall start and end states. The null model 
emits according to a background distribution. The figure is adapted from  (Coin, 
2008).
The most systematically developed collection of domain models, based on 
profile HMMs, is the Pfam database (Finn et al., 2010), (Figure 1.2). The Pfam 
database is composed of two parts: Pfam-A and Pfam-B. Pfam-A is a curated 
section of Pfam that contains documentation and Profile-HMMs for each protein 
family.  Manual annotation of Pfam-A families allows improvement of the initial 
multiple alignments and inclusion of available external information about the 
5proteins. Pfam-B is an automatically generated set of protein families, which is 
currently taken over from the ADDA database (Heger et al., 2005). Pfam-B 
families have no associated functional annotation and no profile-HMMs. They are 
in general of much lower quality than Pfam-A families, as their alignments have 
not been manually checked. Moreover, some Pfam-B families are composed of 
low complexity regions and may not reflect true relationships. Pfam domains are 
predicted solely from conserved sequence features. Some other databases make 
use of available protein structures when assigning domains to proteins. A 
structural classification of proteins (SCOP) database provides comprehensive 
description of the structural and evolutionary relationships of the proteins of 
known structure (Andreeva et al., 2008). The SUPERFAMILY database consists of 
a library of profile HMMs that represent all proteins of known structure (Wilson 
et al., 2009); each model in the library corresponds to a SCOP domain and aims 
to represent an entire superfamily. Thus, this approach enables structural 
assignments to protein sequences. The CATH database is also centred on domain 
structures, but it aims to recognize structural elements shared by different 
domains, as well as distantly related structures (Greene et al., 2007). The four 
main levels of CATH classification are protein class (C), architecture (A), 
topology (T) and homologous superfamily (H). Class describes the secondary 
structure composition of each domain, architecture the shape revealed by the 
orientations of the secondary structure units, such as barrels and sandwiches. At 
the topology level, sequential connectivity is considered, such that members of 
the same architecture might have quite different topologies. When structures 
belonging to the same T-level have suitably high similarities combined with 
similar functions, the proteins are assumed to be evolutionarily related and put 
into the same homologous superfamily. Gene3D assigns structural domains from 
the CATH database to whole genes and genomes (Yeats et al., 2008). Matches to 
structural domains are found using the PSI-Blast (Altschul and Koonin, 1998). 
Two automatically generated databases that cluster protein domains are the 
ProDom (Bru et al., 2005) and ADDA databases .  ProDom iteratively invokes PSI-
Blast to cluster protein domains, and ADDA Automatic Domain Decomposition 
Algorithm. This algorithm first aligns representative protein sequences with 
BLAST (Altschul et al., 1990), splits them into domains and then organizes these 
6domains into protein domain families.  Other domain databases that use HMMs 
for domain classification are SMART (Letunic et al., 2006) and TIGRFRAM (Haft 
et al., 2003). The SMART (Simple Modular Architecture Research Tool) database 
is focused on certain types of domains, such as extracellular and signalling 
domains, while TIGRFRAM strives for broad coverage of microbial proteins. The 
Prosite database consists of a library of profiles and patterns that describe 
protein domains, families and functional sites (Hulo et al., 2006). The PRINTS 
database is a collection of nonoverlapping motifs for the identification of family 
members (Attwood et al., 2003). The motifs are derived from ungapped multiple 
sequence alignments that help to identify the most conserved regions of the 
protein family. Prints families tend to be more specific and are useful for 
detecting subfamilies. The BLOCKS database contains blocks, i.e. ungapped 
multiple sequence alignments, for each family (Henikoff et al., 2000). These are 
equivalent to the motifs in the PRINTS database, and in fact the families in 
BLOCKS are currently derived from Prosite and Prints families. Finally, InterPro 
is an integrated database - a result of collaboration between different domain 
family databases and the UniProt Knowledgebase (Hunter et al., 2009). The goal 
of this collaborative project is to have a centralized resource for protein 
classification and automatic annotation. 
Presence of an already described domain in protein sequence is one of the 
most informative indications of protein function. Therefore, protein domains are 
used as the basis for automatic protein functional classification and annotation. 
Presence of other functional elements in a protein sequence can also aid in better 
understanding of protein’s role in a cell. In the following text, I discuss the 
function of, and methods to characterize, disordered regions and 
posttranslationfally modified sites in proteins. When disordered regions are 
conserved, it is possible that they are also classified as protein families, so 
protein domain annotations can overlap with disordered segments in proteins. 
However, these segments are crucially distinct from standard protein domains -
both from the aspect of structure and function. Other classes of functional 
elements in proteins, such as transmembrane regions, or signal peptides, are also 
well described and methods for their detection are in use (Kall et al., 2004), but I 
don’t address them here separately.  
7Figure 1.2: An example of a seed multiple alignment for the Pfam Globin 
family (Pfam accesion: PF00042).  The seed alignment is used to build an 
HMM model of a family, which is the used for identifying the same domain in 
other proteins.
1.1.2 Disordered protein regions
Intrinsically unstructured, or disordered, regions in proteins are characterized 
with the lack of stable secondary and/or tertiary structure (Dunker et al., 2001; 
Dyson and Wright, 2005). In some cases, though, disordered segments can adopt 
a fixed three-dimensional structure after binding to other macromolecules in a 
cell, as exemplified with DNA binding domains of different transcription factors 
(Gsponer and Babu, 2009). The discovery of proteins that are unstructured over 
their whole length challenged the traditional view that a well-defined structure 
is required for correct protein function. Moreover, further work demonstrated 
that the flexibility of disordered residues actually provides these proteins with 
specific functional benefits. The functional importance of protein disorder is 
underlined with the observations that disordered proteins commonly play a role 
in signal transduction, cell-cycle regulation, gene expression and chaperone 
activity (Tompa, 2005; Wright and Dyson, 1999). 
Experimentally, the lack of a stable tertiary structure in proteins is 
usually demonstrated by using solution-state NMR, circular dichroism, 
fluorescence spectroscopy and small angle X-ray scattering measurments 
(Gsponer and Babu, 2009). The database DisProt (Vucetic et al., 2005) is a 
repository of proteins with experimental evidence of a lack of structure. In 
addition to this, since disordered protein segments have a distinct amino-acid 
8composition, they can also be predicted from protein sequence. Disordered 
regions tend to be enriched in hydrophilic and charged amino acids that do not 
tend to form stabilizing interactions with other neighbouring amino acids; 
Alanine, Arginine, Glycine, Glutamine, Serine, Proline, Glutamic acid and Lysine 
(Tompa, 2005). Specific properties of disordered segments have been differently 
applied in disorder prediction methods. These methods can generally be 
classified into those that apply machine-learning approaches and use known 
disordered proteins for training, and those that predict disorder just from 
sequence properties. PONDR (Garner et al., 1998), Disopred (Ward et al., 2004), 
and DisEMBL (Linding et al., 2003) are examples for the former class of methods 
and IUPred (Dosztanyi et al., 2005) and SEG (Wootton, 1994) for the latter – SEG 
actually predicts low complexity regions which can serve as a good indication of 
disorder. 
The functional classification of disordered protein regions, as explained 
here and as shown in Figure 1.3, is adapted from the classification suggested by 
Peter Tompa (Tompa, 2005). Disordered proteins or protein segments can be 
divided depending on whether their function results from the entropic 
properties of disordered chains or from the ability to flexibly bind other partner 
molecules. Examples for the former one are Phe-Gly (FG) disordered repeat 
regions of nucleoporins that regulate transport through nuclear pore complex 
via spatial exclusion (Denning et al., 2003), or the microtubule-associated 
protein 2 (MAP2) repeat domain that provides spacing in cytoskeleton (Ludin et 
al., 1996). Disordered regions or proteins that interact with other molecules can 
be further divided in those that achieve the interactions through permanent 
binding and those that bind their partners only transiently. Those that bind the 
partner molecules permanently are usually inhibitors of different enzymes, take 
part in different cellular complexes as assemblers, or, if partner molecules are 
small ligands, regulate the ligand dynamics. Disordered regions and proteins, 
which form only transient interactions, do that either by exposing flexible 
binding sites, such as those for posttranslational modifications, or they function 
as protein or RNA chaperones (Tompa and Csermely, 2004). 
Comparison between fractions of disorder in proteins from fully 
sequenced representative genomes from the three kingdoms of life revealed a 
9significant increase of native disorder between eukaryotic genomes compared to 
archean or eubacterial genomes (Ward et al., 2004). Moreover, among 
eukaryotes the fraction of disorder increases with organism complexity (Haynes 
et al., 2006). In eukaryotes, disorder is especially abundant in hub proteins, i. e. 
in proteins with a high number of interaction partners (Dosztanyi et al., 2006; 
Haynes et al., 2006). In line with this, independent studies reported that cancer-
associated and signalling proteins are also enriched in disorder (Iakoucheva et 
al., 2002). Furthermore, there are indications that contacts between two 
disordered regions might be the most frequent type of interactions in the 
protein-protein interaction network (Shimizu and Toh, 2009). Hence, disordered 
proteins are suggested as attractive novel drug targets (Cheng et al., 2006).
The benefit of using disordered regions in protein interactions is most 
obvious when binding sites are exposed for transient interactions, such as sites 
of post-translational modifications. Disordered segments can be easilfy accessed 
by modifying enzymes which add or remove a modification, and by effector 
proteins which are regulated by the (un)modified proteins (Gsponer and Babu, 
2009). Easy accessibility of these sites enables precise time regulation of a 
process. Therefore, it is not surprising that disordered regions in proteins 
frequently contain short linear peptide motifs (Neduva and Russell, 2005) that 
are important for protein function and recognized by specific protein partners. 
The most comprehensive collection of described linear motifs - small functional 
sites in proteins - is catalogued in the Eukaryotic Linear Motif (ELM) database. 
Disordered proteins are more sensitive to proteolytic degradation and 
have a short lifetime (Tompa, 2005; Wright and Dyson, 1999). Moreover, the 
abundance of disordered proteins is additionally controlled on the level of 
regulation of transcript clearance and translational rate (Gsponer et al., 2008). 
Thus, both life-span and synthesis of these proteins seem to be finely regulated.
Rapid turnover is a desirable characteristic of proteins involved in cell cycle 
regulation and in transcriptional and translational processes. These exactly are 
the functional categories that disordered proteins are enriched in (Tompa, 2005; 
Wright and Dyson, 1999). Therefore, the intrinsic characteristics of disordered 
proteins make them especially adapted to the roles they perform in a cell. This 
ensures that they are available in appropriate amounts and only during a short 
10
time interval (Gsponer et al., 2008). Moreover, disordered proteins that form 
transient interactions and are readily accessible for protein modifications 
provide another advantage for usage in finely regulated signalling pathways. 
Figure 1.3: Functional classification of disordered proteins. Examples of 
disordered proteins from each category are described in the text. Illustration is 
adapted from Tompa (2005).
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1.1.3 Sites of posttranslational modification
Posttranslational modifications (PTMs) are covalent processing events that 
modify proteins. These modifications rely on the activity of other proteins –
enzymes, which either proteolytically cleave the protein or add a modifying 
group to its amino acid(s). The majority of eukaryotic proteins undergo 
posttranslational modifications, which modulate their activity (Mann and Jensen, 
2003). PTMs can modify stability, activity state, localization or turnover of a 
protein, as well as its interactions with other proteins (Mann and Jensen, 2003; 
Walsh, 2006). Even though protein modification is a widespread phenomenon 
which regulates numerous aspects of protein function, only a small subset of all 
PTM sites has been discovered (Olsen et al., 2006). This is exemplified with 
protein phosphorylation, which is the most intensively studied type of protein 
PTM, and estimated to affect about one-third of all proteins (Cohen, 2001). 
However, currently only a small fraction of protein PTM sites are described 
(Olsen et al., 2006). Development of mass spectrometry methods, which provide 
enough sensitivity for large-scale studies, offers great promise in scaling up 
detection and our understanding of different PTMs (Mann and Jensen, 2003).
Protein PTMs are used in numerous cellular processes. Proteolytic 
cleavage is important for the activation of many proteins; these are firstly 
synthesised as inactive precursors that are later on activated through limited 
proteolysis. Examples for this are pancreatic enzymes and enzymes involved in 
blood clotting (Neurath and Walsh, 1976).  Phosphorylation is particularly 
important in signalling, where kinase cascades are regulated by reversible 
addition and removal of phosphate groups (Mann and Jensen, 2003). Similarly, 
ubiquitination plays an essential role in the cell cycle where it marks cyclins for 
destruction at defined time points (Mann and Jensen, 2003). Methylation and 
acetylation can both modify the activity of histones and hence regulate gene 
expression (Rice and Allis, 2001). Addition of fatty acids, such as palmitoyl or 
myristoyl, is used to promote membrane binding and target proteins to specific 
organelles (Resh, 1999). Glycosylation is used both in signalling (Haines and 
Irvine, 2003) and in defining proteins that are excreted or exposed on a cellular 
surface (Gahmberg and Tolvanen, 1996).  
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PTM sites frequently reside in disordered protein segments (Fuxreiter et 
al., 2007). Advantages of this are discussed above in the text. In particular, 
protein phosphorylation has been strongly linked to intrinsically disordered 
protein segments (Iakoucheva et al., 2004). Since these regions evolve rapidly, 
and phosphosites are relatively short, it has been suggested that some of the 
annotated sites are not functional, and that the process of signal transduction 
tolerates a certain level of noise (Landry et al., 2009). Moreover, phosphosites of 
known function are significantly more conserved than those of unknown
function, and hence it has been suggested that evolutionary conservation could 
give an indication of the actual functionality of a phosphosite (Landry et al., 
2009). However, studies on yeast have suggested that the position of most 
phosphorylation sites is not conserved in evolution and that clusters of sites tend 
to shift positions in rapidly evolving disordered regions, which could also be the 
mechanism for the faster evolution of kinase-signalling circuits (Holt et al., 
2009). 
1.2 Protein evolution
Evolutionary footprints are evident in protein sequences, where in general the 
level of sequence divergence reflects divergence times between organisms. 
Hence, present day protein sequences, together with ribosomal sequences, are 
often used to assign organisms to their phylogenetic groups (Feng et al., 1997). 
Additionally, divergence in protein sequences represents a molecular clock, 
which, after calibration with the available fossil record, can be applied to 
estimate divergence times between more distant organisms (Feng et al., 1997). 
However, it is important to note that protein sequence divergence is not a 
random evolutionary process, but mutation patterns are largely shaped by 
proteins structural and functional constraints. Even a single point mutation in a 
protein can have a dramatic effect on the protein function. For example, amino 
acids in an enzyme’s active site are usually highly conserved and their mutations 
can completely abolish the original function. Sometimes, substitutions of the 
active-site residues can lead to catalytically inactive forms that can later adopt 
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new functions, such as those in regulatory processes (Pils and Schultz, 2004). 
Additionally, mutation in an enzyme’s catalytic site can adapt its specificity to a 
different substrate, and there are examples of enzymes that have evolved to 
catalyse different reactions on the same structural scaffold using this mechanism 
(Bartlett et al., 2003).
When a protein is folded into a stable structure, mutations in the primary 
sequence introduce a risk to its structural stability. The first level of protein 
structural hierarchy is defined with elements of secondary structure, and the 
next higher level – protein fold – with the arrangement of secondary structure 
elements. Examples of protein folds are helix bundle, which is a fold composed of 
several alpha helices; beta-barrel, which is a large beta-sheet that forms a closed 
structure; and Rossman fold, which is a fold composed of interchanging beta 
strands and alpha-helices, commonly found in nucleotide-binding proteins. 
Interestingly, analysis of known structures suggests that the total number of 
folds in nature is limited (Chothia, 1992; Goldstein, 2008). Moreover, some folds 
are extremely common while other folds are shared only between a few related 
proteins (Goldstein, 2008). A possible explanation for this is that folds that are 
suitable for common functions in cells, or for a wider range of different functions, 
have been most often adopted in evolution (Goldstein, 2008). As a consequence 
of this, the introduced mutations are likely to disrupt the structural stability. 
Additionally, many other factors - apart from protein structure and function -
affect protein evolution. Other genomic factors that play an important role are: 
positions of the encoding genes in genomes, gene expression patterns, protein 
positions in biological networks (Pal et al., 2006) and also availability of 
buffering mechanisms, such as chaperones, which can stabilize intermediate, 
slightly deleterious, protein mutations (Tokuriki and Tawfik, 2009). Apart from 
experiencing mutations on the amino acid level, whole genes encoding proteins 
can be gained or lost during evolution. Gains can occur either through 
exonisation of non-coding sequences, or through gene duplications – discussed 
below. Gene propensities to be lost, similarly to the mutation propensities of 
protein amino acid sequences, depend on their essentiality for the organism, 
level of expression and a number of interaction partners (Krylov et al., 2003). 
Finally, another principal mechanism of protein evolution is domain shuffling. 
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The unit of evolution here is a protein domain and, hence, the changes in 
proteins are of larger scale than those observed in amino acid divergence. In the 
following section, I will discuss reports from the studies on how new domain 
combinations are formed, and what role they play in protein and organism 
evolution. 
1.2.1 Domain shuffling
Above in the text, I introduced the terms ‘protein fold’ and ‘protein domain’. 
When sequences with the same fold are evolutionary related, and the protein 
domain is structurally independent from the rest of the protein, fold and domain 
definitions overlap. In my thesis, I focus on protein domains and their roles as 
independent evolutionary units. The majority of proteins consist of at least two 
domains, and many domains can occur in combinations with different domain 
partners. Thus, multidomain proteins are frequently created through 
rearrangements between domains (Moore et al., 2008). Since the same domains 
are reused in different combinations, domain duplication is an important 
prerequisite for novel domain rearrangements. The majority, i.e. 98%, of 
domains in humans are present in at least two copies in the genome (Chothia et 
al., 2003). Additionally, when the same domain combination, i.e. two or more 
domains, are present in two otherwise non-homologous proteins, domain order 
is conserved in more than 90% of the instances (Vogel et al., 2004). This implies 
that these regions share a common ancestor and underscores the role of domain 
duplication in creation of novel multidomain proteins. 
Observed domain combinations are only a small fraction of all possible 
combinations (Chothia et al., 2003). This shares a similarity with the evolution of 
protein folds and suggests that protein evolution could be affected by functional 
and structural constraints on all levels. In line with this, analysis of 
experimentally characterized protein structures of multidomain proteins 
reported that independent folding of structured domains can be achieved 
through loosely packed or small interfaces between the domains (Han et al., 
2007). Another observation from the studies of multidomain proteins is that 
domains that occur most often in the genomes also have many different 
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combination partners (Vogel et al., 2005). Interestingly, these domains are often 
shared between members of larger phylogenetic groups. Study of domains with 
known structure (Chothia et al., 2003) showed that domains that are shared 
between all eukaryotes or all animals make more than 80% or 95%, respectively, 
of domains in the human genome. A significant fraction of this is a result of 
lineage-specific expansions of some of the shared domains (Chothia and Gough, 
2009). 
Similar domain architectures are usually explained with shared ancestry 
and convergent evolution is considered to be rare (Apic et al., 2001; Gough, 
2005). Studies of rearrangements in the evolution of multidomain proteins have 
shown that the evolution of the majority of multidomain proteins can be 
explained with insertions and deletions of domains from protein termini 
(Bjorklund et al., 2005; Weiner et al., 2006), with the expection of domain 
repeats, where the changes in the number of domains also occur in the middle of 
proteins (Bjorklund et al., 2006). These studies were performed by comparing 
proteins with similar, but not identical, domain assignments. However, domain 
architectures can also be used to build evolutionary trees, which can be useful 
when frequent domain rearrangements make it difficult to recognize related 
proteins from the amino acid level. This method has been used in a number of 
studies for inferring phylogeny - covered in the review by Moore and colleagues
(Moore et al., 2008), and tools for finding related proteins based on domain 
architecture are also available (Geer et al., 2002; Storm and Sonnhammer, 2001). 
A recent study used a tree based on the distances between domain architectures 
from all species with good quality genomes as a guide in the study of evolution of 
multidomain proteins (Ekman et al., 2007). Mapping the changes in multidomain 
proteins to species divergence times showed that the major changes in domain 
architectures have occurred in the process of multicellularization and then 
within the metazoan lineage (Ekman et al., 2007). This suggests that accelerated 
formation of novel domain architectures was needed for the emergence of novel, 
more complex traits. Jin and colleagues propose that changing combination 
partners relieves the pressure for a domain to maintain the original function and 
allows it to acquire an entirely new intrinsic function (Jin et al., 2009), as 
illustrated in Figure 1.4. This can expand the function of an original protein and 
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modify the cellular process that this protein is involved in. Frequently, domains 
with a number of different domain partners are involved in signalling and it was 
suggested that shuffling of these domains was a crucial step in the evolution of 
complex cellular networks (Pawson, 2003). Similar to this, the distinguishing 
feature of the proteomes of multicellular eukaryotes is a high fraction of domain 
repeats (Ekman et al., 2005). Domain repeats often have a role in protein-protein 
interactions or binding to other ligands (Bjorklund et al., 2006). Thus, this could 
be another category of domain architecture rearrangement events that was 
important for the development of complex intra- and intercellular networks and 
subsequently for the evolution of novel phenotypic traits in the metazoan 
lineage.
Figure 1.4: Domain shuffling and domain evolution. When domain shuffling 
changes the enviroment of a domain, the domain is likely to experience more 
radical changes in sequence and function. The domain enviroment is defined by 
the subcellular localization and interaction partners of a domain. The figure is 
adapted from Jin et al. (2009). If, through shuffling, a domain is attached to a 
protein that has similar interaction partners and localization as the ancestral 
protein that the domain was a part of (left panel in the figure), domain sequence 
and function evolve more slowely than if the domain is attached to a protein that 
operates in a different cellular compartment and/or has different proten 
partners (right panel in the figure) compared to the ancestral protein.  
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Several studies focused on specific examples of domain shuffling and 
demonstrated its importance in the development of complex systems or 
evolution of signalling pathways. One of these studies investigated the role of 
domain shuffling in the evolution of vertebrates (Kawashima et al., 2009). The 
evolution of vertebrates included a number of important and novel events, such 
as the development of cartilage, the immune system and craniofacial structures 
(Kawashima et al., 2009). The study showed that proteins which are components 
of vertebrate-specific structures, such as cartilage and the inner ear, had novel 
domain combinations, thus suggesting that domain shuffling made a strong 
contribution to the evolution of vertebrate-specific traits (Kawashima et al., 
2009). An interesting example from the study is the Xlink domain in the aggrecan 
protein, which is one of the major components of cartilage. This domain appears
to be recruited in the cartilage matrix protein by domain shuffling, while in 
protochordate ancestors, Xlink was most likely used as a surface molecule of 
blood cells (Kawashima et al., 2009). An example of a cellular pathway where 
domain shuffling played an important role is the Notch signalling pathway. This 
pathway regulates cellular identity, proliferation, differentiation and apoptosis, 
and plays an important role in development (Gazave et al., 2009). Systematic 
study of genes involved in this pathway in a number of eukaryotic species 
showed that this pathway is specific to Metazoans, and moreover, that the origin 
of several components of the pathway occurred through shuffling of pre-existing 
domains (Gazave et al., 2009). 
Research that puts domain shuffling in context with other types of protein 
evolution – point mutation and protein duplication - suggests that this is the 
most powerful source for innovation of gene function (Conant and Wagner, 
2005). Experimental evolutionary studies show that function evolves at a much 
faster rate following domain rearrangements than following point mutations 
(Leong et al., 2003; Powell et al., 2000) or gene duplications (Peisajovich et al., 
2010). The incidence of domain shuffling in eukaryotes is reported to be 
significantly less frequent than gene duplication events (Conant and Wagner, 
2005). However, evolution by domain shuffling is most likely closely linked to 
other types of protein evolution: there is evidence that domain shuffling relies on 
gene duplication, which provides domain copies for shuffling (Vogel et al., 2005), 
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and after new domain combinations are formed, point mutations in the shuffled 
domain can occur with a higher frequency than in the original domain context
(Jin et al., 2009).
1.2.2 Mechanisms for formation of novel genes
Domain shuffling is a powerful mechanism for protein evolution. However, a 
change in a protein that we observe as domain shuffling could be a result of 
different gene rearrangement mechanisms. Comparisons of protein domain 
architectures can only give indications on which mechanisms could have caused 
the observed changes (Bjorklund et al., 2005; Weiner et al., 2006). On the other 
hand, studies on the origins of new genes are primarily focused on mechanisms 
that underlined the emergence of novel genes and functions (Long, 2001). The 
two approaches to a study of evolution of novel functions are complementary to 
each other; mechanisms that underlie the evolution of novel genes could have 
also caused changes in protein domain architecture, and alternatively – gain or 
loss of a protein domain is a strong indicator of a change of function during gene 
evolution. Here, I cover recent work that addressed emergence of novel protein 
coding genes and discuss which of the underlying mechanisms could have also 
played a role in domain shuffling. 
The main interest in studying the occurrence of novel genes, and 
underlying mechanisms for it, comes from a notion that novel genes might have 
played a significant role in the evolution of lineage- or species-specific traits 
(Kawashima et al., 2009; Khalturin et al., 2008). A powerful mechanism that can 
lead to the evolution of novel functions is gene duplication. The role of gene 
duplications in evolution of novel traits has been debated for more than four 
decades (Ohno, 1970) and I discuss it as a separate aspect of gene and protein 
evolution in the next section. Next, recombination of either duplicated or single 
copy genes can result in the creation of proteins with novel domain 
arrangements. The two best-studied means of recombination are non-allelic
homologous recombination (NAHR, Figure 1.5) (Hurles, 2004) and non-
homologous end joining (NHEJ) (Arguello et al., 2006). These mechanisms 
recruit different proteins (Haber, 2000) and differ in whether they require short 
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regions of sequence similarity for their action or not; NAHR, unlike NHEJ, acts 
between the short blocks of high identity sequences. These blocks could have 
originated through previous duplications of genetic material, or even through 
expansion of transposons in the genome (Babushok et al., 2007). An example of a 
gene that evolved through DNA recombination is the Hun gene in the Drosphila
lineage (Arguello et al., 2006). This gene is a partial duplicate of Baellchen gene, 
from another chromosome, and after its duplication it has recruited intergenic 
sequence and evolved independently in each Drosophila species. A lack of 
obvious direct repeats around the duplicated region led the authors to propose 
that the underlying recombination mechanism was NHEJ (Arguello et al., 2006). 
Another example is a primate-specific chimeric gene family that expanded as a 
result of intrachromosomal segmental duplications, and was derived through 
joining of exons from the RanPB2 gene with exons from the neighbouring GCC2 
gene, which code for the GRIP domain (Ciccarelli et al., 2005). RanBP2 is the 
largest protein found in the nuclear pore complex, while the GRIP domain has 
been shown to be sufficient for targeting to Golgi. The new chimeric protein -
named RGP (for RanBP2-like, GRIP domain containing protein) - was indeed 
found to localize inside cytoplasmic regions, while the ancestral RanPB2 protein 
is almost exclusively found at the nuclear envelope (Ciccarelli et al., 2005). 
Emergence of this chimeric protein is closely connected to segmental 
duplications of the RanBP2 gene in primates. The observed intrachromosomal 
duplications could have occurred through NAHR, which more frequently acts 
between the regions on the same chromosome (Arguello et al., 2006). However, 
the birth of the RGP gene also required joining of exons from two adjacent genes, 
and this supports the theories that intergenic splicing could play an important 
role in assisting gene fusions in eukaryotes (Babushok et al., 2007). 
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Figure 1.5: Possible effects of Non-allelic homologous recombination 
(NAHR) on genome evolution. NAHR between two highly similar segments in 
the genome can cause different types of rearrangements, depending on the 
location and orientation of these segments. Thus, NAHR between adjacent 
duplicated sequences can result in tandem duplications and deletions (top 
figure). When the similar segments are on different chromosomes NAHR can 
result in translocation (middle figure), and intrachromosomal recombination 
between inverted similar segments can result in inversions (bottom figure). 
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In prokaryotes, the dominant mechanism for domain gains is fusion of 
adjacent genes (Pasek et al., 2006). However, more complex gene structures in 
eukaryotes make simple fusion of coding sequences less likely. So far, there is 
one example for this in the literature (Ponce and Hartl, 2006). Sdic is a new gene 
in Drosophila melanogaster that arose after its ancestral genes Cdic and AnnX, 
that are next to each other in the genome, were duplicated. This was followed 
with several deletions that eliminated regions between the two gene copies in 
the middle – in the order AnnX and Cdic -  and fused them into a chimeric Sdic
gene, as illustrated in Figure 1.6. Even though such scenarios are likely to be rare 
in the evolution of eukaryotic genes, there are other mechanisms which can 
assist fusion of adjacent genes with complex structure. Intergenic splicing was 
observed to be relatively frequent in mammalian genomes. By this mechanism, 
novel chimeric proteins can be created. It was suggested that when new proteins 
are advantageous for the organisms they are created in, mutations inside the 
regulatory regions that distinguish expression of two different genes will be 
selected for and the chimeric product will be also fixed on the gene level 
(Babushok et al., 2007). An example for this is a fusion of two adjacent human 
genes, KUA and UEV (Thomson et al., 2000). The resultant intergenic transcript 
skips the exons with stop and start codon between the two originally separate 
genes to ensure successful translation of a final product. Interestingly, KUA and 
UEV were most likely also initially juxtaposed as a result of a recombination 
event. 
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Figure 1.6: Example of a chimeric gene formed by gene fusion. The model is 
a simplified scenario of the evolution of the Sdic gene. Steps in the evolution of 
this gene include tandem duplication of neighbouring genes named C and A. This 
is followed with the deletion of parts of genes A and C as well as intergenic 
regions between them which results in the fusion of two partial coding regions. 
Finally, later evolutionary events include the emergence of new start and stop 
codons and recruitment of regulatory elements of the new gene.
Another mechanism that can underlie evolution of novel proteins is 
retroposition. Retrotransposons, such as for example LINE1, expand in the 
genome by reversely transcribing their own mRNA and inserting a copy 
randomly in the genome (Babushok et al., 2007). However, their machinery can 
also be used to reversely transcribe cellular mRNA, and that is the mechanism 
for the emergence of processed pseudogenes. Additionally, only portions of 
cellular mRNA can be transcribed, or templates can be switched during 
transcription, thus resulting in combination of different cellular mRNAs, or 
cellular mRNA and a transposable element (Babushok et al., 2007). Furthermore, 
this mechanism can fix mRNAs created by intergenic splicing as novel genes. One 
such example is the emergence of the gene PIPSL in primates, which combines 
the lipid kinase domain of PIP5K1A and the ubiquitin-binding motifs of PSMD4 –
its two ancestral genes (Babushok et al., 2007a).  PIPSL is reported to have
experienced strong positive selection, and is found to be transcribed specifically 
in the testes (Babushok et al., 2007a). Testis is in general a more permissive 
environment for gene expression, and the organ where young retrogenes can be 
found expressed (Betran et al., 2002). Because of that, testis has been proposed 
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as a tissue where accelerated evolution of genes takes place, assuming at the 
same time that the newly evolved genes can later adapt to other tissues 
(Kaessmann et al., 2009).
Retrotransposons, together with retroviruses and other parasitic 
elements in the genome, can contribute to gene evolution also by directly 
incorporating into the other genes in the genome (Deininger et al., 2003). It has 
been reported that new exons can arise through exonisation of Alu elements or 
other parasitic elements in the genome (Sorek and Ast, 2003; Sorek et al., 2004). 
An important example identified in these studies is the ADAR2 enzyme – a 
double-stranded RNA-specific adenosine deaminase that is involved in the 
editing of mammalian messenger RNAs by site-specific conversion of adenosine 
to inosine (Rueter et al., 1999). This enzyme contains 40 amino acids in its active 
site that are derived from an Alu element. This addition changes the activity of 
the enzyme essential in mammals. Another example is the incorporation of a 
DNA transposon into a cellular gene which gave rise to the ZBED6 transcription 
factor in eutherians (Markljung et al., 2009). ZBED6 has an important role in the 
regulation of muscle growth, and might affect the expression of numerous genes 
involved in other biological processes (Markljung et al., 2009). An example of 
genes that evolved from retroviruses are syncytin genes, which stem from the 
envelope genes of endogenous retroviruses and have evolved in mammals (Mi et 
al., 2000). Importantly, syncytin genes play key roles in placentation. 
Evolution of novel protein coding genes was long believed to be strongly 
linked to gene duplication (Ohno, 1970) and the probability that new functional 
proteins are created de novo was argued to be extremely unlikely (Jacob, 1977). 
In line with this, it was noted that novel folds that are created during evolution 
can be presented as modified topological combinations of already known motifs 
of secondary sequence (Fernandez-Fuentes et al., 2010). Hence, recent reports of 
protein coding genes that have evolved completely from scratch were rather 
surprising. One example for this is morpheus gene family, that evolved in 
primates, and after its birth has experienced a series of segmental duplications 
and positive selection in hominoids (Johnson et al., 2001). Studies in Drosophila
also reported 14 de novo-originated genes (Levine et al., 2006; Zhou et al., 2008). 
Finally, three de novo human specific genes were recently reported (Knowles and 
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McLysaght, 2009). Comparison of these genes with related, non-coding 
sequences in other primates revealed mutations that allowed formation of 
functional open reading frames, and available protein evidence proved that these 
genes are indeed translated. Interestingly, two out of the three human-specific 
genes fall within introns of the genes on the opposite strand. This suggests that 
possibly transcription of the genes on the opposite strand and open chromatin 
structure permits transcription of the de-novo genes even without the presence 
of sophisticated regulatory signals (Siepel, 2009). Therefore, if whole genes can 
evolve from previously non-coding regions, this also implies that novel domains 
–fractions of coding genes - could also originate from scratch during evolution.
Nonetheless, this is more likely to be the mechanism for emergence of domains 
defined on the basis of sequence conservation rather than emergence of novel 
structural units. Alternatively, novel domains can be created through point 
mutations of already existing domains, and hence, lineage-specific domains that 
hence contribute to novel domain arrangements, are likely to be of both sorts.
Finally, exon shuffling has often been referred to as a separate mechanism 
of gene evolution (Long, 2001; Long et al., 2003). However this phenomenon is in 
fact a result of an already described mechanism - recombination events and 
possibly retroposition. Exon shuffling is a term that could include any novel 
combination of exons, but was frequently associated with insertions of novel 
middle exons that encode protein domains (Patthy, 1996), and hence is now also 
often used in that context (Marsh and Teichmann, 2010).
1.2.3 Gene duplication and protein evolution
As already stated in the previous section, gene duplication is believed to be the 
strongest driving force behind the evolution of novel functions (Ohno, 1970). 
The rationale behind this is simple; the majority of mutations are deleterious, 
and since, in general, each gene has evolved a specific role in the organism, 
disruption of gene function in parallel affects the organism fitness. However, 
when a gene is duplicated, it is theoretically possible that one copy evolves freely 
and goes through intermediate stages that change its original function - as long 
as this does not interfere with the function of the other copy. Gene duplicates can 
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be created through recombination or retrotransposition events, or as a result of 
chromosome or whole-genome duplications (Zhang et al., 2003). Similarly, 
duplicate genes in the human genome originated mostly from one or two rounds 
of whole genome duplication before the divergence of vertebrates, subsequent 
smaller segmental duplications (Gu et al., 2002) and more recent expansion of 
retrogenes (Kaessmann et al., 2009).  Interestingly, gene survival is dependent 
upon the mechanism of duplication. For example, duplication of a single gene 
that is a part of protein complexes or is involved in signalling processes can 
disrupt the dosage balance in the cell. Therefore, duplicates of such genes are 
underrepresented in the genomes (Makino and McLysaght, 2010). On the 
contrary, after whole genome duplications, dosage-sensitive genes are present in 
two copies. Hence, losing a dosage-sensitive gene disrupts the newly created 
dosage balance and is likely to be selected against. 
Genes duplicated through retroposition lack regulatory elements – since 
only their mRNA has been duplicated (Kaessmann, 2009). However, a 
surprisingly large number of such retrogenes are found to be transcribed (Zheng 
et al., 2005). One means of transcription could be usage of the open chromatin 
state and regulators of nearby genes (Kaessmann et al., 2009). Moreover, specific 
examples have been described where a gene after retroposition evolved a novel, 
positively selected, function. An example is the duplication of the enzyme 
glutamate dehydrogenase (GDH) (Burki and Kaessmann, 2004). GDH is 
important for the recycling of glutamate during neurotransmission. In humans, 
this enzyme exists as a ubiquitously expressed form GLUD1 and as a brain-
specific form GLUD2. Interestingly, GLUD2 originated by retroposition of GLUD1 
in the hominoid ancestor and went through a period of positive selection during 
which it acquired changes necessary for its brain-specific function. Another 
example for the possible effect of gene retroposition is the impact of a retrocopy 
derived from a growth factor gene (fgf4) in several common dog breeds, where 
this extra gene copy is solely responsible for a short-legged phenotype (Parker et 
al., 2009). The resulting phenotype seems to be consequence of gene dosage 
alteration.
Many fixed duplicated genes acquire mutations that make them non-
functional over time; they become pseudogenes, and are often deleted from the 
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genome (Zhang, 2003). It has been proposed that important processes that lead 
to retention of duplicate genes in the genome are neofunctionalization and 
subfunctionalization (Roth et al., 2007). Neofunctionalization, or the origin of 
new function, is a particularly important aspect of gene evolution after 
duplication. Proteins with new functions underline the emergence of novel 
phenotypic traits, and adaptation of the function of an already existing protein to 
a new context is a much faster means of evolution than creation of a protein de 
novo. An example for the adaptation of gene function after duplication is the 
creation of the red- and green-sensitive opsin genes in humans and Old World 
monkeys (Yokoyama and Yokoyama, 1989). After gene duplication in this 
primate lineage, the two opsin proteins have diverged in function, which 
resulted in a 30-nm difference in the maximum absorbtion wavelength and 
enabled a sensitivity to a wider range of colours. In addition, a duplicated gene 
can also evolve an entirely new function. One example for this is another gene 
duplication event in the ancestors of humans and Old World monkeys. This 
duplication resulted in another gene in the RNase A gene family – eosinophil 
cationic protein (ECP), which after duplication went through accelerated 
evolution (Zhang et al., 1998). As a result, the encoded protein experienced 
multiple changes of its amino acids compared to the progenitor eosinophil-
derived neurotoxin (EDN) protein and developed novel antibacterial activity, 
which seems to be independent of the ribonuclease activity (Rosenberg, 1995). 
During subfunctionalization, each daughter gene adopts part of the function of 
the parental gene (Force et al., 1999). One form of subfunctionalization is the 
division of gene expression after duplication (Force et al., 1999). An example for 
this is a pair of transcription factors, engrailed-1 and engrailed-1b in zebrafish, 
which are expressed in different tissues, while their mouse orthologue is present 
in a single copy and is expressed in all the tissues where either engrailed-1 or 
engrailed-1b is found in zebrafish (Force et al., 1999). Alternatively, 
subfunctionalization can occur on the protein level when one of the copies 
becomes specialized for only a certain aspect of the ancestral gene function
(Hughes, 1999). An example for this are two paralogs of the RNA endonuclease 
gene in the archea species Sulfolobus solfataricus (Tocchini-Valentini et al., 
2005). The two genes encode different subunits of the orthologous RNA 
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endonuclease that is present in one copy in other archea species, as for example, 
Methanocaldococcis jannaschii, and both of these subunits are required for 
enzymatic activity and cleavage of the pre-tRNA substrate. Another example for 
temporal gene subfunctionalization is the evolution of the -globin cluster in 
humans. One gene from this cluster is expressed specifically in embryos, another 
in foetuses and another from birth onwards. In addition, each encodes a protein 
product with different oxygen binding affinity that is optimised for each 
developmental stage (Hurles, 2004). It has been proposed that genes with 
greater regulatory complexity are more likely to undergo subfunctionalization 
after duplication (Force et al., 1999), while the genes that are rapidly evolving, 
such as those involved in reproduction and immunity, are more likely to undergo 
neofunctionalization (Emes et al., 2003). In addition to the processes of 
neofunctionalization and subfunctionalization, gene duplication is sometimes a 
mechanism that ensures a higher level of gene expression (Zhang, 2003). In this 
scenario, it is beneficial to conserve the original function and it has been 
proposed that this is achieved either through frequent gene conversions and 
hence concerted evolution of the paralogues (Li, 1997) or through strong 
purifying selection against mutations that modify gene function (Nei et al., 2000). 
It is suggested that histones and ribosomal RNA genes have experienced several 
rounds of duplication because it was advantageous to increase expression of 
these essential genes in the cell (Hurles, 2004).
Gene duplications can also be a driving force for the evolution of novel 
domain arrangements. Firstly, point mutations in an already existing domain can 
create signatures of a novel domain with an original function (Weiner et al., 
2006). Secondly, gene duplications can correlate with the creation of novel 
domain rearrangements (Vogel et al., 2005). Interestingly, duplicate genes in 
eukaryotes seem to have longer protein sequences and more functional domain 
than singleton genes (He and Zhang, 2005) Because of this, it was proposed that 
the majority of fixed duplicates undergoes sub- or neo-functionalization after 
duplication; complex genes are more likely to experience successful 
subfunctionalization and gene complexity can be regained after subsequent 
neofunctionalization (He and Zhang, 2005). An example for subfunctionalization 
on the level of domain arrangement is the one of the monkey king gene (mkg) 
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family in Drosophila melanogaster (Wang et al., 2004). Genes from the mkg 
family have originated recently as retroposed duplicates and due to 
complementary partial degradation evolved into fission genes that separately 
encode protein domains from a multidomain ancestor. Thus, gene duplication 
could result not only in the increase of a gene number, but also gene diversity. 
However, gene duplication is a slightly deleterious process and hence is more 
likely to become fixed in a population only when purifying selection is weak
(Koonin, 2009). Since purifying selection is much weaker in smaller populations 
- such as the ones of higher eukaryotes, in contrast to bacteria - it has been 
suggested that there is no consistent tendency of evolution towards increased 
genomic complexity. Rather, that complexity is a non-adaptive consequence of 
evolution under low purifying selection (Koonin, 2009). 
1.2.4 Evolutionarily related proteins
A crucial step in studying protein evolution is to find related sequences 
and understand relationships between them. The concept of homology describes 
a relationship between genes or proteins that share a common evolutionary 
origin (Reeck et al., 1987). The terms orthology and paralogy have been 
introduced to extend the definition of homology; if the homology is the result of 
gene duplication the genes are defined as paralogous and if the homology is the 
result of speciation  as orthologous (Fitch, 1970).
Databases that assign paralogous and orthologus proteins play a valuable 
role in finding homologous proteins and studying protein evolution. These 
databases either use pairwise protein comparisons to find the true orthologues, 
such as InParanoid (Berglund et al., 2008), use gene synteny to assist similarity 
as Ensembl Compara (Vilella et al., 2009), or build phylogenetic trees and base 
orthologue and paralogue assignments on them like TreeFam (Li et al., 2006).
29
1.3 Protein isoforms of the same gene
In the previous section, I addressed different means for the change of protein 
function during evolution. Point mutations, domain shuffling and gene
duplications acted in concert to bring to expansion of the protein repertoire 
which was necessary for the emergence of more complex organisms. However, 
the number of genes in an organism shows a low correlation with the organismal 
complexity (Chothia et al., 2003). Therefore, a lot of attention has been drawn to 
the role of alternative splicing in the higher organisms (Flicek et al., 2010). 
Alternative splicing is quite abundant in the genomes of higher eukaryotes, with 
estimates that for example, there are on average four isoforms for every human 
gene (Melamud and Moult, 2009). Hence, this is a powerful mechanism for 
increasing protein diversity in an organism (illustrated in Figure 1.7). Similar to 
gene duplications, intron insertions are slightly deleterious, and it has been 
proposed that novel introns are also fixed only when the purifying selection is 
not strong (Koonin, 2009). Again, this implies that the resulting proteome 
diversity and organismal complexity were not actively selected for. 
During splicing introns are removed from mRNA. Introns can vary 
substantially in size, but they maintain several conserved motifs, most 
prominently dinucleotides in their 5’ and 3’ ends - splice donors and splice 
acceptor sites. Since introns can be very long, it was suggested that splicing does 
not need to always operate by recognizing introns, but also by recognizing exons. 
Indeed, it has been reported that protein evolution is skewed in the vicinity 
intron-exon boundaries and shaped so that the nucleotide composition 
necessary for recognition and removal of introns is preserved (Parmley et al., 
2007). Motifs that define intron positions in mRNA are recognized by 
components of the splicing machinery, which in turn recruit other components 
of the spliceosome – different snRNPs, which results in excision of an intron. 
Additional motifs inside introns and exons can determine alternative exon 
boundaries or exons that are included in the final product only in certain 
isoforms of a gene. Most likely, these events are regulated by additional splice 
factors. However, we still do not have a comprehensive knowledge of this 
process. 
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It has been noted that alternatively spliced exons in the human 
serine/arginine-rich (SR) family of splice regulators overlap with ultraconserved 
elements that are shared with mice (Lareau et al., 2007). Interestingly, it was 
shown that in every member of the human SR family, ultraconserved elements 
were recognized and alternatively spliced either as an alternative ‘poison 
cassette exons’ containing early in-frame stop codons, or as alternative introns in 
the 3’ untranslated region (Lareau et al., 2007). These events target the resulting 
mRNAs for degradation by nonsense mediated mRNA decay (NMD). Since SR 
proteins direct splicing of their own products, this suggested that unproductive 
splicing is important for regulation of the entire SR family. Additionally, this also 
underlines the complexity of the alternative splicing regulation and implies an 
additional role for NMD. NMD is a surveillance mechanism that detects and 
degrades mRNAs with premature stop codons. Importantly, more than a third of 
reliably inferred alternative splicing events in humans result in mRNA isoforms 
with premature stop codons (Hillman et al., 2004). The fact that this 
phenomenon is so widespread indicates that NMD does not necessarily have a 
function to prevent protein mistranslation when errors occur, but could also be a 
regulatory mechanism that silences gene expression on posttranscriptional level.
Evolution of alternative splicing is tightly linked to protein evolution. 
Interestingly, one of the mechanisms for generating new cassette exons – exons 
that are exluded or included in a processed mRNA with their whole length – is 
exon shuffling (Kondrashov and Koonin, 2003; Letunic et al., 2002). By this 
means, either a new exon is inserted into a gene, or an existing exon is duplicated 
within a gene. Alternative cassette exons can also emerge through exonization of 
intronic sequences (Wang et al., 2005). Close to 5% of human genes contain 
motifs of transposable elements in their coding regions, such as of Alu elements
(Sorek et al., 2002). Importantly, newly inserted exons often have a low inclusion 
level, thus the ancestral mRNA remains the main gene product (Mendes Soares 
and Valcarcel, 2006). In line with this, alternative cassette exons with a high 
inclusion level are usually conserved between human and mouse, which is not 
the case for those with a low inclusion level (Modrek and Lee, 2003). In addition 
to this, alternatively spliced exons can also originate from the constitutive 
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ancestral exons  - exons present in all splice isoforms of a gene – through 
creation of novel splice sites (Lev-Maor et al., 2007).
New sequencing technologies are making the studies of alternative 
splicing more comprehensive (Pan et al., 2008) and will surely have a great 
impact on the understanding of this process, but potentially also on disease 
treatment. By now, alternative splicing has been implicated in a number of 
human genetic diseases; in particular different neurodegenerative disorders and 
cancer (Lukong et al., 2008). At this time, therapeutic strategies that target 
splicing defects look promising. A number of these are underway and some, such
as agents that target splicing factors or isoform-specific drugs are already in use
(Garcia-Blanco et al., 2004). An example for the former is an inhibitor of the 
Clk1/Sly kinase, which phosphorylates SR proteins, and for the latter is 
phenacetin, a nonsteroidal anti-inflammatory drug that has a different inhibitory 
effect on the activity of different isoforms of the COX enzyme. However, the role 
of alternative splicing in disease development is most probably still 
underappreciated. We do not have a knowledge of all regulatory signals for gene 
splicing and even synonymous mutations that are usually discarded as disease 
causing can affect splicing and disrupt the protein (Caceres and Kornblihtt, 
2002). Moreover, if the mutated gene interacts with a number of molecular 
partners then the effects of the observed mutation should be viewed in the 
context of the whole molecular network (Schadt, 2009).
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Figure 1.7: Alternative splicing increases the diversity of proteome. 
Alternative inclusion of exons 3 and 4 in this example can change the structure 




1.4 Outline of the thesis
The remaining chapters of this thesis consist of three separate investigations. I 
first analyse general trends in the evolution of protein domain architectures. 
This analysis lays a foundation for the work in the following chapter where I 
focus on the smaller set of confident domain gain events and investigate 
molecular mechanisms that underlined these domain insertions. In the final 
results chapter, I analyse characteristics of protein regions that undergo tissue-
specific alternative splicing. Thus, the overall aim of this thesis is to address 
changes in the architecture of protein functional elements on different levels.
Parts of the results described in Chapters 2 and 3 have been published 
(Buljan and Bateman, 2009; Buljan et al., 2010). Work in Chapter 4 is in 
preparation for submission at the time when the thesis is submitted. 
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Chapter 2
Evolution of multidomain proteins
2.1 Introduction
In this chapter, I investigate the general trends of protein domain architecture 
evolution. To decrease the number of falsely reported domain gain and loss 
events, I first develop a method for the refinement of initial domain assignments. 
Next, I analyse the positions in proteins where the changes in domain 
architectures are reported. Positions of changes are defined by the mechanism 
that caused domain gains or losses and by subsequent natural selection. Here, I 
analyse the differences in trends between the changes that occurred after gene 
duplication or organism speciation and a possible role of natural selection in this. 
Protein domains, as defined here, are conserved regions of a protein’s 
sequence that often convey distinct function. The domain architecture, or order 
of domains in a protein, is considered as a fundamental level of protein 
functional complexity (Holm and Sander, 1994) and assignment of domains to a 
protein is an important step in elucidation of a protein’s function (Bateman et al., 
2002). The majority of the protein repertoire is composed of multidomain 
proteins; two-thirds of the proteins in prokaryotes and about four-fifths 
eukaryotic proteins have two or more domains (Chothia et al., 2003). Moreover, 
an organism’s complexity relates much better to the number of distinct domain 
architectures (Babushok et al., 2007) and expansion in particular domain 
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families (Vogel and Chothia, 2006) than to the number of genes in the organism. 
The prevalence of proteins with more than two domains and the recurrent 
appearance of the same domain in otherwise non-homologous proteins show 
that functional domains are reused when creating new proteins. Because of this, 
domains have been likened to Lego bricks that can be recombined in various 
ways to build proteins with completely new functions (Das and Smith, 2000). 
Hence, one way to study the evolution of protein function and structure is by 
looking at the evolution of protein domain architecture. The average length of a 
protein domain is around 120 amino acids, so changes in domain architecture 
are in general underlined by large alterations at the gene level.
Good quality domain annotations of proteins are important for better 
understanding of protein evolution and function. However, they are also a 
necessary pre-requirement for studies that aim to address the evolution of 
protein domain architecture. Domain prediction methods have successfully 
applied profile hidden Markov models (HMMs) for identifying protein domains 
within amino acid sequences (Bateman et al., 2000). Nonetheless, these methods 
are still not able to successfully predict all domains in proteins and the missing 
domain assignments could assist in explaining protein function. There have been 
several attempts to improve domain annotation of proteins. For example, the 
speech recognition techniques that rely on the usage of language modelling have 
been adapted to find domains in protein sequences (Coin et al., 2003). The 
reasoning behind this approach is that certain word, or domain, combinations 
are more likely than others and hence domain detection relies on context, i.e. the 
presence of other domains in a protein (Coin et al., 2003). Similarly, information 
about the taxonomic distribution of domains has been incorporated into domain 
recognition algorithm, which also resulted in the enhanced domain recognition 
(Coin et al., 2004). The two latter approaches have been applied to increase the 
coverage of proteins with Pfam assignments. Context analysis has also been used 
to add missing domains to proteins that had a highly similar domain architecture 
and sequence similarity in the region that had an extra domain assigned to one of 
the compared proteins only (Beaussart et al., 2007). However, the latter method, 
named AIDAN, has so far been done only for proteins with more than six 
domains and domain assignments from the ProDom database (Beaussart et al., 
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2007). The ProDom database (Bru et al., 2005) uses recursive PSI-Blast search 
for domain annotation and has a lower coverage than the Pfam database.
Previous studies have been addressing the evolution of novel domain 
architectures by comparing homologues with similar domains and investigating 
positions in proteins where the changes occurred. By doing this, the authors 
were able to give predictions about the mechanisms that caused the observed 
rearrangements. Among the molecular mechanisms that can direct protein 
rearrangements are gene fusion and fission (Moore et al., 2008), exon shuffling 
through intronic recombination (Patthy, 1999), alternative gene splicing, 
introduction of novel stop codons and retroposition (Babushok et al., 2007). In 
prokaryotes, gene fusion and fission are reported to be the major drivers of 
changes in protein domain composition (Enright et al., 1999; Pasek et al., 2006). 
However, little is still known about exact mechanisms that underlie these 
changes in eukaryotes (Babushok et al., 2007; Moore et al., 2008). A study by 
Weiner et al. reported that changes in domain architecture preferentially occur 
at the protein termini, which was in agreement with previous reports (Bjorklund 
et al., 2005). In their study, Weiner et al. assumed that the frequency of domain 
deletions is much higher than the frequency of domain insertions and proposed 
that introductions of novel start and stop codons are the major causative 
mechanisms for changes in domain architectures (Weiner et al., 2006). 
A special aspect of the evolution of protein domain architectures is the 
evolution of protein domain repeats; the difference between a gain and loss of a 
single copy domain and a tandemly repeated domain in a repeat is illustrated in 
Figure 2.1. Many proteins, especially in eukaryotes, contain tandem copies of the 
same domain (Bjorklund et al., 2006). Mechanisms that have governed changes 
in the number of domain repeats are not well understood, and they are not 
necessarily the same as the ones that have directed gains and losses of single 
copy protein domains. In fact, Bjorklund et al. found that many of the repeats 
have been duplicated in the middle of the repeat region (Bjorklund et al., 2006). 
Expansion of domain repeats is important for the evolution of protein function; 
domain repeats have a variety of binding functions and proteins with them tend 
to have more interaction partners in protein-protein interaction networks than 
those without (Ekman et al., 2005). An interesting illustration for the important 
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functional role played by domain repeats is in the gene Prdm9. Mouse Prdm9
encodes a protein with a KRAB motif, a histone methyltransferase domain and 
several zinc fingers. A difference in the number of zinc finger repeats is a trait 
that distinguishes alleles which cause hybrid sterility from those that do not 
(Oliver et al., 2009). 
Apart from being reliant on the mechanisms that create them, existing 
domain combinations are also a result of selective forces that enabled them to 
remain in a population. Selective forces, which act on proteins, depend, among 
other factors, on the evolutionary pressure to preserve the original protein 
function as it was. This could be relieved when the changes in domain 
architecture follow gene duplication and one copy can freely evolve while the 
other stays intact. Furthermore, a pressure to remove a protein from a 
population also depends on how the overall protein function is affected by 
domain gain or loss. For example, whether domain loss leads to protein 
subfunctionalization or completely abolishes the original function, and similarly, 
when a domain is gained - whether the function of the gained domain is 
compatible with the function, or localization, of other domains in the ancestral 
protein. Finally, structural stability of a novel protein is also a crucial factor 
which determines whether the new domain architecture will be preserved or 
not. Interestingly, some domains are observed in a number of different domain 
combinations, and are considered to be ‘promiscuous’, whereas others occur in 
only one or a few combinations (Marcotte et al., 1999). These promiscuous 
domains are, typically, involved in protein–protein interactions, and some of 
them play important roles in signalling pathways (Basu et al., 2008). This, 
together with the fact that they show evidence of strong purifying selection 
acting on them (Basu et al., 2008), implies that these domains were able to 
become promiscuous in the first place because they had a potential to be useful 
in various contexts. 
Evolution of protein domain architectures has so far been addressed in a 
number of studies. However, there is no agreement in the field on what is the 
relative frequency of domain gain and loss events. In particular, there were 
different reports on the rate of convergent evolution of domain architectures 
(Forslund et al., 2008; Gough, 2005). Furthermore, depending on the study, 
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changes in domain architectures were interpreted predominately as a result of 
domain gains (Bjorklund et al., 2005) or of domain losses (Weiner et al., 2006). 
Similarly, different algorithms were applied to find domain gains and losses.
Some of these approaches assumed domain gain and loss to be equally likely
(Fong et al., 2007; Forslund et al., 2008; Kummerfeld and Teichmann, 2005), 
while other considered domain loss to be a more likely event than domain gain
(Basu et al., 2008; Itoh et al., 2007).
Figure 2.1 Illustration of domain gains and losses. Figure (a) illustrates gain 
of a novel domain and figure (b) loss of a domain, which was present in one copy 
in the ancestral protein. Figure (c) illustrates a domain gain, which leads to a





2.2.1 Analysis of TreeFam families
The TreeFam database provides information about phylogenetic trees of animal 
gene families. TreeFam infers orthology by fitting a gene tree into a universal 
species tree and finds historical duplication, speciation and gene loss events (Li 
et al., 2006). The database has a very good coverage of fully sequenced animal
genomes, including for example 84.5% of known human protein-coding genes. It 
consists of two parts; gene families whose trees have been manually curated, 
termed TreeFam-A, and those that have only automatically created trees, termed 
TreeFam-B. Genes in the TreeFam-A families are of better quality but are, for 
example, biased to those involved in mitotic processes. Therefore, to have a 
comprehensive view of trends in domain architecture evolution I included both 
TreeFam-A (1,305) and TreeFam-B (14,345) gene families in the analysis 
(TreeFam release 4.0). To infer relations among genes in a family, I used each 
family’s clean tree. Clean trees contain genes from 25 fully sequenced animal 
genomes, together with yeast and plant outgroups. For parsing trees, I used the 
TreeFam API (http://treesoft.sourceforge.net/). Genes in TreeFam trees are 
represented with transcripts that are most similar to other transcripts in the 
tree.
2.2.2 Assignment of domains to proteins with refinement
I assigned Pfam-A domains (release 22.0) to all protein products of TreeFam 
transcripts using the Pfam_scan.pl software. Since domains in the same Pfam 
clan are evolutionary related, I replaced domain identifiers with clan identifiers 
where applicable. Domain prediction methods can both fail to predict bona fide
domains as well as make false predictions, which look like domain losses and 
gains respectively. To address this issue, I applied a refinement process; I firstly 
removed the likely false positive fragmentary domain assignments, i.e. domains 
that were called on only a single sequence in a TreeFam family with an E-value 
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larger than 10-6 and only 30% or less of the domain’s Pfam model covered. Next, 
when some sequences lacked a domain, which was annotated to other family 
members, I used Wu-blastp to search the domain sequence against the protein 
sequences not annotated with the domain. When a significant match was found 
(E-value less than 10-4 and at least 60% of a domain sequence present, or 
alternatively an E-value less than 10-7 and 40% or more of a domain sequence 
present, or only E-value less than 10-10 and any length of the matched sequences) 
I added domain assignments to the sequences. I iterated the procedure for all 
newly assigned domains until no new domain assignments were found.
2.2.3 Domain gains and losses
To identify domain gain and loss events, I applied the maximum parsimony 
algorithm. The rationale behind the algorithm is that the evolutionary scenario 
explained with as few events as possible is the most probable one. The algorithm 
firstly infers domain composition of ancestral sequences in the trees and then 
compares the ancestral with their daughter sequences. To record the position of 
changes in proteins - i.e. N-, C-terminal or middle - I implemented the 
Needleman-Wunsch algorithm, which aligned proteins as strings of domains. 
When changes in the domain architectures could have been explained with gains 
or losses of domains at different positions, I reported the inferred gain or loss for 
each of these positions, but multiplied it with the likelihood of the scenario. For 
example, when a domain repeat at the termini expanded, I assigned the change 
as both - possible domain insertion at the termini and possible insertion in the 
middle of a protein, with the probability for each scenario depending on the 
number of domains in the ancestral repeat. 
To calculate the expected number of domain gains and losses at each 
position, I took into account the domain composition of ancestral proteins that 
experienced changes in domain architecture. I assumed that domain gain or loss 
is equally likely to occur at the N-termini, C-termini or in the middle of a protein. 
Hence, an ancestral protein with three domains is assumed to have equal 
probability of losing a domain at any position, but for an ancestral protein with 
four domains, which then has two middle domains, there is 50% probability that 
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a lost domain will be from the middle of a protein. Similarly, an ancestral protein 
with two domains is assumed to be equally likely to gain a domain at any 
position, but the ancestral protein with three domains has two positions where a 
new domain could be inserted as a middle domain and hence 50% probability 
that a domain gain will occur in the middle of a protein. The total number of 
expected changes at each position is calculated by adding the expected number 
of changes for the ancestral proteins of each length. This is obtained by 
multiplying the probability of the change at each position with a total number of 
gains or losses observed for ancestral proteins with a given number of domains. 
Positions of changes were not defined for ambiguous events where domains 
were added to ancestral sequences with no domains and where all domains from 
ancestral sequences were lost. Statistical significance of the observed trends was 
assessed with the R software.
The costs for domain gain and loss in the maximum parsimony algorithm 
are equal. However, to investigate how a starting assumption about the 
frequency of one event over another influences the ratio of reported domain gain 
and loss events, I implemented a weighted parsimony algorithm. By changing the 
relative costs of domain gain and loss events in the algorithm, one changes the 
assumption about the relative frequency of these events. I studied how the ratio 
of reported events depends on the input parameters of the algorithm. 
The approach in this study was to infer domain architectures of the 
ancestral proteins by looking at the domain composition of present day proteins. 
However, after species divergence or gene duplication, homologous proteins 
evolve at different rates and neither of them necessarily maintains the ancestral 
domain composition. Therefore, the inferred domain gain and loss events do not 
include all possible scenarios. Also, in the cases where neither of the descendants 
has a domain that was present in the ancestral protein, its domain composition 
cannot be correctly reconstructed by this approach.
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2.3 Results
2.3.1 Phlyogenetic trees can guide refinement of domain 
assignments
In order to improve the quality of domain annotations for the proteins in the 
TreeFam database, I made use of their inferred phylogenetic relations. When 
there were inconsistencies in domain assignments between the members of the 
same TreeFam family, I analysed their protein alignments and refined the initial 
domain assignments when this was justifiable. If only one member of a gene 
family had a domain annotated to it; I noted the probability with which this 
domain was assigned, and the fraction of an HMM model for the domain that was 
mapped to a motif in the sequence. If these were not significant (see Methods 
section 2.2.2), the annotation was considered as a false positive. This procedure 
detected 115 false positive domain assignments in all TreeFam proteins (listed in 
Appendix A.1). These matches were reported to the Pfam database so that their 
family thresholds could be redefined and the false positive hits removed. For all 
other inconsistencies in domain annotation, I analysed whether a domain 
assignment was falsely missing from the proteins that lacked the annotation 
present in their homologues. When sequence similarity between the aligned 
protein regions which differed in domain annotation was significant, domain 
annotations were added to the sequences missing them. To look for similarity, I 
used Wu-blastp, which is a faster procedure than using a profile-HMM. However, 
Wu-blastp does not take into account conservation of different amino acids in a 
motif and is not as sensitive as a profile-HMM. To assess its suitability for 
refinement of domain assignments I performed a test where in each TreeFam 
family I deleted Pfam domain assignments in all but one protein and then 
investigated how well these could be recovered with the refinement algorithm. 
For this, I randomly selected 100 TreeFam families and repeated the analysis 10 
times on different sets of families. I found that on average this procedure 
recovered 95% of the initial domain assignments. This is likely an overestimate 
since domains that were recovered were initially predicted and because of that, 
are potentially more significantly similar to the model and hence to each other. 
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Nevertheless, this showed that Wublastp with the criteria described in Methods 
could be used for adding erroneously missing domain assignments. At least one 
missing domain was added to 15% of all TreeFam proteins. This increased both 
sequence coverage - i.e. percentage of proteins with at least one domain assigned 
to them - by 5%, and residue coverage - i.e. percentage of all residues covered 
with Pfam domains - by 10% of the proteins. Residue and sequence coverage of 
the TreeFam proteins before and after domain refinements is shown in Table 2.1. 
Finally, TreeFam families that lacked any domain assignment are interesting 
from the point of view of identification of novel protein domains. There were 
4,445 gene families, out of total 15,656 TreeFam-A and -B families, that lacked 
any domain assignment. I reported these families to the Pfam database so that 
the shared homologues sequences in them could be used for building of new 
Pfam families. All these gene families belonged to TreeFam-B and many of them 
contained only a few protein sequences. Hence, the most interesting here are 
those families with many homologous sequences but no known domain 
assignment; 1,181 TreeFam families had ten or more genes and no domain 
annotation for any of them. 
Success in annotating domains to proteins depends on how well a model 
for each domain represents the domain and how specific it is for a particular 
domain. This is likely to be strongly influenced by the sequence content and 
length of each domain. I have looked at how the quality of domain predictions in 
TreeFam proteins depends on the length of domain models. Quality of domain 
predictions is represented with the consistency of domain assignments between 
proteins that belong to a same TreeFam-A family, i.e. between proteins that are 
with high confidence grouped together in a gene family. I have found that with 
shorter domains, there is more inconsistency in assignments of domains (Figure 
2.2). In particular, domains for which models are shorter than 50 amino acids are 
on average predicted in only half of the proteins in a phylogenetic tree. 
Inconsistency of annotations is partly due to real domain gains and losses. 
However, a strong bias for the quality of annotations to be correlated with the 
length of domain models confirms an expectation that the shorter the domain 
model is, the more difficult it is to get a significant score for the presence of the 
motif in a protein sequence. The refinement of domain annotations affected the
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consistency of annotations for domain models of all lengths, but did not 
completely resolve the issue of incorrectly missing annotations for short 
domains. Therefore, some of the inferred changes in domain architectures are 
still likely not to be true evolutionary changes, but rather related to imperfect 
domain assignments.
In conclusion, refinement of domain assignments improved the quality of 
domain annotations and allowed me to be more confident when comparing 
domain architectures of proteins in the same phylogenetic tree. Additionally, this 
showed that phylogenetic information can in general be used as a tool for 
improving domain annotations in proteins.
Table 2.1 Increase of TreeFam proteins coverage. Sequence and residue 
coverege of proteins in the TreeFam database, before and after the refinement of 
domain assignments, is shown.
Measure Before the refinement After the refinement
Sequence coverage 84% 88%
Residue coverage 42% 46%
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Figure 2.2: Average coverage of TreeFam gene families with Pfam domains 
of different lengths. Consistency of domain annotations between the members 
of the same TreeFam-A family represents the quality of domain annotations. 
Model lengths are grouped in bin categories of 25 amino acids, and all domains 
with model lengths longer than 500 amino acids are grouped together. The red 
line is showing the average coverage of TreeFam families with initial domain
assignments and the green line after the refinement of domain assignments.
A
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2.3.2 Single copy domains are predominantly gained and lost at 
protein termini
Previous comparisons of homologous proteins reported that changes in protein 
domain architectures preferentially occur at protein termini (Bjorklund et al., 
2005; Weiner et al., 2006). I investigated here whether the same bias could be 
observed by directly following the evolution of an individual protein. This 
approach, using a protein’s phylogenetic tree for the study of domain 
architecture evolution, has several advantages. Firstly, it is possible to infer the 
domain composition of an ancestral protein and hence the directionality of 
changes, i.e. distinguish domain gains from losses. Next, it is also possible to tell 
whether a change in the architecture occurred after gene duplication or after
organism speciation. Finally, if the same change occurred multiple times, it is 
possible to map these events onto the tree and count the exact number of times 
when a certain domain architecture was formed. A comparison of homologous 
proteins that differ in domain composition, without using the associated 
phylogenetic information, cannot detect the cases of convergent evolution. To 
identify domain gain and loss events, I applied the maximum parsimony 
algorithm. The assumption here is that domain gains and losses are equally likely 
to occur. Additionally, I took into account only those changes that were 
supported with two or more descendant proteins – i.e. changes that were 
reported for internal nodes in the trees. This was necessary in order to avoid the 
effect of erroneous gene annotations - which were most likely to affect individual 
proteins.
First, I investigated the trends in gains and losses of domains that are not 
present as repeats in proteins; I call these domains ‘single copy domains’ here. 
The study of changes in the number of domains in repeats is described in Section 
2.3.3. For each node in a tree where the inferred domain architecture of 
descendants differed from the inferred domain composition of an ancestral 
protein, I noted the position in the domain architecture where the change 
occurred. I separately studied changes that occurred after gene duplication from 
those that followed organism speciation. This allowed me to investigate if there 
were any differences - either due to the mechanisms or selective forces – that 
acted on proteins after these two types of evolutionary events. For each position, 
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N-, C-terminus, or middle, I also calculated the expected number of changes 
based on the expectation that a change is equally likely to occur anywhere in 
domain architecture.
I observed a strong positional bias for the changes to occur at the protein 
termini, rather than in the middle of proteins (Figure 2.3); the observed 
distribution of the number of changes at each position was significantly different 
from the expected one for all categories of events (P-value was always < 2.2x10-
16, Chi-square test, Table 2.2; 2.2x10-16 is the smallest value in R for this test).
This lent further support to reports from the previous studies (Bjorklund et al., 
2005; Weiner et al., 2006). Interestingly, the bias was present both for the 
changes classified as domain gains and those classified as losses. Similarly, the 
same pattern was present irrespective of whether the change occurred after 
gene duplication or after speciation (Figure 2.3). Different molecular 
mechanisms can underlie gains and losses of domains (Babushok et al., 2007).
Hence, it is interesting to observe that the same positional bias – for the changes 
to occur at the termini - exists when a domain is inserted into an ancestral 
protein and when it is deleted from it. On the other side, the same mechanisms 
for domain rearrangements should be available in the cell after gene duplication 
and speciation events. Hence, the observed similar patterns of positional bias for
the changes following these two types of evolutionary events were in agreement 
with expectations.
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Figure 2.3: Positions of changes in proteins. Positions in proteins where gains 
(a and b) and losses (c and d) of single copy domains have been observed after 
gene speciation (a and c) and duplication (b and d) are shown. Observed and 
expected numbers of events are presented as red and grey columns, respectively. 
Observed numbers of events were obtained by applying maximum parsimony 
algorithm. Expected numbers of gains and losses were calculated based on the 
representation of ancestral proteins as strings of domains and an assumption 
that it is equally likely to observe a gain or loss of a domain at any position in the 
string. The presented data include single copy domains only. The bias for the 




Table 2.2: Statistical significance of the observed bias in positions of 
changes. Observed and expected numbers of changes at each position is 












































P<2.2 x10-16Middle 139 380
C-terminus 370 295
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2.3.3 Gains and losses of domains in repeats
Changes in the number of domains in a repeat, i.e. of domains that exist as 
adjacent copies in a protein, can be caused by different molecular mechanisms 
compared to gains and losses of single copy domains (Bjorklund et al., 2006). For 
example, gains can occur through duplication of a region that encodes a domain 
and losses through deletion of a repetitive region during replication of genetic 
material in germ cells (Bjorklund et al., 2006). Similarly, evolutionary selection is 
likely to differently affect protein’s evolution after the change in the number of 
domains in a repeat and after the gain or loss of a single copy protein domain. 
For example, duplication of an already existing domain can result in functional 
redundancy, but insertion of a new domain can cause a conflict in protein 
function. Similarly, repeating domains are often short – such as the leucine rich 
repeat family or C2H2 zinc fingers (Bjorklund et al., 2006) and hence, a change in 
the number of these domains is less likely to cause a larger structural 
disturbance. Therefore, the evolution of domain repeats has previously been 
studied separately (Bjorklund et al., 2006), and I also addressed it as a separate 
problem in this work. 
The evolution of domain repeats is more complex to study than the 
changes in the overall domain composition of a protein. Firstly, many domains 
that occur in repeats are short and therefore are more likely to be omitted in the 
annotation process (see section 2.3.1). As a result of this, one needs to be more 
careful when interpreting the inferred changes. Secondly, analysis of the 
evolutionary trends is not as direct as in the case of domains that exist in one 
copy only. For instance, when a domain is deleted from a repeat - just by looking 
at the domain architectures - it is not always possible to say which domain from 
an ancestral protein is missing (Figure 2.1). Similarly, when a new domain is 
added to a domain repeat, it is not always possible to distinguish this domain 
from the domains that were present in the ancestral protein (Figure 2.1). I took 
this into account when assigning positions of changes, and treated each possible 
event as equally likely. As a consequence of this, it was more difficult to detect 
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trends that defined evolution of domain repeats than those that directed gains 
and losses of individual domains. 
The analysis of positions at which changes in the number of domain 
repeats were inferred did not reveal as strong a bias for the protein termini as 
was observed for gains and losses of single copy domains (Figure 2.4). In strong 
contrast with the pattern for single copy domains, in one instance – for domain 
gains after gene duplications – the number of observed events at the N-terminus 
was lower than expected (Figure 2.4 b). However, divergence from the expected 
distribution, which was calculated from the assumption that all positions were 
equally likely, was still statistically significant (Table 2.3). Bjorklund et al.
previously reported that the gain of new domains in a repeat frequently occurs 
through duplication of internal domains (Bjorklund et al., 2006). Therefore, it 
was expected that the distribution of positions of domain gains and losses would 
differ from the one for single copy domains. However, the bias for the termini is 
still present here. This implies that a combination of molecular mechanisms and 
evolutionary forces that influence both single copy domains and domain repeats, 
together with the ones specific for domains in repeats, could be at play here. 
However, it is important to note that averaging over all possible events, that 
were able to explain the observed changes, possibly camouflaged less strong 
trends in the evolution of domain repeats. 
Again, a distribution of the positions of changes was similar both for the 
inferred domain gains and losses, and also between the changes that were 
observed after gene duplication and organism speciation events (Figure 2.4). 
This shows that when a domain is gained or lost from a protein, the strongest 
factor that influences positional preference of this event is the fact whether a 
domain is a part of a repeat or whether it exists as a single copy in a protein. In 
the case of a single copy domain there will be a very strong preference for the 
change not to occur in the middle of a protein. If a domain is in a repeat, this 
pressure will be less strong. The pressure for positional preference seems to be 
less dependent on whether the change in the architecture is a domain gain or 
loss, or whether the change occurred after gene duplication or after speciation.
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Figure 2.4: Positions of gains and losses of domains in repeats. Positions in 
proteins where gains (a and b) and losses (c and d) of domains in repeats have 
been observed after gene speciation (a and c) and duplication (b and d). 
Observed and expected numbers of events are presented as red and grey 
columns, respectively. Observed numbers of events were obtained by applying 
the maximum parsimony algorithm. When a position of a change was ambiguous 
all possible scenarios were taken into account and the number of changes was 
weighted with the probability of each event. Expected numbers of gains and 
losses were calculated based on the representation of ancestral proteins as 
strings of domains and an assumption that it is equally likely to observe a gain or 
loss of a domain at any position in the string. There is still bias for the changes to 





Table 2.3: Comparison between distributions of observed and expected 
number of domain gains and losses at each position in a protein for the 
changes in the number of domains in repeats. Observed and expected 
number of changes at each position is indicated. P-value for the comparison 











































P<2.2 x10-16Middle 421 549
C-terminus 205 113
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2.3.4 Changes in domain architectures preferentially occur after 
gene duplications
The evolution of domain architectures does not necessarily need to follow the 
same pattern after gene duplication and after organism speciation. This is why I 
separately investigated domain gains and losses that occurred after these 
evolutionary events. As discussed in sections 2.3.2 and 2.3.3, there was no 
significant difference in the positional preference between the changes that 
followed gene duplications and those that followed organism speciation. 
However, the total number of gene duplication events, or duplication nodes in 
the TreeFam trees, is smaller then the total number of speciation events/nodes, 
and the number of observed changes was higher after gene duplications (Figures 
2.3 and 2.4). Therefore, I compared the frequency of changes after gene 
duplication and speciation events (Table 2.4). On average, change in the overall 
domain composition, i.e. gain or loss of a single copy domain, is observed after 87 
speciation events but almost twice as frequently after gene duplications; on 
average once in 43 gene duplication events. Similarly, a change in the number of 
domains in a repeat occurs on average after 128 speciation events, in 
comparison to after on average 67 gene duplication events; again almost two 
times more frequently after gene duplications. 
As an additional test, I compared the branch lengths in TreeFam trees 
before gene duplication and speciation events for which the changes were 
inferred. This again showed that the average branch length, or the average time 
span, before a domain was gained or lost from a protein was about twice as long 
for speciation compared to gene duplication, irrespective of whether the domain 
existed as a single copy domain in a protein or was a part of domain repeat 
(Table 2.4).  The branch lengths are based on the similarity of proteins and hence 
are influenced by the presence or absence of a protein domain. Therefore, this 
only gives an indication of the evolutionary time that passed before a domain
was gained or lost. Nonetheless, both means for calculating the frequency of 
changes in domain architectures showed that there was a bias for the changes to 
preferentially occur after gene duplications. Table 2.4 shows the total number of 
internal nodes and a sum of branch lengths in all TreeFam trees that I used in 
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calculations. The total number of inferred changes of domain architecture for 
gene duplication and speciation events was calculated from the data in Tables 
2.2 and 2.3.
Table 2.4: Changes in domain architecture occur more frequently after 
gene duplications then after organism speciation. Frequency of the change is 
stated as an average number of events for which the change is observed and as 










length before all 
events of this 
type
Average number of 
events for which 
the change is 
observed
Average branch 





Speciation 269478 34342.29 87 11.14
Gene 
duplication
99106 13526.49 43 5.93
Domain in 
repeat
Speciation 269478 34342.29 128 16.25
Gene 
duplication
99106 13526.49 67 9.12
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2.3.5 Effect of domain gains on the evolution of protein function 
Gains and losses of protein domains are likely to strongly influence the overall 
protein function. If having a protein with new domain architecture is 
disadvantageous for the organism, the protein will probably be removed from 
the population. Therefore, domains that are observed as frequently gained have 
likely conferred functional advantage to proteins, which they were inserted in. 
The most often gained domains from this study are listed in Table 2.5. The table 
includes only domains gained on the internal nodes of the TreeFam trees. All 
these domains belong to one of the following functional categories: extracellular 
processes, regulation through signal transduction or regulation through DNA 
binding. Hence, those domains that act as modifiers of the overall function, 
rather than domains with a specific function, are more likely to combine with 
other protein domains and be useful in different cellular contexts.  Domains with 
extracellular function are the EGF (epidermal growth factor) superfamily, the 
immunoglobulin domain and the CUB (complement protein subcomponents 
C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1) 
domain, and those that act as signal transducers are zinc finger (C2H2 type), 
leucine-rich repeat, SH3 (Src homology 3) domain, the PH (pleckstrin homology) 
domain and RING (really interesting new gene)-finger superfamily.
Additionally, functional compatibility between a gained domain and 
domains present in the ancestral protein also decides on whether the new 
protein will be useful to a cell. I used a method for comparing GO terms 
(Schlicker et al., 2006), which were projected to Pfam domains, to estimate 
functional similarity between gained and ancestral domains. The score for the 
similarity measure, funSim, that I used here ranges from 0 to 1 with a score close 
to 1 corresponding to GO terms with highly similar function and those below 0.3 
to GO terms that are not functionally related. I found that only 454 internal 
domain gain events were applicable for this analysis, meaning they had both 
gained and ancestral domains annotated with GO terms and funSim scores 
available for the annotated terms. Interestingly, only 18% of the gained domains 
were not functionally similar (funSim < 0.4) to any domain in the ancestral 
protein (81 out of 454 events). The other gained domains were reported to be 
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functionally related to at least one domain in the ancestral protein, and 39% of 
the gained domains (176 out of 454 events) highly similar to a domain in the 
ancestral sequence (funSim > 0.8). This implies that domain gain usually does not 
radically change the protein function, but only adapts it to new contexts. 
Table 2.5: Most frequently gained domains in animal phylogenetic trees. 
Pfam IDs, domain/clan descriptions and associated functional categories of 
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85 PF00096 Zinc finger, C2H2 type
Regulation: DNA-
binding 
76 CL0011 Immunoglobulun superfamily
Extra cellular 
processes
66 CL0164 CUB domain Extracellular 
processes















2.3.6 Estimate of domain gain and loss events strongly depends 
on the input parameters
Domain gain and loss events that I discussed in the sections 2.3.2 – 2.3.5 are 
inferred from the assumption that gains and losses are equally likely and that 
differences in domain architectures of related genes can be explained with as few 
changes as possible. However, there is no general consensus on what the relative 
frequencies of these events are. Different studies have used different values for 
the frequencies of domain gain and loss events and applied maximum, weighted 
or Dollo parsimony to infer changes in domain architectures (Basu et al., 2008; 
Fong et al., 2007; Itoh et al., 2007). In this section, I investigate how much the 
estimate of the likelihood of these events influences whether the present domain 
architectures are explained by ancestral gain or loss events. For this, I applied a 
weighted parsimony algorithm. By changing the costs, or weights, for domain 
gain and loss, I was able to change the assumptions about the frequency of these 
events. I found that the total number of inferred gain or loss events was strongly 
influenced by the initial estimates of their frequency (Figure 2.5). Again, to avoid 
the effect of erroneous gene annotations, I included in the analysis only changes 
observed on the internal nodes in the trees. The ratio of reported gains over 
losses (Figure 2.5b) - and the ratio of reported losses over gains (Figure 2.5a) -
exponentially increased as the assumed probability for the ratio of events
linearly increased. Figure 2.5c shows a logarithmic representation of these 
values. The expected, or assumed, ratio of observed changes is indicated by a red 
line and the observed, i.e. inferred, one by blue dots. The assumed probabilities 
of gain and loss events determined the observed ratios to a higher degree then 
expected.
These calculations showed that inferred evolutionary scenarios are 
strongly influenced with their initially estimated likelihoods. When the input 
parameters for the cost of domain gain and loss are equal, the observed number 
of domain gains and losses is also about the same. This is the scenario, which is 
applied in the maximum parsimony algorithm. Hence, this stresses that one 
should be careful when interpreting observed gains and losses in these kinds of 
studies. Furthermore, it shows that in order to obtain a confident set of gain or 
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loss events one needs to be very careful about the algorithm and parameters 
used. 
      
Figure 2.5: The ratio of inferred domain gain and loss events strongly 
depends on the assumed cost of these events. (a) The ratio of inferred domain 
loss and gain events exponentionally depends on the ratio of increasing assumed 
cost for domain gain and loss event. The higher the cost of an event, the smaller 
is the likelyhood of observing the event. (b) Similarly to (a), increasing the cost of 
domain loss results in an exponentional increase of the inferred ratio of domain 
gain and loss events. (c) Logarithmic representation of the data on graphs (a) 
and (b). The red dotted line reprents the logarithm of the expected ratio of 
domain loss and gain events as assumed by the weights for these events. Blue 
data points show the log values of the inferred ratio of these events. The 





2.4.1 Confidence in the comparison of domain architectures
The aim of the research described in this chapter was to investigate the general 
trends in the evolution of protein domain architectures. For annotation of 
proteins with domains and families, I used Pfam-A protein families. Pfam-A 
release 22, that I used here, had nearly 10,000 protein families. This ensured 
much better coverage of proteins with domain assignments than it would have 
been possible if, for example, structural domain annotations had been used. 
Additionally, Pfam-A domains are of very good quality and provide literature 
references for the domains. Hence, after domain gain or loss event, it is often 
possible to analyse consequences of the event on the overall protein function. 
Inclusion of Pfam-B families in the study would have further increased the 
protein coverage with domain assignments and, because of that; a greater 
number of changes in protein domain architectures would have been detected.
However, Pfam-B families are in general of lower quality than Pfam-A families, 
and those composed of low complexity regions may not even reflect true 
evolutionary relationships. Therefore, to increase the confidence of observed 
domain gains and losses, I included only Pfam-A families in the study.  
Apart from reflecting true changes in domain architectures, apparent 
changes of domain composition can also be a result of incomplete domain 
annotations or erroneous gene assignments. To overcome these issues, I 
adjusted the procedure for identifying domain gains and losses. When the 
inconsistency of domain assignments in a TreeFam family was not justified with 
significant differences on the protein sequence level, I added domains to the 
family members that initially lacked them. Additionally, I excluded from the 
analysis the cases where changes in protein domain composition were not 
supported by at least two descendant proteins. The main reason for doing this 
was to avoid the effects of incomplete gene annotations. Both refinement steps 
were done in order to obtain a set of inferred domain gain and loss events 
enriched in the events that describe real changes of domain architectures. 
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Alternatively, apparent differences in domain composition can also assist 
gene and domain annotation methods. For example, when domain assignments 
of a single protein in a phylogenetic tree differ from the ones of its homologues, 
this might be also because not all of the exons are predicted for this gene. In 
particular, genes from the genomes with lower quality annotations, which lack 
domain assignments, could be the candidates for an assessment and refinement 
of their gene boundaries. Additionally, as described in the section 2.3.1, 
phylogenetic trees can be used as a tool to guide the refinement of imperfect 
initial domain annotations. The approach that I applied here is similar to 
previously described context analyses, in a sense that in order to improve 
protein annotations, it uses the information about domains present in related 
proteins. Additionally, this approach, for the first time, utilizes phylogenetic 
relations among proteins as an incentive for examining similarity in the protein 
regions with inconsistent domain assignments.
The increase of TreeFam coverage that this resulted in (Table 2.1) shows 
that this approach can in general be used to assist protein annotation.  
2.4.2 Molecular mechanisms and evolutionary selection shape 
the evolution of domain architectures
I have investigated here several aspects of protein domain architecture 
evolution, including positions of changes in proteins, their frequency after gene 
duplication and speciation events, and function of the most frequently gained 
domains. Characteristics of the present domain architectures reflect the 
interplay of molecular mechanisms and evolutionary selection that shaped their 
evolution. One of the crucial observations from previous work on protein 
evolution, which came from the comparison of homologous proteins, was that 
changes in domain architecture preferentially occur at the N- and C- termini 
(Bjorklund et al., 2005; Weiner et al., 2006). Weiner et al. described this 
observation with the fact that the dominating mechanisms that caused the 
changes are those that acted at protein termini. Hence, they proposed that the 
evolution of novel proteins was mainly defined with gene fusion and fission 
events and in particular, insertions of new start and stop codons. Here, by using 
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gene phylogenies, I was able to distinguish between inferred domain gain and 
loss events. Interestingly, even though there are molecular mechanisms that 
result only in domain gains or only in domain losses, both categories of events 
showed strong bias towards protein termini, particularly in the case of gains and 
losses of single copy domains. Therefore, the observed distribution of changes is 
better explained with the interplay of both: mechanisms that acted to add or 
remove domains at the protein termini, as well as evolutionary selection that 
disfavoured domain gains and losses within a protein (Figure 2.6a). Protein 
termini are normally charged, flexible and found at protein surface (Figure 2.6b), 
so it is easy to imagine that additions or deletions of domains there are less likely 
to disrupt the rest of the structure, especially if the concerned domains are 
independent structural units. On the other hand, connector regions between 
domains direct the contact and interaction of domains they link together. Hence, 
even if those regions themselves are unstructured and do not have a functional 
role; it is still more likely that changes there will disrupt the rest of the structure. 
Because of this, evolutionary selection is likely to strongly favour changes at the 
termini over the changes in the middle of proteins. Since I compared here only 
the overall domain architectures, I could not directly infer the positions of 
insertion and deletion of domains in repeats. Additionally, changes in the 
number of domains in repeats are particularly difficult to study in general. Many 
domains in repeats are short and therefore their assignments to proteins are 
often not of high confidence (Figure 2.2). Therefore, the inferred gains and losses 
of repeated domains in this study are of lower confidence than those of single 
copy domains. To overcome the issue of omitted domain assignments, one 
possibility is to lower the threshold for assignment of domains in repeats 
(Bjorklund et al., 2005). However, this again increases the chance of false 
positive domain annotations. 
The observed trends in the evolution of domain repeats imply that the 
positional bias is not as strong as it is for insertions and deletions of single copy 
domains. It is possible that additional mechanisms, which do not have a 
positional preference, such as duplication and deletion of sequence repeats after 
misalignment of homologous alleles (Bjorklund et al., 2006), play an important 
role in their evolution and hence influence the overall pattern of changes. 
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Nonetheless, even domain repeats with changes at the termini possibly have a 
smaller effect on the structural stability and hence a higher chance to go through 
evolutionary selection. The combination of acting mechanisms and evolutionary 
selection drives both changes in single copy domains and changes in the number 
of domains in repeats. 
Figure 2.6: The evolution of domain architectures is determined by 
molecular mechanisms that cause the changes as well as subsequent 
selection. (a) Different molecular mechanisms can cause changes in domain 
architecture, but only some of the created architectures survive the subsequent 
evolutionary selection. Red and green dots represent mutated proteins in 
different individuals. After evolutionary selection only a mutation shown as a 
green dot became fixed in a population. (b) Protein’s structural stability can have 
a strong influence on the selection of novel domain architecture. The charged 
termini are usually found on the protein’s surface and changes at the surface are 
less likely to severely disrupt the overall structure. This is illustrated with a 
structure of the anti-apoptotic Bcl-2 protein.
TreeFam phylogenies distinguish between gene duplication and organism 
speciation events. Comparison of the positions of changes, which followed these 
two types of evolutionary events, did not show a difference in trends. This 
implies that the same basic mechanisms and evolutionary forces influenced 
emergence of new domain architectures and drove evolution of an individual 
protein both after gene duplication and after speciation. However, the frequency 
with which the changes are observed is nearly two fold greater after gene 
duplications (Table 2.4). This suggests that an important difference between the 
(a) (b)
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two types of events is played by evolutionary selection, which is more 
permissive towards changes in proteins when the original gene exists in two 
copies and the introduced changes do not imply complete loss of the ancestral 
function (Zhang, 2003).
Domains that were most frequently gained during animal gene evolution 
either have a role in extracellular processes or in cell regulation - such as signal 
transduction or DNA binding (Table 2.5). Interestingly, Vogel and Chothia (Vogel 
and Chothia, 2006) reported previously that the number of genes in an organism 
with these same domains (apart from the leucine-rich repeat protein family) is in 
a strong correlation with organism complexity. In accordance with this, they 
have suggested that these domains were responsible for the emergence of new 
complex traits in metazoans. Vogel and Chothia (Vogel and Chothia, 2006) have 
assigned the expansion of these domains primarily to duplications of the genes 
that already contained them. However, this study implies that insertion of these 
domains into genes that have not previously coded for them has also contributed 
to their expansion. Hence, not only duplication of these domains, but their 
combination with other domains could have played a role in the evolution of 
novel, animal specific, traits. Additionally, when functional annotation of both 
ancestral and gained domains was available, the study showed that in the 
majority of the cases the gained domain was of the similar function as the 
ancestral domains. This is in agreement with previous studies that showed that 
gene fusion usually occurs between genes of similar function (Yanai et al., 2001)
and once again underlies the role of evolutionary selection, which over time 
eliminates from the population domain combinations that are not likely to confer 
an advantage to the organism.
In conclusion, protein evolution is evident at different scales of events. On 
the small scale, single amino acids are mutated, and, on the large scale, whole 
domains are lost or gained in the protein. The observed changes are primarily 
defined with the molecular mechanisms that cause the mutations. However, 
selective constraints imposed by the necessity for structural stability and for the 
functional protein product also play a crucial role in protein evolution. Of course, 
a protein’s function and evolution is defined not only by its sequence, but also by 
its genomic position, expression pattern, and partners in its interaction network 
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and a systematic approach is needed to fully understand the evolutionary path of 
an individual protein (Pal et al., 2006). 
2.4.3 Set of confident domain gain or loss events
Novel domain architectures are the result of a joint action of mechanisms that 
created them and subsequent evolutionary selection. Hence, the observation that 
changes preferentially occur at the termini also implies that molecular 
mechanisms that act at protein termini are the ones that play the most important 
role in protein evolution. However, to draw concrete conclusions about the 
relative contributions of different mechanisms it is important to firstly obtain a 
set of confident domain gain or loss events. In the section 2.3.6, I have showed 
that inference of domain gains and losses is strongly influenced by the applied 
algorithm and assumed probability of these events. Therefore, even though 
inference of domain gains and losses by the maximum parsimony algorithm 
gives an indication of general trends in the evolution of protein domain 
composition, it does not provide a high enough quality set of events for the 
further investigation of the causative mechanisms. In Chapter 3, I am discussing 
the approach that I applied to obtain such a confident set of domain gains and 
the analyses I performed to investigate evidence for the action of each possible 
mechanism. I focus the study on domain gains and the evolution of more 
complex domain architectures. As indicated also here by the character of the 
most frequently gained domains (Table 2.5), the addition of novel domains to 
proteins likely played a crucial role in the evolution of complex animal traits. 
However, domain losses also change the function of the resulting protein 
products and protein evolution through domain loss could be an important 
mechanism for subfunctionalization of proteins.
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Mechanisms of domain gain in 
animal proteins
3.1 Introduction
In the previous chapter, I discussed general trends in the evolution of animal 
protein domain architectures. However, I also showed there that reported 
domain gain and loss events strongly depend on their initially assumed relative 
frequencies. Hence, to be able to investigate signatures of the causative 
mechanisms for these changes it is necessary first to compose a set of clear, 
confident events. The creation of more complex domain architectures is crucial 
for the evolution of complexity in animals and this chapter focuses on the 
mechanisms for insertion of novel domains into ancestral proteins. Novel 
domain combinations are a basis for the invention of original protein functions 
and lay at the heart of evolution of species-specific traits (Kawashima et al., 
2009). 
Eukaryotic domain architectures are far more complex than prokaryotic 
ones, and it is believed that the underlying reason for this is a greater choice of 
mechanisms that can create novel domain combinations (Chothia et al., 2003). 
The main eukaryote-specific mechanisms are intronic recombination, joining of 
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adjacent genes’ exons preceded by intergenic splicing and retroposition. I will 
first introduce here the concept of ‘exon shuffling through intronic 
recombination’, which was widely discussed as a powerful means for evolution 
of novel domain architectures, and then elaborate further on other mechanisms 
that are assumed to be active in eukaryotic genomes and are able to cause 
domain gain.
It has been recognized for a long time that intronic sequences can 
mediate gene recombination and thereby cause exon shuffling (Gilbert, 1978). 
Intronic recombination can either join the termini of two different genes or 
insert novel exons into ancestral introns. To date, specific examples in animals 
have been reported for domain gains through exon insertions into introns and a 
term ‘domain shuffling through intronic recombination’ was devised to describe 
this phenomenon (Patthy, 1996). The extracellular function of the inserted 
domains indicates the importance of this mechanism for the evolution of 
multicellular organisms. Additionally, more recent whole-genome studies of 
domain shuffling have also focused on domains that are candidates for exon 
insertions into introns, for example; domains that are surrounded by introns of 
symmetrical phases (Kaessmann et al., 2002; Liu and Grigoriev, 2004; Long et al., 
1995). Phase of an intron is defined by the break point in the codon next to the 
intron. For example, if an intron is placed after the first nucleotide in the codon, 
it is phase 1 intron. Analogously, if it is placed after the second nucleotide, it is 
phase 2, and if it is placed after all three nucleotides in the codon, it is phase 0 
(Figure 3.1). When a new exon is inserted into an ancestral intron, it needs to be 
surrounded by introns of symmetrical phases for it to be translated in frame and 
not to disrupt the translation of the downstream sequence. The studies that 
found an excess of domains surrounded by symmetrical introns in the genomes 
of higher eukaryotes suggested that domain insertions into introns have had an 
important role in the evolution of eukaryotic proteomes. It is noteworthy that 
even though initial studies attributed intronic insertions solely to intronic 
recombination, authors of the more recent studies have also acknowledged the 
potential role of retroposition (which is described below) in this process.
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The question of what mechanisms underlie domain gains is related to the 
question of what mechanisms underlie novel gene creation (Babushok et al., 
2007b), (Arguello et al., 2007; Long et al., 2003). The recent increased 
availability of animal genome and transcriptome sequences offers a valuable 
resource for addressing these questions. The main genetic mechanisms that are 
capable of creating novel genes and also causing domain gain in animals are 
retroposition, gene fusion through joining of exons from adjacent genes, and 
DNA recombination (Arguello et al., 2007; Babushok et al., 2007b; Long et al., 
2003) (Figure 3.2). Since these mechanisms can leave specific traces in the 
genome, it may be possible to infer the causative mechanism by inspecting the 
DNA sequence that encodes the gained domain. By using the retrotransposon 
machinery, in a process termed retroposition, a native coding sequence can be 
copied and inserted somewhere else in the genome. The copy is made from a 
processed mRNA, so sequences gained by this mechanism are usually intronless 
and have an origin in the same genome. This was proposed as a powerful means 
for domain shuffling, but the evidence for its action is still limited (Babushok et 
al., 2007a; Zhou et al., 2008). Recent studies observed a phenomenon where 
adjacent genes, or nearby genes on the same strand undergo intergenic splicing 
and create chimerical transcripts (Akiva et al., 2006; Magrangeas et al., 1998; 
Figure 3.1. Illustration of intron phases. Phase of an intron is defined by the 
breakpoint in the codon adjacent to the intron.
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Parra et al., 2006). This suggested that if promoter and terminator sequences 
between the two genes were degraded during evolution then exons of the genes 
could be joined not only on the transcript level, but also as a novel chimeric gene. 
As a consequence of this, one would observe a gain of novel exon(s) at the 
protein termini. One example for this mechanism is the creation of the human 
gene Kua-UEV (Thomson et al., 2000). Recombination can aid novel gene 
creation by juxtaposing new gene combinations, thereby assisting exons from 
adjacent genes to combine. When recombination occurs between intronic 
sequences of two genes and joins the genes by creating a novel chimerical intron, 
then joining of exons from the adjacent genes is in concordance with the theory 
of exon shuffling through intronic recombination. Alternatively, recombination 
could occur between exonic sequences of two different genes (Patthy, 2008). The 
two main types of recombination are non-allelic homologous recombination 
(NAHR) (Arguello et al., 2007; Turner et al., 2008), which relies on short regions 
of homology, and illegitimate recombination (IR) – also known as non-
homologous end joining (Arguello et al., 2007; Long et al., 2003; van Rijk and 
Bloemendal, 2003). IR does not require homology regions for its action, but 
instead can join DNA breaks with no similarity at all, or with similarity of only 
several nucleotides. In addition to these mechanisms, a new protein coding 
sequence can be gained through (i) deletion of the intervening sequence
between two adjacent genes and subsequent exon fusion (Nurminsky et al., 
1998); (ii) by exonisation of previously non-coding sequence (Zhang and Chasin, 
2006); (iii) through insertion of viral or transposon sequences into a gene 
(Cordaux et al., 2006). Interestingly, direct examples for any of these 
mechanisms are still rare (Babushok et al., 2007a; Thomson et al., 2000).
In this chapter, I will first describe a procedure that I applied for 
identification of a set of confident domain gain events and the control steps I 
implemented to ensure that the reported gain events are not due to gene 
annotation errors or method bias. Next, I will describe the results of the analysis 
of the sequences that encode these domains. The study of signatures of possible 
causative mechanisms for these domain gains suggested that gene fusion 
through joining of exons from adjacent genes has been a dominant process 
leading to gains of new domains. Two other mechanisms that have been 
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proposed as important mediators for gains of new domains in animals -
retroposition and ‘exon shuffling through intronic recombination’ - appear to be 
minor contributors. In concordance with the results in Chapter 2, I observe here 
that gene duplications play an important role in domain gains. Finally, several 
lines of evidence suggest that these domain gain events were assisted by DNA 
recombination, and trends in these gain events point to NAHR as a possible 
acting mechanism. 
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Figure 3.2: Summary of mechanisms for domain gains. This figure shows 
mechanisms that can lead to domain gains and the signals that can be used to 
detect the causative mechanism. Domain gain by retroposition is illustrated as 
an example where the domain is transcribed together with the upstream long 
interspersed nuclear element (LINE), but other means of retroposition are also 
possible (Babushok et al., 2007b). The list of possible mechanisms is not 
exhaustive and other scenarios can occur, as, for example, exonisation of 




3.2.1 Assignment of domains to proteins with refinement
Pfam domains (release 23.0) were assigned to all protein products of genes in 
the TreeFam database (release 6.0) using the Pfam_scan.pl software. The same 
procedure for refinement of domain assignments that is described in Chapter 2 
was applied here; domain identifiers were replaced with clan identifiers, false 
domain assignments were removed and missing domain assignments were 
added to proteins. Methodological details of this are explained in Chapter 2.2.2.
3.2.2 Exclusion of possible false domain gain calls
Domain refinements described above added Pfam domains to proteins that 
shared significant similarity with annotated domain sequences but were not 
recognized by searching with the Pfam HMM library. However, apart from these 
clear cases of a lack of domain annotation, there are also cases where proteins 
share only moderate similarity with domain sequences and it is difficult to say 
whether a domain should be annotated to these proteins as well. To be able to 
do this analysis, a set of confident domain gains was crucial. Hence, in order to 
avoid false calls of domain gains, domain gain events where sequences in the 
same gene family shared a similarity with the gained domain but were not 
annotated with that domain were excluded. This included all gain events where a 
domain sequence had 16% or more identical amino acids aligned to any 
sequence in the same TreeFam family that lacked the gained domain. This 
threshold was justified by distribution of fractions of identical amino acids in the 
initially reported domain gain events (Appendix B.1). This is in agreement with 
the expectation that initially reported domain gain events are a mixture of true 
gain events and false calls caused by errors in domain annotations. A 16% 
sequence identity was noted as a threshold that apparently separated the 
majority of these events. This filtering step further reduced the chances of
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erroneously calling domain gains due to a lack of sensitivity of some Pfam HMM 
models.
3.2.3 Parsing trees
To identify the branch points in the phylogenetic trees at which new domains 
were gained the TreeFam API (Ruan et al., 2008) was used. In TreeFam families 
each gene is represented with a single transcript. However, to be able to claim 
that a gene has gained a domain it was necessary to take into account protein 
domains present in all splice variants of the genes in the TreeFam families. The 
weighted parsimony algorithm (Sankoff et al., 1982) was applied on the 
TreeFam phylogenies, with the cost for a domain gain of 2 and the cost for a 
domain loss of 1. Because gains are more costly, the ones that are reported are 
more likely to be correct. However, only those reported gain events that 
occurred once in a tree - which is the rationale of the Dollo parsimony (Farris, 
1977) – were taken into account. This condition removed from the set instances 
where domain gains were inferred several times in a gene family, and where 
multiple domain losses could have also explained the differences in domain 
architectures of present proteins. This method was applied to the 17,050 
TreeFam clean trees, i.e. trees containing genes from completely sequenced 
animal genomes. Events that were in concordance with both algorithms were 
considered as likely gain events – these included 4362 gained domains.
Gain events that appeared on the leaf nodes of the trees, i.e., which had 
only one sequence with the gained domain, were excluded from further analysis. 
When a domain gain is not supported by at least two proteins, the gain is less 
reliable because it could also be a consequence of an incorrect gene annotation 
process. This left 1372 domains gained on internal nodes of the tree. Next, one 
representative transcript for each gain event was chosen. The approach for 
choosing the representative transcript was the following: the transcript had to 
be the one present in the TreeFam tree, a representative transcript had to have a 
gained domain predicted initially by the Pfam software and finally, the 
representative transcript had to belong to one of the following species: 
Drosophila melanogaster (fruit fly), Xenopus tropicalis (frog), Danio rerio
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(zebrafish), Gallus Gallus (chicken), Mus musculus (mouse), Rattus norvegicus
(rat) or Homo sapiens (human). Thus, the study included the major animal model 
organisms. The advantage of this is that a majority of these organisms have 
genomes of better quality; an exception being chicken and rat genomes. There 
were 653 gained domains that had representative transcripts which fulfilled all 
conditions. Since each representative sequence was chosen from a descendant 
with the genome of best quality, for all gains in the human lineage the 
representative sequence was a human transcript (protein). Exclusion of leaf 
gains and selection of representative transcripts from better quality genomes 
were necessary to ensure that the reported gain events were not due to gene 
annotation errors. Next, all instances where a sequence from the same family 
that lacked the gained domain was found to have diagnostic motifs for that 
domain, as recognized by profile comparer (Madera, 2008), were excluded, as 
well as the instances where a sequence without domain annotation had an 
amino acid stretch similar to one in the gained domain (16% or more identical 
amino acids, explained above). This left us with 378 gained domains in the set. 
Some of these domains appeared to be gained as a result of the same event that 
extended the ancestral gene, so the total number of domain gain events was 349. 
Finally, the following cases were also excluded from the analysis: the gain events 
for which a representative transcript was no longer in the Ensembl database, 
release 50 (3 cases), events for which protein sequence alignment downloaded 
from the TreeFam database did not clearly support domain gain (13 cases) and 
the cases that were later found to be most likely consequences of inconsistencies 
in gene annotation (3 cases). The final set had a total of 330 high confidence 
domain gain events (Appendix B.2). Still, sometimes the same gene has 
experienced more then one domain gain, and a total number of representative 
sequences for the 330 domain gains was 322 (Appendix B.2).
To investigate whether the set of high-confidence domain gains 
discriminates against any mechanism because of a small number of events, a set 
of medium confidence domain gain events was created. For this, the same initial 
set of reported gain events was taken and the applied condition was that each 
gain had to occur in at least one genome of better quality. Other filtering steps 
were omitted. Hence, gains on the leaf nodes, as well similarity of the ‘gained 
89
domain’ with sequences in the same family that were not annotated with that 
domain were allowed. Consequently, this also increased the rate of false calls of 
domain gains. There were 849 gained domains in the set of medium confidence 
domain gain events. The flow of the procedures for obtaining of the high and 
medium confidence sets of gain events is illustrated in Figure 3.3 and the flow of 
the procedures for the analysis of these gains in Figure 3.4.
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Figure 3.3: Flowchart of methods for obtaining sets of high and medium 
confidence domain gain. The numbers of gained domains I was left with after 
each filtering step are noted. In some cases more domains were gained at the 
same time; hence the number of gain events that we looked at for the high 
confidence domain gains differs from the number of gained domains.
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3.2.4 Intron-exon structures of genes
The TreeFam table Map with gene structures was used to project the intron-
exon boundaries and intron phases on the representative protein sequences for 
each domain gain event. The goal of the analysis was to investigate the type of 
changes that occurred on the gene level when a domain was gained; in particular 
whether a domain gain was the result of a gain of a new exon or extension of an 
already existing exon. To infer this, protein sequence alignments for each 
TreeFam family with a gained domain were downloaded from the TreeFam 
website. In order to establish whether the gained protein domain was part of a 
completely new exon or an extension of a pre-existing exon, the similarity in 
regions close to the exon boundaries was examined. If the region in the same 
exon close to the exon border shared partial similarity with an exon from the 
protein in the same family that lacked the domain, a domain gain was considered 
to be the result of an exon extension. The criterion for similarity was that the 
first or last third of the sequence outside of the domain – adjacent to the exon 
border - had 30% or more identical residues to one of the sequences without the 
inserted domain. It was required that this ’boundary’ region was at least seven 
amino acids long. However, because of this criterion that only a short stretch of 
sequence similarity is enough to claim that a gained domain is coded by an 
extended ancestral exon, the number of extended exons is likely to be an 
overestimate. 
3.2.5 Positions of gained domains
When a new domain was coded by the first or last coding exon the gain was 
called an N- or C-terminal gain, respectively. In addition, when an inserted 
domain was not coded by the terminal exons, it was checked whether additional 
exons towards the termini were gained together with the ones coding for the 
gained domain. If there was no significant similarity between these exons and 
the ones in the sequences without the gained domain, the exons were called 
novel and the gain still called terminal. Conditions for calling an exon as novel 
were the following: 85% or more novel amino acids in an exon (i.e. residues 
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unaligned with amino acids in the sequences without the domain), or less then 
10% identity with any of the sequences without the domain. For short exons 
coding for 20 amino acids or less, the requirement was changed to less than 40% 
identity. All other domain gains were classified as middle gains. 
It is important to note that examining the sequences that surround the 
gained domains helps to infer the full length of a protein segment that was 
inserted. In this way, I did not rely solely on domain boundary assignments, 
which might be imperfect. 
3.2.6 Genomic origin of the inserted domain
For all domain gain events that have a human descendant, the gained domain 
sequence from a representative protein was searched with Wu-blastp against 
the rest of the human proteome. The best significant hit that was not in one of 
the gene’s paralogues was considered to be a potential donor of the gained 
domain. A set of paralogs for each gene was composed of other human genes 
from the same TreeFam family and Ensembl paralogues for that gene. The 
condition for a significant hit was an E-value of less than 10-4 with 60% or more 
of the domain sequence aligned. 
The structures of the genes with gained domains and of their best hits 
were visually examined using Ensembl (release 50) and the Belvu viewer 
(http://sonnhammer.sbc.su.se/Belvu.html). 
The Fisher Exact test in R was used to estimate statistical significance of 
observed trends (http://www.r-project.org/).
The Segmental Duplication Database: 
http://humanparalogy.gs.washington.edu/ was used to obtain the coordinates of 
segmental duplications in the human genome. It was investigated whether any 
segment from the database spanned any of the representative genes with a 
domain gain, and if so, whether the other copy of that segmental duplication was 
placed on the gene that was a potential donor of the domain. It was also checked 
whether the other copy overlapped with any of the paralogs of the 
representative gene.
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Figure 3.4: Flowchart of analysis for the sets of high and medium 
confidence domain gain events. For the set of high confidence domain gain 
events, I looked at characteristics of the gained domains, their potential origin 
and other trends that could imply potential causal mechanism. For the set of 
medium confidence domain gain events, I only looked at the characteristics of 
the domains since this set is enriched with false positives and it was obtained 
only to test whether the set of high confidence domain gains biased conclusions 
towards any of the causal mechanisms.
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3.3 Results
3.3.1 Set of high confidence domain gain events
To obtain a set of high confidence domain gains I implemented an algorithm that 
ensured that a gain is not falsely called when other genes in that family had 
actually experienced multiple losses of the domain in question. I also took into 
account only those gains that had at least one representative sequence in a 
genome of better quality and discarded gains where there was only one 
sequence with the gained domain, i.e. gain was on the leaf of the phylogenetic 
tree. I did this to overcome the issue of erroneous gene annotations, such as, for 
example, the instances where two neighbouring genes are annotated as one 
because regulatory segments that distinguish the genes are not yet identified. 
Finally, I refined the initial domain assignments to find domains that were 
missed in the initial Pfam based annotation and discarded all dubious domain 
gain cases where there was evidence that a domain gain was called due to 
missing Pfam annotations. After filtering for these confounding factors that could 
cause false domain gain calls and taking into account only examples where the 
same transcript contains both the ancestral portion of the gene and a sequence 
coding for a new domain, I was left with 330 events where I could be confident 
that one or more domains had been gained by an ancestral protein during 
animal evolution – I took into account only gains of new domains, and not 
duplications of existing domains. 
The final set is not comprehensive, but these filtering steps were 
necessary to ensure that the set of domain gain events is of high confidence. 
Moreover, none of these steps introduces a bias towards any one mechanism 
over another.  The only mechanism of domain gain that I cannot detect after this 
filtering is the case where amino acid mutations in the sequence created 
signatures of a domain that was not previously present in the protein; for 
example, when point mutations in the mammalian lineage created signatures of 
a mammalian-specific domain.
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3.3.2 Characteristics of the high confidence domain gain events
To investigate which molecular mechanisms have caused domain gains in the set 
of high confidence domain gain events, I examined the characteristics of the 
sequences that code for the gained domains. As a requirement, each gain event 
in the set has as descendants two or more genes with the gained domain. To 
simplify the investigation, I only considered one representative protein for each 
gain event, and most (232 or 70%) of these were drawn from the human genome 
as its gene annotation is of the highest quality. Sometimes the same protein was 
an example for more than one domain gain that occurred during evolution. I 
projected intron-exon boundaries and intron phases onto the representative 
protein sequences to help identify the possible causative mechanism. I also 
compared each representative protein sequence with the orthologs and paralogs 
in the same TreeFam family that lacked the gained domain. This helped in 
assigning the characteristics of the gained domains.
I recorded domain gain position (N-, C-terminal or middle) as well as the 
number of gained exons and whether the domain was an extension of an existing exon 
(Figure 3.5). I observed two pronounced trends: firstly, most of the domain gains (234 
or 71% of the events) occurred at protein termini. This was in agreement with 
previous studies (Bjorklund et al., 2005; Weiner et al., 2006). Secondly, the majority 
of the gained domains (again 234 or 71%) are coded for by more than one exon and 
therefore retroposition is excluded as a likely causative mechanism for them.
I found that different methods for classification of the gain events gave similar 
results with the most prominent categories of domain gains being gains of multiple 
novel exons (Appendix B.3). This gave me confidence that domains that are called to 
be gained on new exons in this analysis indeed are. 
Other domains in the same representative proteins that experienced domain 
gains were also mostly encoded by more than one exon. Namely, 304 out of total 353 
domains, or 86% of domains that were present in only one copy in the representative 
proteins were encoded by two or more exons.
I chose a single representative transcript for each gain event, but as a 
control, I compared characteristics of the gained domain in all descendant 
TreeFam transcripts with the domain in the human representative transcript. I 
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found that in the majority of cases, other descendants of the gain event had the 
same characteristics of domain gain as the representative protein (on average in 
76% descendants of a gain event). This suggests that the causative mechanism 
can be investigated by looking at the characteristics of the domain in one 
representative protein for each gain. 
Figure 3.5: Distribution of domain gain events in the high confidence set of 
domain gains according to the position of domain insertion and number of 
exons gained. Gains at N- and C- termini and in the middle of proteins are 
shown separately. The first column in each group shows the fraction of gains 
where the gained domain is coded by multiple new exons and the second where 
it is coded by a single new exon. The third column shows the fraction of gains 
where the ancestral exon has been extended and the gained domain is coded by 
the extended exon as well as by additional exons. Finally, the fourth column in 
each group shows cases where only the ancestral exon has been extended with 
the sequence of a new domain.
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3.3.3 Characteristics of the medium confidence domain gain events 
The approach for obtaining a set of high confidence domain gains does not bias 
the final set towards any of the mechanisms. However, the total number of gain 
events in the set is relatively small and this could introduce apparent dominance 
of one mechanism over another. Hence, I composed a bigger, but lower 
confidence, set of events to investigate whether the same trends in domain gains 
are present in this set; in particular, whether the distribution of characteristics 
of the gained domains is similar to the one of the high confidence set. I named 
this set ‘Medium confidence’ gain events. For this, I used the initially reported set 
of domain gain events and excluded the filtering criterion which asked for a 
domain to be present in at least two descendant proteins, and the one which did 
not allow any similarity between the gained domain and other sequences in the 
same gene family (Figure 3.3.). I left only the criterion of necessity for domain 
gains to be supported by a gain in an organism with a better quality genome, 
since the distribution of domain gains that are reported only in one species – e.g. 
on the leaf nodes in the trees - showed a bias towards the genomes of lower 
quality (most gains were reported in Schistosoma mansoni and Tetraodon 
nigroviridis: 320 and 303 gains, respectively, and among the organisms with 
least reported gains were human and mouse: 25 and 19 gains, respectively). I 
compared the distribution of domains with different characteristics between the 
high and medium confidence sets of gain events (Figure 3.6). I found that the 
distribution of domain gains in the two sets is similar overall thus supporting the 
major conclusions I draw here. The major difference was in the number of 
middle domains coded by one exon: there were 1.8 times more gains of a domain 
coded by a single novel middle exon, and 1.6 times more gains of a domain coded 
by an extension of a middle exon. The set of a medium confidence domain gains 
is enriched with false domain gain calls caused by discrepancies in the domain 
annotation of proteins from the same TreeFam families. However, I cannot rule 
out that a fraction of these gains is real; hence, more supporting cases for the 
mechanisms that can add domains to the middle of proteins could be found in a 
larger set. Mechanisms that could be at play here are retroposition and 
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exonisation of previously non-coding sequence, but also recombination inside 
the gene sequence. 
Figure 3.6: Distribution of domain gain events according to the position of 
domain insertion and number of exons gained in the set of high confidence 
domain gains and in the set of medium confidence domain gains. 
Distribution of characteristics of domains from the high confidence set of 
domain gains (graph a) is for the same – high confidence - gain events 
represented in Figure 3.5. Graph b) shows the distribution of characteristics of 
domains from the set of medium confidence domain gains. There are in total 330 
high confidence domain gain events and 849 medium confidence domain gains 
(of which 19 gains have ambiguous position and are not shown in the graph). 
The flowchart in the Figure 3.3 shows the procedures for creation of these two 
sets of domain gains.
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3.3.4 Supporting evidence for the representative transcripts
I based this work on the Ensembl gene and transcript predictions. However, 
Ensembl predictions rely on the supporting transcriptome and proteome 
evidence which is still incomplete. Mistakes in the transcript models can cause 
false domain gain calls for two reasons: firstly, a transcript that has apparently 
gained a domain coding sequence can actually exist as two separate transcripts 
that are falsely annotated as one longer, and secondly, if a domain gain is 
reported in the genomes with better quality annotations it could be that in the 
genomes of lower quality the domain is missing only due to incomplete 
annotation.
To investigate the possible extent of errors introduced by the first type 
of annotation errors, I checked if there was available supporting evidence for the 
transcripts that were representatives for domain gain events. I retrieved 
supporting evidence on the transcript level by using the Ensembl API and 
checked individual human and mouse representatives without the supporting 
evidence through the Ensembl website. I found that there was known mRNA 
supporting the transcript structure in 226 out of 232 human representative gain 
events and that there were 4 additional cases where evidence was on the exon 
level. Therefore, 99% (230 of 232) of human representatives have valid 
supporting evidence. For mouse, there is evidence on the transcript level for 14 
out of 18 representative gain cases, and two other transcripts are supported on 
the exon level. Hence, supporting evidence exists for 89% of the gain events (16 
of 18) with mouse representative transcript. For other organisms I took only 
automatically retrieved transcript evidence into account and I found that in rat 
there was supporting evidence for 60% (3 of 5) of the events, in chicken and 
zebrafish for 25% (1 of 4 and 5 of 20 events, respectively), and for frog and fruit 
fly none of the representative transcripts had available supporting evidence 
(there were 9 and 43 representative transcripts in frog and fruit fly 
respectively). It is important to note that the small number of reported gain
events with the rat and chicken representative transcripts is possibly also a 
reflection of the incomplete gene annotations in these species. In conclusion, I
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am confident the transcripts with gained domains in human and mouse are 
correct, but am more cautious about representative transcripts with the gained 
domain coding sequences in other organisms. 
I addressed the level of possible false domain gain calls due to the 
second type of annotation errors on a smaller set of domain gains which 
represented a set of gain calls likely to be affected by this error. Namely, domain 
gains that occurred in the human lineage after the divergence of vertebrates 
(121 reported domain gain events) can have on one side well studied genomes 
as human and mouse and on the other side, as an outgroup, lower quality
genomes like the one of C. intestinalis. For 49 of these gain events the TreeFam 
family with the reported domain gain also contained orthologous genes in C. 
intestinalis without that domain. I took sequences of C. intestinalis orthologs 
together with 5kb of sequence upstream and downstream of them and 
performed tBLASTn (http://blast.wustl.edu/) to test whether the missing 
domains were present but only lacked annotation. I found that in four cases at 
least one of the domains reported to be gained in vertebrates is present in the 
neighbourhood of C. intestinalis orthologous (P-value < 0.1, tBLASTn). However, 
for two of these cases gene annotation is of very good quality, and the predicted 
UTR signals and proximity to their neighbouring genes do not support the 
assumption that the ‘missing domains’ should be added to these genes. 
Therefore, I estimate that 4% (2 of 49) of the apparently gained domains could 
be reported due to errors in gene annotations. However, since these domains are 
found only in vertebrate genes in the corresponding TreeFam families, these 
might still be the cases of domain gain but only the time points of the gain events 
could be before the divergence of C. intestinalis from vertebrates. Domains found 
next to the C. intestinalis orthologues, which are possibly missed by incomplete 
gene annotations were: the Calx-beta domain (PF03160) next to the Ensembl 
gene ENSCING00000003141 which was gained in the TreeFam family TF105392 
together with the Ig-like superfamily (clan CL0159), then the ADP-ribosylation
superfamily (clan CL0084) next to the gene ENSCING00000005839 which was 
gained in the TreeFam family TF329720 together with the BRCA1 C terminus 
domain (PF00533). The two other domains which were found next to C. 
intestinalis genes with good quality annotation are the Sema domain (PF01403) 
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next to the gene ENSCING00000006805 - which was gained in TreeFam family 
TF317402, and the Kunitz/Bovine pancreatic trypsin inhibitor (PF00014) next 
to the gene ENSCING00000011322 - which was gained in the TreeFam family
TF331207.
3.3.5 Donor genes of the gained domains
                                                                  
I investigated whether duplication of the sequence of the ‘donor genes’ preceded 
gains of these domains. I selected the 232 gain events with human 
representative proteins. The selected domain gain events cover those events 
where at least one of the descendants is a human protein. Hence, the time scale 
for these events ranges from the divergence of all animals – which was around 
700 mya to the divergence of primates – around 25 mya. I grouped descendants 
of each gain event into the evolutionary group (primates, mammals, vertebrates, 
bilaterates and animals) they span. In appendix B.2, all gain events together with 
the information about the evolutionary group of the descendants with the gained 
domain are listed. I looked for protein regions in the human proteome that are 
similar to gained domains and, in the case that duplication preceded domain 
gain could possibly be the source of the gained domains. For this, I used wu-
blastp (http://blast.wustl.edu). I found a potential origin for 129 (56%) of the 
gained domains. For the remaining ones it is possible that the mechanism for 
domain gain either did not involve duplication of an existing ‘donor’ domain, or 
that the two sequences have diverged beyond recognition. Hence, the set of 
domains without the potential ‘donor’ is enriched in events where the domain 
has been gained through gene fusion or recombination without previous 
duplication of the region that encodes the domain or through exonisation of 
previously non-coding sequence.
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3.3.6 Investigation of cellular mechanisms that caused domain 
gain events
There are several cellular mechanisms, described in the introduction of this 
chapter, which could have caused the observed domain gain events. I have 
looked at the characteristics of the gained domains in human representative 
proteins and attempted to relate these gain events to their possible causative 
mechanisms.
These gain events illustrate characteristics of domains that were gained 
during evolution of the human lineage. However, it is important to note that at 
different stages of evolution different mechanisms could have dominated. The 
same is valid for domain gains in different species after species divergence. This 
is why I looked at the characteristics of the gained domains in representative 
proteins of each species separately. I found that gain of multiple terminal novel 
exons was a dominant mechanism for domain gains in human, mouse and frog -
these gains made 34, 50 and 56%, respectively of all gains with representative 
protein in these species. In fruit fly, the dominant category of gains was 
extension of exons at C-terminus - 29% of domain gains - and dominant gains in 
zebrafish were a mixture of two - 35% of gains were novel terminal domains and 
20% C-terminus exon extensions. For rat and chicken there were too few 
domain gains for me to draw conclusions.
3.3.6.1 Retroposition as a mechanism of domain gain
Domains in the human lineage for which I could identify a potential donor 
protein and which are gained within a single exon are possible candidates for 
retroposition (26 cases). I further investigated these gain events. Retroposition 
would be supported as a causative mechanism if there were no other exons
gained together with the one that encodes the new domain, and also if a long 
interspersed nuclear element (LINE) retrotransposon was present before the 
gained domain and/or ‘donor’ domain. Inspection of the candidate domains 
showed the supporting evidence for the gain of pre-SET and SET domains in the 
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SETMAR gene by this mechanism (described in Figure 3.7) but not for other 
candidate gained domains. However, this inspection was hampered with the fact 
that the gained domain often existed in multiple copies in the ‘donor’ protein so 
it was difficult to judge which of the domain repeats was the potential origin. 
Finally, in the cases where extra exons appeared to be gained with the one that 
encodes the new domain, retroposition could be excluded as a likely mechanism. 
The lack of a LINE element does not rule out retroposition as a possible 
mechanism, rather it does not show additional support for it. Even if isolated, the 
example of the SETMAR gene is very relevant, since there are only a few cases 
reported of the role of retroposition in the creation of novel genes in the human 
lineage (Babushok et al., 2007a). The pre-SET and SET domains in the SETMAR
gene most likely have an origin in the gene SUV39H1. Interestingly, the SETMAR
gene lies in the intron of another gene (SUMF1) and hence possibly uses its 
regulatory mechanism for transcription.
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Figure 3.7: Retroposition as a causing mechanism for domain gain.
An example of a domain gain mediated by retroposition. TreeFam family 
TF352220 contains genes with a transposase domain (PF01359). The primate 
transcripts in this family have been extended at their N-terminus with the pre-
SET and SET domains. The representative transcript for this gain event is 
SETMAR-201 (ENST00000307483, left in the figure). Both gained domains have a 
significant hit in the gene SUV39H1 (ENSG00000101945, right in the figure - the 
Set domains of the donor and recipient proteins share 41% identity). Previously, 
it has been reported that the chimeric gene has originated in primates by 
insertion of the transposase domain (PF01359, with a mutated active site and no 
transposase activity) in the gene that had had the pre-SET and SET domains 
(Cordaux et al., 2006). Here, I propose that the evolution of this gene involved 
two crucial steps: retroposition of the sequence coding for the pre-SET and SET 
domains and insertion of the MAR transposase region described by Cordaux et 
al. The SET domain has lost the introns present in the original sequence and the 
Pre-SET domain has an intron containing repeat elements in a position not 
present in the original domain suggesting it was inserted later on. The likely 
evolutionary scenario here includes duplication of pre-SET and SET domains 
through retroposition, insertion of transposase domain and subsequent joining 
of these domains. The SETMAR gene is in the intron of another gene (SUMF1), 
which is on the opposite strand so it might be that SETMAR is using the other 
gene’s regulatory regions for its transcription. The top of the figure shows the 
genomic position of depicted genes. Arrowheads on the lines that represent 
chromosomal sequences indicate whether the transcripts are coded by the 
forward or reverse strand. Transcripts are always shown in the 5’ to 3’ 
orientation and proteins in the N- to C-terminal orientation. Exon projections 
and intron phases are also shown on the protein level. Pfam domains are 
illustrated as coloured boxes. Figures 3.8 and 3.9 use the same conventions. 
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3.3.6.2 Joining of adjacent genes as a mechanism of domain gain
Terminal gains of domains coded by multiple novel exons are particularly 
interesting because for these events there is only one plausible causative 
mechanism: joining of exons from adjacent genes (Figure 3.2). Because of the 
criteria I used here, the number of new exons gained at termini is a lower 
estimate. Nonetheless, this is still the most abundant type of event. 104 or 32% 
of all events are N-terminal (63 events) or C-terminal (41 event) gains of 
domains coded by multiple new exons (Figure 3.5). I can discard retroposition 
and recombination assisted insertions into introns as likely mechanisms for 
these gains. However, it is possible that recombination preceded domain gains, 
and even that recombination did not juxtapose fully functional genes but only, 
for example, certain exons of one or both of the genes. Indeed, I have not found 
that these genes exist as adjacent separate genes in the modern genomes 
(described below) and it is likely that these gains were preceded by DNA 
recombination.
The search for the ‘donor gene’ of the gained domains identified the 
possible origin of the domain for 60% of domains coded by new terminal exons. 
This implies that duplication of a donor domain has frequently provided the 
material for subsequent exon joining and new exon combinations. An illustration 
of this mechanism is the gain of the UEV domain in the UEVLD gene (Figure 3.8
and 3.9). The gain has most likely occurred after the neighboring gene TSG101
has been duplicated and exons of one copy joined with the UEVLD ancestor’s 
exons. Two similar examples, for the evolution of genes CELSR3 and AC093283.3, 
are also illustrated in Figure 3.8. 
Gains of multiple novel terminal exons make up 32% of all domain gains 
and are best explained with joining of adjacent exons. On the other hand, 
terminal gains of domains coded by a single novel exon can be explained either 
by the joining of exons from adjacent genes or with other mechanisms such as 
retroposition. The former mechanism is more likely since, together with the 
novel exon that codes for the gained domain, extra exons, that do not code for 
the gained domain, have frequently been gained (in at least 42% events, or 18 of 
total 42 cases). Also, further inspection of the candidate gains in the human 
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lineage did not find LINE elements that preceded a gained or ‘donor’ domain and 
hence did not lend support for retroposition as a causative mechanism 
(described above). With regard to other categories of domain gain events in 
Figure 3.5., because of the strict criteria I used to call a gained domain terminal 
and coded by novel exons, a number of exon extensions and middle gains are 
possibly misclassified terminal gains and gains of novel exons. 
Recent segmental duplications in the human genome are a possible 
source of new genetic material (Bailey et al., 2002) and their role in the 
evolution of primate and human specific traits has been debated (Bailey and 
Eichler, 2006). Hence, I investigated whether recent domain gains in the human 
lineage could be related to the reported segmental duplications. I found two 
domain gains that were best explained by recent segmental duplications and 
subsequent joining of two genes (Figure 3.10). Both of these gains occurred at 
the protein termini after divergence of primates. The mechanism of their 
evolution is the same as in the case of the UEVLD gene: joining of exons from 
adjacent genes after gene duplication. Additionally, for these two examples, 
there is also evidence of a likely connection between recent genomic duplication 
and domain gain. In spite of this, it is necessary to be cautious when assessing 
the possible role of these proteins. For both examples, there is only transcript 
evidence and some of the transcript products of these genes appear to have a 
structure that would lead to them being targeted by nonsense mediated decay 
(NMD) (Wilming et al., 2008). However, it is still not sure if these genes are 






Figure 3.8: Examples for domain gains by joining of exons from two 
ancestral genes. A representative protein for a domain gain is always shown on 
the left and a protein which is a potential origin of the gained domain is shown 
on the right. (a) An example of a domain gain by gene duplication followed by 
exon joining. TreeFam family TF314963 contains genes with lactate/malate 
dehydrogenase domain where one branch with vertebrate genes has gained the 
additional UEV domain. Homologues, both orthologues and paralogues, without 
the gained domains are present in a number of animal genomes. A 
representative transcript with the gained domain is UEVLD-205
(ENST00000396197, left in the figure). The UEV domain in that transcript is 56% 
identical to the UEV domain in the transcript TSG101-201 (ENST00000251968) 
that belongs to the neighboring gene TSG101 and the two transcripts also have 
introns with identical phases in the same positions. The likely scenario is that 
after the gene coding for the TSG101-201 transcript was duplicated, its exons 
have been joined with the ones of the UEVLD-205’s ancestor and the two genes 
have been fused. 
(b) Another example for a domain gain after gene duplication and exon joining. 
Family TF334740 in the TreeFam database contains genes that code for the Rho-
guanine nucleotide exchange factor (RhoGEF). However, the RhoGEF domain 
was not present in the ancestral protein but was inserted later on together with 
the C1_1 domain when mammals diverged from other vertebrates (TreeFam 
release 6.0 that we used in the analysis had chicken, fish and frog genes without 
the gained domains). The representative transcript for the gain event is 
AC093283.3-201 (ENST00000296794). The gene ARHGEF18 
(ENSG00000104880) has both of these domains, and the two RhoGEF domains 
between the genes are 52% identical. Hence, ARHGEF18 is a plausible donor for 
this gain event. Again, the mechanism for the gain of these domains most likely 
involves gene duplication and exon joining. 
(c) TreeFam family TF323983 contains ‘Cadherin EGF LAG seven-pass G-type 
receptor (CESLR) precursor genes. One branch of the family, containing 
vertebrate genes, has gained the Sulfate transport and STAS domains in addition 
to the ancestral cadherin, EGF and other extracellurar domains. The gain 
occurred after the other vertebrates diverged from fish, and homologues 
without the gained domains are present in all animals. A representative for the 
gain is the transcript CELSR3-207 (ENST00000383733) and its 3’ end is shown 
left in the figure (the whole transcript is too long to be clearly presented). Right 
in the figure is shown a gene that is the plausible donor of these domains. 
Namely, the gene SLC26A4 (ENSG00000091137) contains both domains, and its 
STAS domain is 31% identical to the one in the CELSR3 gene. In addition, the 
alignment with the Zebrafish genome is shown below the CELSR3-207 
transcript. The yellow arrows represent the alignment with the chromosome 8 
in Zebrafish, and pink arrows with the chromosome 6 (information taken from 
the USCS browser: http://genome.ucsc.edu). The alignment with the fish 
genome shows that the synteny is broken exactly in the region where the new 
domain is gained. Therefore, the plausible scenario for domain gain involves 
gene duplication, recombination and joining of newly adjacent exons. 
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Figure 3.9: Gain of the UEV domain in the TreeFam family TF334740.
Structure of a representative gene that was extended with the UEV domain is 
shown in Figure 3.8a. Here, the evolutionary tree of lactate dehydrogenase genes 
is shown. Vertebrate genes in the tree – the red coloured branch – have gained 
the UEV domain during evolution. This should influence both protein structure 
and function. Models of the protein structures of example proteins in different 
branches of the tree are shown. The structure is predicted from protein 
sequence, based on similarity with proteins with solved structures, using Swiss-
model (http://swissmodel.expasy.org). The domain gain occurred after gene 
duplication and subsequent joining of exons from adjacent genes, which appears 






Figure 3.10: Examples for domain gains by joining of exons from adjacent 
genes assisted by recent segmental duplication. (a) An example for a domain 
gain after segmental duplication and exon joining. TreeFam family TF351422 
contains only primate genes, and after a gene duplication event one branch of 
the family has gained the PTEN_C2 domain. A representative transcript for this 
gain is AL354798.13-202 (ENST00000381866). There are few segmental 
duplications spanning across the gene AL354798.13 and one of them is covering 
only the ancestral portion of the gene – without the gained domain. The pair of 
that segmental duplication is on the gene’s paralog that has not gained the 
domain, the gene AP000365.1 (ENSG00000206249). Hence, a possible scenario 
is that a recent duplication of a paralog gene has changed its genetic 
environment and brought it to the proximity of the PTEN_C2 domain which 
subsequently became part of the gene. 
(b) Another example of a gain of a domain coding region by segmental 
duplication followed by exon joining. A branch with primate genes in the 
TF340491 family of vertebrate proteins that contains the KRAB domain has 
gained the additional HATPase_c domain. The representative transcript is the 
human PMS2L3-202 (ENST00000275580). The HATPase_c domain exists in the 
gene PMS2 (ENSG00000122512) and on the protein level the gained domain is 
98% identical to the sequence in the protein product of the PMS2’s transcript 
PMS2-001. There is a segmental duplication that spans across the gained 
sequence in the transcript PMS2L3-202 and is a pair of the segmental duplication 
that covers the same domain in the gene PMS2. The pair of segmental duplication 
regions are presented as grey boxes and connected with arrows. Therefore, the 
mechanism underlying this gain appears to be a segmental duplication of the 
sequence belonging to PMS2 after which the copy next to the PMS2L3-202’s 
ancestor was joined with it. An important caveat is that PMS2L3-202 has a 
structure that can be targeted by NMD.
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3.3.6.3 Insertion of exons into ancestral introns as a mechanism of 
domain gain
Because of the special attention that has been given to domain insertions into 
introns in discussions on exon shuffling (Liu and Grigoriev, 2004; Patthy, 1999), 
I have studied the middle gains of novel exons in more detail. The theory of 
domain shuffling by intronic recombination states that the exons inserted into 
ancestral introns are surrounded by introns of symmetrical phases (Patthy, 
1999).  I looked at the phases of introns surrounding the domains inserted into 
the ancestral introns. A list of all intronic gains is in Appendix B.4. Twenty six of 
them had the agreeing phases on the boundaries of exons that encoded them, 
and two more were gained with extra exons that also had agreeing phases on 
boundaries. Only one in three possible intron phase combinations gives the same 
intron phases, and here I observed a strong bias in agreement of intron phases 
surrounding the gained domains (57% or 28 out of 49 domains are surrounded 
with introns of the same phase) and among these I also observed an excess of 1-
1 phases on exon borders (79% or 22 out of 28). Both symmetrical phases and 
an excess of 1-1 phases are considered to be supporting evidence for intronic 
insertions (Patthy, 1999). Moreover, intronic insertions have been shown to be 
widespread in extracellular matrix proteins and the gained domains in this 
subset of domains are well known extracellular domains (such as EGF, Sushi, 
Fibronectin and Immunoglobulin domains) (Patthy, 1999). However, these 
potential examples for domain insertions into introns cover less than 10% of all 
gain events; which does not support the expectation that this was the major 
mechanism for domain gains in the evolution of metazoa (Kaessmann et al., 
2002; Liu and Grigoriev, 2004). It is also worth noting that the majority (82% or 
40 of 49 intronic gains) of domains inserted into ancestral introns were coded 
by multiple exons, which implies that intronic recombination, rather than 
retroposition, would be more likely the causative mechanism for the majority of 
intronic gains. In conclusion, the majority - 28 out of 49 - domains coded by 
novel exons and gained into the middle of proteins are surrounded by introns of 
symmetrical phases, and hence give support to the assumption that the causative 
mechanism for them included insertions into ancestral introns.
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Related to exons insertions into introns; it has been shown that a class 
of domains whose borders strongly correlate with their encoding exon borders 
had experienced significant expansion during animal protein evolution (Liu et 
al., 2005). Moreover, these domains were also found to be frequent in novel 
metazoan multidomain architectures (Ekman et al., 2007). It has been 
hypothesised that these domains have contributed to exon shuffling in metazoa 
(Liu et al., 2005) and a correlation with symmetrical intron phases surrounding 
these domains was attributed to their intronic insertions (Liu et al., 2005). I 
investigated how well represented these domains were in the set of high 
confidence domain gain events. I found that they make up about 28% of the set 
(101 out of 362 gained domains, or 97 out of 333 gain events) which is a 
significant overrepresentation since only 103 out of total 8,634 domains or clans 
in the Pfam 23 are in the class of exon-bordering domains (1.2% of all domains).
The significant fraction of these domains in the dataset confirms their important 
role in domain shuffling in metazoa, but the fact that they have been gained 
about as equally frequently at N- or C-terminus as in the middle of proteins (35, 
30 and 32 events, respectively) shows that they have been important not only 
for intronic gains, but for domain rearrangements in animals in general. 
3.3.6.4 Exonisation of previously non-coding sequences as a mechanism 
of domain gain
Figure 3.5. shows that a relatively high fraction of domain gains occurred as 
extensions of C-terminus exons. If exonisation of a previously non-coding 
sequence was a causal mechanism for some of the domain gains, one would 
expect that these gains would preferentially occur as extension of exons at C-
termini. Extensions of exons at N-termini and in the middle of proteins have a 
risk of introducing a frame-shift and being selected against. Additionally, one 
would expect that when a new Pfam family is formed from previously non-
coding sequence (by exon extension) that it is more likely that this will be an 
intrinsically unstructured region.  Intrinsically unstructured or disordered 
regions do not have a stable globular structure, but are associated with 
important functions (Wright and Dyson, 1999; Gsponer and Babu, 2009; 
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Gsponer et al., 2008). I predicted disordered regions in all proteins from the 
study with the IUPred software (Dosztanyi et al., 2005) and looked at the 
average percentage of disordered residues in each gained domain in the set 
(Figure 3.11) and in all other domains present in these proteins. I observed two 
prominent trends: firstly, gained domains in general have a greater percentage 
of disordered residues (on average only 5% of residues of all other domains in 
proteins are predicted to be disordered compared to on average 21% of residues 
in the gained domains) and secondly, domains with the greatest percentage of 
disordered residues are those that have been gained by extension of existing 
exons. 
Figure 3.11: Distribution of disordered residues in the gained domains 
according to the position of domain insertion and number of exons gained.
This graph shows the percentage of disordered residues in each category of 
domain gains. The number of events in each category can be seen in Figure 3.5.
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Next, I investigated the individual examples for domain gains through 
extension of C-terminal exons in the human lineage. By looking at the alignments 
for these gains, it was possible to find four convincing events of true exon 
extensions. None of these had a potential ‘donor gene’ identified in the human 
proteome. Further inspection of these domains showed that they have actually 
occurred at that point in the evolution for the first time and the possible 
mechanism for inclusion of these novel domains was reading through the stop 
signal and exonisation of previously non-coding sequences (for the gains in 
primates and mammals alignments at the UCSC genome browser (Kent et al., 
2002) show similarity of the gained domains with non-coding regions in the 
genomes of non-primates and non-mammals, respectively). These examples are: 
(1) Gain of a proline rich Pfam family PF04680 in primates – in the TreeFam 
family TF331377, (2) gain of a selenoprotein P C-terminal Pfam family PF04593 
in mammals – in the TreeFam family TF333425, and gain of the families: (3) 
connexin 50 C-terminal - PF03509 and (4) the Kv2 voltage gated K+ channel -
PF03521 in vertebrates – in the TreeFam families TF329606 and TF313103, 
respectively. Representative transcripts for these gains can be found in 
Appendix B.2. It is noteworthy that none of these Pfam families has a solved 
structure and it is possible that they are not true structurally independent 
protein domains. Even so, their sequences are conserved in the organisms in 
which these Pfam families are present (it was possible to recognize these 
domains in the sequence), which implies that they could be functionally relevant. 
3.3.7 Domain gains most frequently occur after gene duplications
One advantage of using TreeFam phylogenies is the ability to distinguish 
between gene evolution that follows gene duplication and the one that follows 
speciation. I investigated whether there was any correlation between domain 
acquisition and gene duplication. In the entire database, speciation nodes are 
more frequent than duplication nodes (there are 3.43 times more internal 
speciation nodes; in total there are 394,853 internal speciation and 115,013 
internal duplication nodes). However, in the set of domain gain events that have 
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a human representative for the gain, duplication nodes were more frequent (a 
change in domain architecture was 1.32 times more frequent after gene 
duplication; 101 gain events occurred after speciation event and 133 after gene 
duplication). Hence, when comparing the observed versus expected frequency of
domain gains after duplication and speciation events I found that domain gains 
occurred nearly five times more frequently than expected (1.32 relative to 0.29). 
As a control, I also checked the branch lengths after speciation and duplication 
nodes and found that domain gains occurred after every 3,455 units of branch 
length when the event was speciation and after 1,274 units of length when the 
event was duplication. Hence, the lower estimate is that domain gains occurred 
2.72 (~3) times more frequently after gene duplication compared to after 
speciation. This shows that not only duplication of the ‘donor gene’, but also of 
the ‘recipient gene’ assisted domain gains. Taken together with the gain events 
that had the ‘donor genes’ identified, in 80% of the domain gains, duplication of 
either the ancestral protein or donor protein has been involved. Moreover, when 
two genes were fused together then the assignment of ‘donor’ and ‘recipient’ 
genes depends solely on whose phylogeny is one looking at.
When I grouped the gain events with the identified ‘donor genes’ 
according to the age of the event and looked at the chromosomal position of the 
‘donor genes’ I observed a trend that in the human lineage the younger the gain 
event was, the more likely it was that the 'donor gene' would be found on the 
same chromosome (Figure 3.12). However, the numbers of domains found on 
the same chromosomes are small (Figure 3.12). Therefore, I grouped values for 
domain gains before and after divergence of mammals and found that in spite of 
the small set of domain gains, the difference in trend is still present (P-value = 
0.03, Fisher exact test). The fact that the tendency was decreasing for the older 
gains could be related to continuous chromosomal rearrangements. In addition 
to that, I observed that in general the 'donor genes' were found on the same 
chromosomes as the genes with the gained domains more frequently than would 
be expected by chance. I calculated this as follows: I compared the number of 
gains on each chromosome with the number of best hits that I would expect to 
observe if the duplicates could be inserted equally likely anywhere in the 
genome (calculated as the portion of the genome length on each chromosome –
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i.e. individual chromosome length divided by the total length of all autosomes 
together with X and Y chromosomes - times number of gains on that 
chromosome). The number of observed 'donor genes' on the same chromosome, 
16, is 2.5 times higher than the expected 6.5. This suggests that the duplication 
mechanism favored creation of duplicates on the same chromosomes.
However, not all domain gains rely on gene duplication. As already 
discussed, exonisation of previously non-coding sequence does not have to be 
preceded by gene duplication. Additionally, a closer look at domain gains after 
primate divergence showed that two domain gain events are actually gains of 
transposon (CL0219 in the TF328297 TreeFam family) and retroviral (CL0074 
in the TF331083 TreeFam family) domains. Gains of domains from mobile 
genetic elements can also be relevant for the evolution of protein function 
(Cordaux et al., 2006) and are not necessarily connected with gene duplication.
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Figure 3.12: Chromosomal position of the ‘donor gene’ and the relative age 
of the gain event. The graph is showing the fraction of events for which the 
‘donor gene’ of the gained domain is identified, and is on the same chromosome 
as the gene with the gained domain, with respect to the relative age of the gain 
event. The gain events were divided into five groups according to the expected 
age of the event as judged by the TreeFam phylogeny. The X axis shows the 
evolutionary group in the human lineage which descendants of the gain event 
belong to, and the Y axis percentage of gain events in each evolutionary group 
for which both of the conditions were valid: I was able to find the donor gene 
and the donor gene was on the same chromosome as the gene with the gained 
domain (3 out of 9 gain events in Primates, 2 out of 20 in Mammals, 7 out of 121 
in Vertebrates, 1 out of 27 in Bilateralia and 1 out of 55 gain events in all 
animals). Appendix B.2 has information about domain gain events that belong to 
each phylogenetic group. Estimated divergence times (in million years ago –
mya, as taken from Ponting (Ponting, 2008) are the following: 25 mya for 
Primates, 166 for Mammals, 416 for Vertebrates and 700 for all animals (we 
were not able to estimate divergence time for Coelomata).
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3.3.8 Gained domains do not have their origin in the adjacent 
genes
When a domain gain occurred through joining of exons from adjacent genes then 
it is possible that this process was assisted with gene recombination, which 
juxtaposed the sequences of the two ancestral genes together. Alternatively, it is 
possible that the ‘donor’ gene with the gained domain was adjacent to the 
‘acceptor’ gene for a long period of time and then in a certain evolutionary 
lineage the two genes fused. I investigated whether there were instances where 
a homologue, which lacked the domain, had a gene coding for the gained domain 
adjacent to it. I found three cases in the present animal genomes where a 
homologue of a gene with a gained domain did not have that domain but was 
annotated adjacent to the gene which encoded the domain. If these were true 
separate genes, these would be examples for joining of exons from adjacent 
genes and subsequent gene fusion. However, further inspection showed that 
they were most likely results of gene annotation discrepancies and were 
possibly not even true domain gains. Therefore, I excluded these gain events 
from the set of high confidence domain gains. These were the following gains: 
gain of the BRCA1 C Terminus domain (PF00533) in the TreeFam family 
TF329705, gain of Kuntiz/Bovine pancreatic trypsin inhibitor (PF00014) in the 
TreeFam family TF316148 and gain of the LEM domain (PF03020) in the 
TreeFam family TF317729. In conclusion, for the obtained set of gain events, 
there is no evidence in the current animal genomes that the gained domains had 
an origin in the genes that were for long evolutionary times adjacent to the 
ancestors without the gained domains.
3.3.9 Domain gain events affect cellular regulatory networks
It has been proposed that the novel combinations of preexisting domains had a 
major role in the evolution of protein networks and more complex cellular 
activities (Pawson and Nash, 2003; Peisajovich et al., 2010). In agreement with 
this, I found that the most frequently gained protein domains in the human 
lineage - domains independently gained 5 or more times in the set of confident 
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gain events - are all involved in signaling or regulatory functions; the Ankyrin 
repeat (gained 6 times) and SAM domain (gained 5 times) are commonly 
involved in protein-protein interactions, and the Src homology-3 and PH 
domain-like superfamily (both gained 6 times) have frequently a role in 
signaling pathways. Furthermore, I used the DAVID service (Dennis et al., 2003)
to investigate if human representative transcripts (from the table in Appendix 
B.2) were enriched in any GO terms. Significantly enriched GO terms are listed in 
Table 3.1, and are in general involved in signal transduction; among the 
significant terms are ‘adherens junction’, ‘protein modification process’ and 
‘regulation of signal transduction’. This further supported the role of novel 
domain combinations in the evolution of more complex regulatory functions.
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Table 3.1: Significant GO terms (P-value < 0.05 after correcting for multiple 
testing) for human genes that have been extended with a new protein 
domain. GO terms are obtained and clustered by using the DAVID service. 
Abbreviation CC is for Cellular Component, BP for Biological Process and MF for 
Molecular Function. EASE P-values represent modified Fisher exact P-values. 
'Benjamini' shows P-values after applying the Benjamini correction for multiple 
tests.














CC 0016323 basolateral plasma membrane 1.1 x10-6 3.1 x10-4
CC 0005924 cell-substrate adherens junction 4.3 x10-5 5.8 x10-3
CC 0030055 cell-substrate junction 6.3 x10-5 5.8 x10-3
CC 0005925 focal adhesion 2.3 x10-4 1.3 x10-2
CC 0005912 adherens junction 5.9 x10-4 2.7 x10-2













BP 0006793 phosphorus metabolic process 5.4 x10-6 9.2x10-3 
BP 0006796 phosphate metabolic process 5.4 x10-6 9.2x10-3
MF 0030554 adenyl nucleotide binding 5.6 x10-6 8.4 x10-4
BP 0043687 post-translational protein modification 6.2 x10-6 5.3 x10-3
MF 0001883 purine nucleoside binding 8.2 x10-6 7.4 x10-4
MF 0001882 nucleoside binding 9.7 x10-6 7.3 x10-4
MF 0005524 ATP binding 1.5 x10-5 9.6 x10-4
MF 0032559 adenyl ribonucleotide binding 2.1 x10-5 1.2 x10-3
MF 0003824 catalytic activity 7.5 x10-5 3.1 x10-3
BP 0006468 protein amino acid phosphorylation 8.6 x10-5 3.6 x10-2
BP 0043412 biopolymer modification 1.1 x10-4 3.8 x10-2
BP 0019538 protein metabolic process 1.4 x10-4 3.4 x10-2
BP 0006464 protein modification process 2.0 x10-4 3.7 x10-2
MF 0017076 purine nucleotide binding 2.7 x10-4 8.2 x10-3
MF 0004672 protein kinase activity 5.9 x10-4 1.4 x10-2
MF 0032553 ribonucleotide binding 8.0 x10-4 1.7 x10-2
MF 0032555 purine ribonucleotide binding 8.0 x10-4 1.7 x10-2
MF 0004713 protein tyrosine kinase activity 1.9 x10-3 3.5 x10-2
MF 0016301 kinase activity 2.1 x10-3 3.7 x10-2
MF 0000166 nucleotide binding 2.2 x10-3 3.6 x10-2
MF 0016772
transferase activity, transferring 














MF 0008270 zinc ion binding 7.3 x10-4 1.6 x10-2
MF 0043169 cation binding 1.9 x10-3 3.6 x10-2
MF 0046872 metal ion binding 2.3 x10-3 3.6 x10-2
MF 0043167 ion binding 2.8 x10-3 4.2 x10-2















Ras guanyl-nucleotide exchange factor 
activity
2.9 x10-6 6.5 x10-4
MF 0005089
Rho guanyl-nucleotide exchange factor 
activity
6.9 x10-6 7.7 x10-4
BP 0035023 regulation of Rho protein signal 
transduction
5.4 x10-5 3.0 x10-2
MF 0005085
guanyl-nucleotide exchange factor 
activity
2.3 x10-4 7.2 x10-3




5.1 x10-4 1.3 x10-2
MF 0005083 small GTPase regulator activity 1.3 x10-3 2.6 x10-2















inositol trisphosphate phosphatase 


















MF 0004386 helicase activity 1.2 x10-4 4.5 x10-3
MF 0070035
purine NTP-dependent helicase 
activity
2.1 x10-3 3.6 x10-2

















MF 0005044 scavenger receptor activity 2.6 x10-6 1.2 x10-3
MF 0019992 diacylglycerol binding 3.6 x10-5 1.8 x10-3
MF 0005488 binding 6.7 x10-5 3.0 x10-3
MF 0005515 protein binding 3.0 x10-4 8.3 x10-3
MF 0016787 hydrolase activity 3.1 x10-3 4.1 x10-2
BP 0007160 cell-matrix adhesion 1.9 x10-4 4.0 x10-2
CC 0044459 plasma membrane part 2.2 x10-4 1.5 x10-2
BP 0009966 regulation of signal transduction 1.1 x10-4 3.2 x10-2
MF 0004713 protein tyrosine kinase activity 1.9 x10-3 3.5 x10-2
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3.4 Discussion
3.4.1 Scope of the study
By looking at the evolution of multi-domain proteins, I address here the question 
of mechanisms of creation of novel animal genes. The current state in the field is 
that the approach to this problem is more theoretical and centers around the 
rare clear examples of novel gene creation (Long, 2001). This is the first study 
that systematically looked at the mechanisms that created novel, more complex, 
animal genes. My approach to this was to present proteins as strings of 
functional domains and look at the domain rearrangements. Earlier studies that 
examined characteristics of gained or lost protein domains were comparing 
proteins with similar domain architectures, which alone did not allow 
distinction between gain and loss events (Bjorklund et al., 2005; Weiner et al., 
2006). Here, I use direct phylogenetic relations among animal genes to identify a 
high-confidence set of protein domain gain events, which enabled me to study 
general trends in evolution of more complex domain architectures in the animal 
kingdom. Secondly, I relate information from the proteins to the underlying exon 
structures to help elucidate the causative mechanisms. To assign domains to 
proteins, I used Pfam-A domain annotations. However, Pfam-A is not 
comprehensive, and inclusion of unassigned regions could have increased the 
number of inferred domain gains in the study. Additionally, profile HMMs for 
individual Pfam domains do not necessarily cover all related sequences. I have 
tried to overcome this by grouping domains into clans, which include more 
distantly evolutionarily related domain profiles. However, even after domain 
refinements, it is possible that domain assignments are sometimes falsely 
omitted from the sequences. To avoid false domain gain calls, I excluded all 
similar sequences that differed in domain assignments from the analysis 
(Section 3.2.2). This again lowered the number of inferred domain gain events. 
The main aim of this study was to obtain a set of high confidence domain gain 
events. However, by excluding possible false cases of domain gain events, real 
cases might have been missed too.
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To find a set of high confidence domain gain events, I used gene 
phylogenies of completely sequenced animal genomes from the TreeFam 
database (Ruan et al., 2008). TreeFam contains phylogenetic trees of animal 
gene families, and is able to assign ortholog and paralog relationships because it 
records the positions of speciation and duplication events in the phylogenies. I 
assigned domains to the protein sequences in these families according to Pfam 
annotation (Finn et al., 2008). The Pfam database provides the most 
comprehensive collection of manually curated protein domain signatures. Its 
family assignments are based on evolutionarily conserved motifs in the protein 
sequences.
3.4.2 Approach for obtaining the set of confident domain gain 
events
The relative frequencies of domain gain and loss events are not known and most 
probably not universal for different domains and organisms. Hence, different 
approaches have been undertaken to address this issue. Several previous studies 
have assumed that the frequency of gain and loss events are equal and have 
identified domain gains and losses by applying maximum parsimony 
(Kummerfeld and Teichmann, 2005); (Buljan and Bateman, 2009; Fong et al., 
2007; Forslund et al., 2008). Other studies have assumed that domain loss is 
slightly more likely than domain gain (Itoh et al., 2007) or that the difference in 
the frequency of gains and losses is very significant and hence have suggested 
Dollo parsimony (which allows a maximum of one gain per tree) for identifying 
domain gains (Basu et al., 2008; Przytycka et al., 2006). I found that the set of 
domain gains obtained by applying maximum parsimony was heavily enriched 
in cases that were misidentified multiple domain losses in the tree. Therefore, it 
is also possible that the frequency of gene fusions and reinvention of domain 
architectures is smaller than previously proposed (Kummerfeld and Teichmann, 
2005; Fong et al., 2007; Forslund et al., 2008). On the other hand, if there were 
situations where the same domain was gained more than once in the same gene 
family, Dollo parsimony would still predict only one domain gain and would not 
distinguish different gain events. Therefore, my approach was to identify domain 
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gains by assuming that the losses were slightly more likely than gains (by 
applying Weighted parsimony) and then filter these to only include trees with a 
single gain (using the rationale of Dollo parsimony). This strategy appeared to 
reduce the number of likely false domain gains as judged by inspection of the 
results.
3.4.3 Mechanisms of domain gain
Present domain combinations are shaped by the causative molecular mutation 
mechanisms followed by natural selection. In this chapter, I addressed the 
question of what mechanisms have been and possibly still are creating novel, 
more complex, animal domain architectures and hence new functional 
arrangements. I investigated the supporting evidence for the mechanisms that 
are believed to be candidates for the observed domain gains and found several 
examples of domain gain that can be clearly connected with their causal 
mechanisms. These examples illustrate domain gain through retroposition and 
through joining of exons from adjacent genes. 
The SETMAR gene, an example for the role of retroposition, is of 
particular interest because it adds to the list of only a few known examples of 
novel gene creation in the human lineage assisted by this mechanism. It was 
discussed before that retroposed domains are most likely to be found at the C-
termini of genes (Babushok et al., 2007b). By this means, the issue of 
transcription regulation would be avoided. In the case of the SETMAR gene, the 
retroposed domains are at the N-terminus. However, this gene lies in the intron 
of another gene on the opposite strand. This suggests that transcription of the 
SETMAR gene could be facilitated by open chromatin structure and transcription 
of the gene that it overlaps with. Interestingly, a similar phenomenon was 
reported for the novel human genes that evolved from noncoding DNA (Knowles 
and McLysaght, 2009). A lack of evidence for other candidate cases is not a 
definite proof that retroposition was not the active mechanism. Frequency of 
multi-exon domains is higher among the ‘ancestral’ domains in the 
representative proteins, i.e. among those domains that were not categorized as 
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gained domains in this study (86% of the ‘ancestral’ domains in the 
representative proteins are encoded by two or more exons, Section 3.3.2). This 
could imply that domains encoded by a single exon were more easily inserted 
into proteins during evolution, or even that among the gained domains are other 
cases of domain retroposition. In addition, intron insertions during evolution of 
animal genes could have camouflaged the cases of domain gains through 
retroposition. However, more than 70% of the gained domains in the whole set 
are encoded by more than one exon, and extra exons have also frequently been 
gained together with the gained domains which are encoded by a single exon 
(Section 3.3.6.2). Intron presence in the majority of the gained domains would 
therefore suggest that retroposition did not have a major role in the evolution of 
animal domain architectures.
With regard to other lineages, only the gains in insects, with 
representative proteins from Drosophila melanogaster, have numerous examples 
(22 cases) of a gain of domain coded by one exon, leaving open the possibility 
that retroposition might be a more important mechanism for domain gain in 
insects than it is in other lineages. However, overall this seems to be a rare 
mechanism for domain gain in animals. Additionally, it is important to note that 
previous work also underlined the role of adjacent gene joining (Zhou et al., 
2008) and NAHR (Yang et al., 2008) in the formation of chimeric genes in the 
Drosophila lineage.
The dominant mechanism for domain gains in the animal genomes 
appears to be joining of exons from adjacent genes. Additionally, this mechanism 
seems to be in a strong connection with gene duplication. Apart from showing 
here the evidence for the dominant role of adjacent genes’ exons joining, I also 
find the examples that directly illustrate how this mechanism operates. These 
examples are shown in Figure 3.8. After duplication, exons that encode one or 
more domains are joined with exons from an adjacent gene. The examples are 
interesting from the point of view of evolution of protein diversity, but also as 
additional examples for novel gene creation during animal evolution. In addition, 
I addressed here the possible role of recent segmental duplications in gene 
evolution. As a result, I found two genes that were created after a segmental 
duplication event. The possible mechanism for creation of these genes is 
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illustrated in Figure 3.10. However, it is necessary to be cautious when assessing 
the possible roles of these proteins. For both examples, there is only transcript 
evidence and some of the transcript products of these genes appear to have a 
structure that would lead to them being targeted by NMD (Wilming et al., 2008). 
Sometimes it is possible for a transcript to avoid the NMD signal and in this case 
these examples would be of high interest as possible sources of novel function. 
In the case that these transcripts are silenced by NMD, these genes are still 
interesting examples from the theoretical point of view; they directly illustrate 
the mechanism of how gene evolution can work. Initially, part of a gene sequence 
gets duplicated and recombined with another gene; if juxtaposed exons are in 
frame, a joint transcript can be created and through NMD deleterious protein 
variants can be silenced at the transcript level while allowing at the same time 
introduction of novel mutations that can be tested later on.
Another mechanism that can cause gain of a novel protein domain is 
exonisation of a previously non-coding sequence. Here, I observe that domains 
which are gained as exon extensions are preferentially disordered (Figure 3.11). 
If a new protein domain is gained from a previously non-coding sequence it is 
more likely that the encoded protein region will not be structured and that the 
sequence will be inserted through exon extension rather than as a completely 
new exon. Hence, disordered protein regions, which are gained as exon 
extensions are likely candidates for a domain gain through exonisation of non-
coding sequence. Conversely, this also suggests a possible mechanism for 
evolution of disordered protein regions. An illustration from the literature for 
the significance of inclusion of novel disordered segments into proteins is the 
evolution of NMDA receptors. These receptors display a vertebrate specific 
elongation at the C-terminus. Gained protein regions are disordered and govern 
novel protein interactions, and it is believed that this might have contributed to 
evolution and organization of postsynaptic signalling complexes in vertebrates 
(Ryan et al., 2008). 
Further support for the assumption that domain gains through exon 
extensions are enriched in gains caused by exonisation of previously non-coding 
sequences comes from the observed bias for these gains to occur at the C-
terminus (Figure 3.5). Namely, it is expected that gains by exonisation are most 
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likely to be observed at C-terminus since extension of exons at N-terminus or in 
the middle of proteins can introduce frame shifts and hence can be selected 
against. However, Pfam families that are classified as exon extensions are also 
likely to be shorter so it is possible that this introduces some bias, since shorter 
families are less likely to be domains with defined structures. Moreover, an 
important caveat is that only a systematic study can confirm domain gain by this 
mechanism; apparently non-coding sequences, which are homologous to gained 
domains, might only lack transcript and protein evidence in the less studied 
species and thus miss domain assignment. In addition, it is important to note 
that exonisation of previously noncoding sequences is not the only mechanism 
that can explain exon extensions. Other possible mechanisms are gene 
recombination inside exon regions and deletion of sequences between exons of 
two adjacent genes.
Analysis of the high confidence set of domain gain events suggests that 
retroposition and recombination-assisted intronic insertions, in contrast to 
previous expectations (Kaessmann et al., 2002; Liu and Grigoriev, 2004), are 
minor contributors to domain gains. Therefore, it is possible that the role of 
intronic insertions had been overestimated previously. It will be interesting to 
see if the observed excess of symmetrical intron phases around exons coding for 
domains (Kaessmann et al., 2002) is due to exon shuffling or to some other 
mechanism such as selective pressure from alternative splicing (Lynch, 2002).
3.4.4 Domain gains were assisted by recombination events 
Gained domains can have an origin in the neighboring genes or non-coding 
sequences, or they can be inserted into another gene by the transposon 
machinery. Results presented in this chapter suggest that exonisation of non-
coding sequence and retroposition were not the mechanisms that caused the 
majority of the high confidence gain events. Additionally, the analysis showed 
that in animals without the reported gain, genes homologous to those whose 
exons were joined together were not adjacent to each other on the genome. 
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Hence, the most probable explanation is that the majority of these events were 
preceded by recombination, which juxtaposed novel gene combinations.
In 80% of the gain events, a domain gain has occurred after duplication 
of either a ‘donor’ or ‘acceptor’ gene. Retroposition does not seem to be a valid 
explanation for the majority of these duplications and it is possible that they 
were created by a recombination mechanism. Additionally, I observed a bias in 
the chromosomal positions of the plausible ‘donor genes’ in the way that they 
were preferentially found on the same chromosomes as genes with the gained 
domains. The bias was more prominent for the younger gain events (Figure 
3.12), possibly due to continuous chromosomal rearrangements.  NAHR creates 
duplicates more frequently than IR does (Freeman et al., 2006; Roth et al., 1985), 
creates them preferentially on the same chromosome (Freeman et al., 2006) and 
provides ground for gene rearrangements. Therefore, it is possible that NAHR 
assisted domain gains, and in particular preceded joining of exons from adjacent 
genes. I do not exclude IR as a possible causative mechanism but NAHR seems 
more likely given the bias in chromosome locations of domain duplicates and 
reliance of the gain mechanism on gene duplication. Moreover, recent work by 
Kim and colleagues (Kim et al., 2008) has suggested that even though IR might 
be important for the formation of new copy number variants in the human 
genome, NAHR - mediated by Alu elements and existing segmental duplications 
themselves - had a dominant role in the formation of fixed segmental duplicates.
If recombination acted to juxtapose novel domain combinations, it is 
possible that it directly created novel introns and joined exons from the two 
adjacent genes. However, it is more likely that recombination only brought novel 
exons from two different genes into proximity, allowing alternative splicing to 
create novel splice variants. As discussed above, there are indications that NAHR 
could have caused the initial duplications and rearrangements. The implications 
for the role of NAHR in animal evolution in general are particularly interesting 
since this mechanism is still primarily associated with more recent mutations in 
the human genome (and primate genomes in general), structural variations in 
human population and disease development (Bailey and Eichler, 2006; Conrad 
and Hurles, 2007; Stankiewicz and Lupski, 2002). It has, however, recently been 
proposed that other mechanisms, such as Fork Stalling and Template Switching 
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(FoSTeS) mechanisms could have also had a role in genome and single-gene 
evolution. FoSTeS (Zhang et al., 2009), a replicative mechanism that relies on 
microhomology regions, seems to provide a better explanation for complex 
germline rearrangements, but also for some tandem duplications in the genome, 
than NAHR and IR (Gu et al., 2008). Hence, the exact relative contributions of 
these different mechanisms are still to be determined. However, this might be 
hampered by sequence divergence after domain gain events, which have 
occurred millions years ago.
In conclusion, work presented in this chapter gives evidence for the 
importance of gene duplication followed by adjacent gene joining in creating 
genes with novel domain-combinations. The role of duplicated genes in donating 
domains to adjacent proteins is a potentially important, and powerful, 
mechanism for neofunctionalisation of genes.
3.4.5 Different trends in domain gains in different lineages and at
different time points during evolution
It is important to note that even though I have attempted here to draw general 
conclusions about dominant mechanisms for evolution of animal genes, it is 
possible that contributions of different mechanisms differ between different 
species and at different time points during evolution. The percentage of active 
retrotransposons, rates of chromosomal rearrangements and intergenic splicing 
can be different in different genomes. Similarly, selection force, which decides on 
toleration of intermediate stages in gene evolution, depends on the population 
size and will differ between different species. Therefore, it is possible that we 
will find evidence that some mechanisms are more relevant in some species than 
they are in others. This is illustrated with differences in characteristics of the 
gained domains in vertebrates and Drosophila. The dominant mechanism in 
Drosophila seems to be the extension of exons at the C-terminus. Additionally, 
even though the majority of gain events are represented by human proteins, 
different mechanisms could have dominated at different evolutionary time 
points in the human lineage. For example, LINE-1 retrotransposons are 
abundant in mammals but not in other animals (Han and Boeke, 2005), and 
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whole genome duplication that occurred after divergence of vertebrates (Dehal 
and Boore, 2005) could have preferred recombination between gene duplicates 
at that point in time. 
3.4.6 Functional implications of domain gain events
Creation of novel genes is assumed to play a crucial role in the evolution of 
complexity. Previous studies have put a considerable effort into identifying gene 
gain and loss events during animal evolution, as well as into analyzing functional 
and expression characteristics of these genes (Blomme et al., 2006; Hahn et al., 
2007; Milinkovitch et al., 2010; Tzika et al., 2008). In this study, my aim was to 
investigate functionally relevant changes of individual proteins. Implications of 
observed domain gains on the evolution of more complex animal traits are 
highlighted by the frequent regulatory function of the gained domains in the 
human lineage. Shuffling of regulatory domains has already been proposed as an 
important driving force in the evolution of animal complexity (Peisajovich et al., 
2010; Pawson and Nash, 2003), and an increase in the number of regulatory 
domains in the proteome has been directly related to the increase of organism 
complexity (Vogel and Chothia, 2006).
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Protein products of tissue-specific 
alternative splicing
4.1 Introduction
In the previous chapter, I have described evolutionary mechanisms that can 
increase diversity in the proteome of an organism. Cellular processes that I have 
addressed there can modulate a protein’s role in a cell by adding novel 
functional segments to the ancestral proteins. I have also discussed there the 
potentially important role of intergenic alternative splicing in protein evolution. 
Intergenic splicing can be an intermediate step in gene fusion, and after gene 
fusion, alternative splicing can enable expression of both the ancestral protein 
variant, and a novel protein with a gained protein domain. Moreover, because of 
alternative splicing, many genes in the higher eukaryotic genomes are able to 
express a number of different protein products. Thus, for example, there are on 
average four isoforms for every gene in the human genome (Jin et al., 2004). 
Protein isoforms produced by alternative splicing increase protein diversity. 
Additionally, a particular isoform can modulate processes different to those 
modulated by other products of the same gene. Expression of these isoforms, 
that have a function distinct from other products of the same gene, is likely to be 
carefully regulated.
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It is well known that the same gene can be used in more than one 
signalling pathway. Sometimes, for example in the case of genes involved in the 
well studied extracellular signal-regulated kinase (ERK) cascade of the mitogen-
activated protein kinase (MAPK) pathway, regulated cellular processes can be as 
distinct as proliferation, differentiation, apoptosis, learning and memory (Shaul 
et al., 2009). Nonetheless, central genes in this cascade, such as MEK and ERK,
play a crucial role independently of the process that will eventually be induced. 
The position of these genes in the ERK cascade is illustrated in Figure 4.1. Thus, 
one of the fundamental questions is how fidelity in signalling is achieved, as it is 
clear that other regulatory mechanisms, apart from the sole level of gene 
expression, are necessary for attainment of the specific cellular response. One 
level of regulation is expression of different protein isoforms (Shaul and Seger, 
2007). For example, in the MAPK pathway, the interaction of specific alternative 
splice forms of the ERK1 and MEK1 genes facilitates mitotic Golgi fragmentation 
while interaction of other ERK1 and MEK1 splice forms plays a role in the
response to growth factor signals (Shaul and Seger, 2007). 
Here, I investigate the hypothesis that, due to alternative splicing, genes that are 
used in different cellular networks often express protein isoforms with distinct 
binding motifs. Exposition of different binding peptides would provide a 
powerful mechanism for enabling  the same gene to function in different cellular 
pathways. Moreover, it is likely that these differentially expressed binding 
peptides lie in disordered protein regions. There are several reasons for 
proposing this. Firstly, disordered protein regions are known to play crucial 
roles in regulation and signalling (Gsponer and Babu, 2009; Gsponer et al., 2008; 
Wright and Dyson, 1999). Furthermore, these regions are preferred over 
structured protein segments in protein‐protein interactions (PPI) (Shimizu and 
Toh, 2009) and are abundant in hub proteins of higher eukaryotes (Dosztanyi et 
al., 2006; Haynes et al., 2006). Finally, alternative inclusion of short disordered 
regions is less likely to disrupt the overall protein structure (Romero et al., 
2006).
140
Figure 4.1: Schematic representation of the ERK signaling cascade. The bold 
arrows show the main pathway upon growth factor activation. Red arrows show 
activatory phosphorylation events, green accessory phosphorylation and blue 
inhibitory phosphorylation and dephosphorylation. The illustration is adapted 
from (Shaul et al., 2007).
Previous studies of alternative splicing at the protein level have shown 
that the residues that are differentially present between the splice isoforms 
frequently fall in the intrinsically disordered protein regions (Romero et al., 
2006). This can be a consequence of avoidance of structured protein domains, 
but could also imply a connection between the individual isoform and specific 
function. If alternative inclusion of protein segments with distinct binding motifs 
is used to modify the behaviour of the protein in cellular pathways, then this 
process should be carefully regulated. Hence, protein segments encoded by 
finely regulated alternative splicing are more likely to be enriched in functionally 
significant regions compared to all other alternatively spliced segments. The 
structure of a protein with both ordered and disordered regions is illustrated in 
Figure 4.2.
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Figure 4.2: The structure of a human mitochondrial protein apoCox17 
illustrates a protein with both ordered and disordered regions. The change 
of the structure colour from blue to red indicates direction of the sequence from 
N- to C-terminus. The positions of amino acids at the disordered N-terminus 
(blue) are flexible and cannot be clearly defined in the structure. The illustration 
is taken from the PDB database (www.pdb.org).
Wang et al. recently reported a set of human exons that were 
differentially expressed between different tissues (Wang et al., 2008). In their 
study, Illumina deep sequencing of complementary DNA fragments was used to 
assess the level of alternative splicing in the human genome. Ten different 
human tissues and five different cell lines were used in the study: adipose, brain, 
breast, cerebellum, colon, heart, liver, lymph node, skeletal muscle, and testes; 
BT474, HME, MB435, MCF7 and T47D.  Tissue-specific expression was assessed 
by comparing read data in each tissue sample to that in the other. Since tissue-
samples were taken from different individuals, a portion of the differentially 
expressed exons might have represented allele specific splicing. The authors 
addressed this issue by comparing samples from the same tissue – cerebellar 
cortex – between different individuals and showed that the main difference in 
exon expression was indeed due to tissue-specific splicing regulation.
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In this chapter, I discuss the function of tissue-specifically expressed 
protein segments and the possible role that these regions have in regulation of 
processes in the tissues where they are expressed. I investigate a hypothesis that 
in humans, and most likely higher eukaryotes in general, protein functions in 
different tissues can expand through alternative inclusion of functional 
disordered segments. In this way, the same gene could be used in different 
cellular pathways.
4.2 Methods
4.2.1 Sets of tissue-specific, cassette and constitutive exons
Co-ordinates of tissue-specific exons were obtained from the study by Wang and 
colleagues (Wang et al., 2008) and then mapped to the longest Ensembl transcripts 
(Ensembl release 54) where the difference between these coordinates and the 
coordinates of known Ensembl exons was at most two nucleotides. Next, sets of 
cassette and constitutive exons were composed for a comparison (Figure 4.3). The set 
of cassette exons was composed from all cassette Ensembl exons. The aim here was 
to follow the rationale of the ASTD database (Koscielny et al., 2009) in classifying 
cassette exons and include in the set those instances where an entire exon was either 
present or absent in at least two transcripts. Finally, each gene in Ensembl 54 was 
represented with the longest transcripts it encodes. All other exons in the 
representative transcripts, which did not overlap with tissue-specific or cassette 
exons, made a set of constitutive exons. It is important to note that the annotation of 
an exon as any of these three types does not necessarily describe the exon correctly. 
For example, exons classified as cassette exons likely contain tissue-specific exons 
that have not been reported in the study by Wang et al., which is used here as a 
reference for tissue-specific exons. Furthermore, among the constitutive exons are 
most likely also the cases of exons that are differentially included in different 
isoforms, but not all gene isforms have been experimentally verified yet. Finally, as 
indicated by the study by Wang et al. a list of all exons in the human genome is still 
far from being complete. Only the transcripts with two or more exons were 
considered in the analysis and a script was used to map exon borders to the 
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corresponding protein coding sequences. Information about exon borders was 
obtained through the Ensembl BioMart and API.
4.2.2 Enrichment of genes with specific function in the set of tissue-
specific exons
The DAVID service (Dennis et al., 2003) was used to investigate whether genes 
that were reported to have a tissue-specific exon, which also mapped to a known 
Ensembl exon, were enriched in any molecular function GO terms. Genes with 
tissue-specific exons were uploaded and compared against the database 
background of human genes. The DAVID service was also used to test over-
representation of specific BioCarta cellular pathways in the set of tissue-specific 
genes. 
Figure 4.3: Scheme of exon classification. Tissue-specific exons are obtained 
from the study by Wang et al., while sets of cassette and constitutive exons are 
made by classifying Ensembl coding exons according to this scheme. 
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4.2.3 Prediction of disordered protein residues
Disordered regions were predicted for protein sequences of the representative 
transcripts that contained previously described tissue-specific, cassette or 
constitutive exons, using the IUPred (Dosztanyi et al., 2005) and VSL2B (Peng et 
al., 2006) software. The IUPred software predicts unstructured protein regions 
based on the lack of favourable interactions between adjacent amino acids. 
VSL2B is a baseline predictor of the VSL2 method, which uses a support vector 
machine method for prediction of disordered residues. VSL2B takes into account 
only the amino acid composition of a protein, and since it is faster than VSL2 it is 
recommended for genome-scale studies (Peng et al., 2006). This prediction 
method recognizes only the symbols for the standard 20 amino acids, so all non-
standard symbols (positions with ambiguously assigned amino acids) were 
removed from the sequences and after the prediction was carried out the 
removed amino acids were assigned the same status that the surrounding amino 
acids were predicted to have (disorder or order). 
4.2.4 Prediction of functional residues
Binding motifs in the sequences of all proteins included in the study were 
predicted using the ANCHOR software. When it was possible to find the identical 
protein sequence for the proteins from this study in the Swiss-Prot section of the 
UniProt database (UniProt release 15.5, which was in concordance with the 
Ensembl version 54), the Ensembl transcript identifiers from this study were 
mapped to the corresponding UniProt protein identifiers, and information about 
the positions of post-translationally modified (PTM) sites in these proteins was 
obtained. PTM sites that were included in the analysis were: phosphorylation, 
methylation, acetylation, amidation, addition of pyrrolidone carboxylic acid, 
isomerisation, hydroxylation, sulfation, flavin-binding, cystein oxidation and 
nitrosylation sites. When it was possible to find the corresponding international 
protein index - IPI identifier - for proteins in this study in the Phosida database, 
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positions of experimentally predicted phosphosites were mapped onto proteins. 
It was required that proteins analysed in this study contained the reported 
Phosida phosphopeptides.
4.2.5 Conservation of exons in the three different datasets
The representative genes with exons from the tissue-specific, cassette or 
constitutive set were mapped to orthologous mouse genes using the Galaxy 
service (Taylor et al., 2007). It was investigated whether the mouse genome had 
regions homologous to the exons from this study, and when the homologous 
regions were present, the level of similarity between them was assessed. Mouse 
sequences that are orthologous to the exons in these three sets were 
downloaded from the Galaxy website - pairwise alignments for human genome 
18 and Mus musculus 9 were used in the study. Fractions of identical aligned 
nucleotides per exon in the three sets were calculated. The same analysis was 
performed for aligned disordered residues only  - those predicted by IUPred -
and for aligned binding peptides only – those predicted by ANCHOR. 
Additionally, for each set of exons, a fraction of all coding residues for which it 
was possible to extract the orthologous mouse sequence was calculated. 
Similarly, a fraction of disordered residues and of the residues in the binding 
peptides for which it was possible to extract the orthologous sequence was 
calculated.
4.2.6 Significance of observed trends
To test whether the differences in the fractions of disordered residues, predicted 
binding motifs, annotated PTM sites and experimentally predicted phosphosites 
in the three sets of exons were significant Chi-square tests were applied by using 
the R software. Significance of exon and peptide conservation in the tissue-
specific set compared to two other sets, as well as conservation of peptide versus 
all other residues in the tissue-specific set, were tested with the Mann-Whitney 
tes (Wilcox test in the R software). The Mann-Whitney test was applied because 
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the distribution of exon conservation values did not follow the normal 
distribution (P<2.2x10-16, Shapiro-Wilk test for the distribution of values for 
tissue-specific exons). Test sets of cassette and constitutive exons with the same 
average length as in the set of tissue-specific exons were composed and fractions 
of predicted binding motifs and annotated PTM sites were calculated. The 
significance in the difference of fractions of the predicted functional residues 
was tested with the Chi-square test, again using the R software.
4.2.7 Comparison of MEK1 and MEK2 protein sequences
Mouse MEK1 and MEK2 protein sequences were downloaded from the Ensembl 
database. Proteins were aligned using the Needleman-Wunsch algorithm (with a 
gap opening cost of 10.0 a and gap extension cost of 0.5) from the EBI online 
service  (www.ebi.ac.uk/Tools/emboss/align/index.html). Disordered residues 
were predicted in these sequences with the IUPred software and fractions of 
disordered residues between the aligned and unaligned protein segments were 
calculated.
4.2.8 Enrichment of known disease genes in the set of tissue-
specific exons
Genes with phenotype annotations and assigned human homologues were 
downloaded from the Mouse Genome Informatics database. The significance in 
the fraction of genes with tissue-specific isoforms among the genes related to 
embryonic lethality was tested with the ChiSquare test, using the R software. 
Cancer gene census (downloaded on 21 Sep 2009) and genes from the COSMIC 
database (release 43) were downloaded from the corresponding databases. 
Genes with tissue-specific variants and the background set of all human genes in 
the Ensembl version 54 were mapped to their human gene nomenclature 
identifiers, using the Ensembl API. The significance in the fraction of disease 
causing genes between the two sets of genes was calculated again with the Chi-
square test.
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4.2.9 Disorder signatures in the protein products of the p73 gene
The protein sequence of the longest isoform of the p73 gene, TP73-001, was 
taken from the Ensembl database. Disorder and binding peptides were predicted 
using the IUPred and ANCHOR online services, respectively. 
4.3 Results
4.3.1 Sets of exons with different expression profiles
I investigated whether genes with protein coding tissue-specific exons were 
associated with any particular molecular function. I found that these genes were 
enriched with protein-binding, transferase and kinase activity GO terms (Table 
4.1). Hence, it is possible that they mediate processes which in different tissues 
include different protein partners. One possibility for achieving this is through 
utilization of functional disordered protein segments.
To test this hypothesis, I analysed three different sets of exons: (i) Protein 
coding exons that map to known Ensembl (Hubbard et al., 2009) transcripts and 
are differentially expressed between at least two different tissues or cell lines 
(tissue-specific exons), as reported by Wang et al. (Wang et al., 2008). (ii) Coding 
exons that differ in whether they are present or absent between at least two 
transcripts of the same gene (cassette exons), as annotated in Ensembl. I 
excluded from this set those exons that overlapped with other cassette exons or 
with the tissue-specific exons. (iii) Coding exons that cannot be classified as 
alternatively spliced according to the current Ensembl gene annotations 
(constitutive exons). There were 1 426 tissue-specific, 49 024 cassette and 149 
938 constitutive coding exons in their respective sets. Figure 4.3 illustrates the 
classification scheme.
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Table 4.1: Significant molecular function GO terms enriched in the genes 
with tissue-specific exons (P-value < 0.05). Subset of significantly enriched 
molecular function GO terms in the set of genes with tissue-specific exons (P-
value < 0.1). EASE P-values represent modified Fisher exact P-values (Hosack et 
al., 2003). Column ‘Benjamini’ shows P-values after applying the Benjamini 
correction for multiple tests.
GO term descripttion GO term ID EASE P-value Benjamini
P-value
Protein binding 0005515 5.4x10-16 1.6x10-12
Cytoskeletal protein binding 0008092 9.7x10-13 1.4x10-9
Actin binding 0003779 4.3x10-10 4.1x10-07
Binding 0005488 1.1x10-05 7.7x10-03
Catalytic activity 0003824 1.8x10-05 1.0x10-02










Enzyme binding 0019899 1.1x10-04 3.2x10-02
Nucleotide binding 0000166 1.3x10-04 3.4x10-02
Ras GTPase binding 0017016 1.9x10-04 4.3x10-02
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4.3.2 Tissue-specific exons are enriched in disordered residues
I compared the fractions of disordered residues in the three sets of exons with 
different expression profiles. Figure 4.2 shows a protein which contains both 
ordered and disordered regions. Disordered regions were identified using the 
IUPred software (Dosztanyi et al., 2005), which predicts unstructured protein 
regions in the segments with biased amino acid composition, such as those 
enriched in polar or charged residues, which do not allow formation of sufficient 
stabilizing interactions. I found that both sets of alternatively spliced exons - the 
set of tissue-specific and the set of cassette exons - were enriched with exons 
encoding disordered amino acids, when compared to the set of constitutive 
exons (Figure 4.4). The fraction of exons coding for unstructured protein regions 
was the highest for the tissue-specific exons (31% of tissue-specific exons were 
predicted to have 50% or more disordered residues, compared to 25 and 16% of 
cassette and constitutive exons, respectively). The difference in the number of 
disordered exons was significant when tissue-specific exons were compared to 
both cassette and constitutive exons (P<5.1x10-7 and P<2.2x10-16, respectively, 
Chi-square test, where the value of 2.2x10-16 is the smallest P-value in R). 
Furthermore, to investigate whether protein disorder is in general a feature of 
genes that undergo tissue-specific splicing or if it is a specific characteristic of 
tissue-specific exons, I compared the fraction of disordered residues among the 
tissue-specific exons to the fraction of disordered residues in all other exons 
encoded by the representative transcripts with these exons. This showed that 
disordered residues are indeed characteristic for alternatively spliced tissue-
specific exons (444 out of 1426 tissue-specific exons were encoding mostly 
disordered protein segment, compared to 3,543 out of 16,850 all other exons in 
these transcripts, P<2.2x10-16, Chi-square test).
To ensure that observations about the prevalence of disordered residues 
in the tissue-specific exons are not biased by the applied disorder prediction 
method I used another method for identification of disordered regions. The 
VSL2B software is trained on datasets of disordered proteins and uses a linear 
support vector machine approach based on amino acid composition. Prediction 
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of intrinsically disordered residues by this method confirmed that disordered 
residues are most common in the set of tissue-specific exons, followed by 
cassette exons. The fractions of exons with at least 50% predicted disordered 
residues were 53, 46 and 36% in the sets of tissue-specific, cassette and 
constitutive exons, respectively (Table 4.2). Hence, the observed enrichment of 
tissue-specific exons in disordered regions seems to be independent of the 
method for disorder prediction.
Figure 4.4: Protein regions encoded by tissue-specific exons are enriched 
in intrinsically disordered residues. The fraction of exons with at least 50% 
disordered residues in the three different sets of exons is shown. The number of 
exons with mostly disordered residues was significantly higher among tissue-
specific exons when compared to cassette and constitutive exons (P=5.1x10-7
and P<2.2x10-16, respectively, Chi-square test, details in Appendix C.1). 
Disordered residues were predicted with the IUPred software.
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Table 4.2: Fractions of exons with at least 50% disordered residues, as 
predicted by the VSL2B software. The fraction of exons with mostly 
disordered residues is still predicted to be the highest in the set of tissue-specific 
exons followed by the cassette exons. The column P-value shows significance of 
this enrichment compared to the two other sets of exons as calculated by the
Chi-square test.















4.3.3 Functional residues in disordered segments encoded by 
tissue-specific exons
My hypothesis in this study is that disordered regions encoded by tissue-specific 
exons expose functional protein segments (Romero et al., 2006). Alternatively, 
these regions could act as fillers between functional structured domains (Tress 
et al., 2008; Tress et al., 2007). Functional disordered residues are frequently 
used in transient interactions in the cell, since their intrinsic flexibility allows 
them to be readily accessible to the proteins they interact with (Gsponer and 
Babu, 2009). I investigated here whether tissue-specific disordered residues 
indeed encode segments that could be used in protein interactions. Possible 
short protein binding sites and sites of post-translational modifications (PTMs) 
reflect disordered protein regions. Here, I analyzed whether there is evidence for 
a connection between tissue-specific disordered regions and protein binding 
sites. Firstly, I investigated whether unstructured segments contained peptide 
motifs that were likely to be bound by other proteins. For this, I used the 
ANCHOR software (Meszaros et al., 2009), which identifies disordered regions 
with a potential to bind protein domains on the hypothetical interaction 
partners. I found enrichment for the predicted functional peptide motifs in the 
tissue-specific exons compared to cassette and constitutive exons (P<2.2x10-16
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and P<2.2x10-16, respectively, Chi-square test). Among the tissue-specific exons, 
29% had a binding motif, compared to 18% of cassette exons and 18% of 
constitutive exons, see Figure 4.5a. 
In addition, I investigated whether PTM sites were enriched in tissue-
specific exons. For this, I looked at the annotated PTM sites in the Swiss-Prot 
portion of the UniProt database (Consortium, 2009). The analysis covered 
phosphorylation, methylation, acetylation and other PTM sites (Methods). This 
revealed that enrichment of PTM sites was indeed present in the set of tissue-
specific exons. Tissue-specific exons had significantly more predicted PTM sites 
than cassette and constitutive exons (P<9.9x10-12 and P<3.2x10-7, respectively, 
Chi-square test). Among the tissue-specific exons from those transcripts that 
were successfully mapped to the UniProt isoforms, 13% had a PTM, compared to 
7 and 8% of cassette and constitutive exons, respectively, see Figure 4.5b. PTM 
sites are frequently associated with unstructured regions (Holt et al., 2009; 
Iakoucheva et al., 2004) and in the set of tissue-specific exons, the majority 
(69%) of exons with at least one PTM site had a PTM in the predicted disordered 
region.
As a control, I investigated if the same signal could be detected for an 
independent set of experimentally identified PTM sites. For this, I used the 
information about human phosphorylation sites stored in the Phosida database
(Gnad et al., 2007). These data came from the mass spectrometry experiment 
that studied phosphorylation sites in HeLa cells in their basal state and upon 
stimulation with the epidermal growth factor (Olsen et al., 2006). I computed the 
fraction of exons with Phosida phosphosite(s) in each of the three sets of exons 
and found that tissue-specific exons had a significantly higher fraction of 
phosphosites compared to cassette and constitutive exons (Table 4.3). Taken 
together, several independent analyses confirmed that the set of tissue-specific 
exons is enriched in functionally annotated sites associated with disorder. 
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Figure 4.5: Tissue-specific exons encode protein segments enriched with 
predicted binding motifs and annotated PTM sites. (a) Fraction of exons with
encoded binding motifs in the three different sets of exons. Binding motifs were 
predicted with the ANCHOR software. Tissue-specific exons were found to have 
a significantly higher fraction of predicted binding motifs than cassette and 
constitutive exons (P<2.2x10-16 and P<2.2x10-16, respectively, Chi-square test, 
details in Appendix C.1). (b) Fraction of exons with annotated PTM sites in the 
three different sets of exons. Tissue-specific exons were found to have a 
significantly higher fraction of PTM sites than cassette and constitutive exons 
(P<=9.9x10-12 and P<=3.2x10-7, respectively, Chi-square test, details in Appendix 
C.1). Positions of PTM sites in proteins were taken from the Swiss-Prot portion 




Table 4.3: Fractions of exons with a phosphosite identified in a single large 
scale experiment (Olsen et al., 2006). The fraction of exons with a phosphosite 
is the highest in the set of tissue-specific exons followed by the constitutive 
exons. The column headed P-value shows the significance of the enrichment in 
tissue-specific exons compared to the two other sets as calculated by a Chi-
square test.
Analysis Set of exons
Fraction of exons 






4.3.4 Distribution of functional residues in the control sets of 
cassette and constitutive exons 
Comparison of average exon lengths in the three sets of exons showed that 
tissue-specific exons were on average longer than cassette and constitutive 
exons; the average length of tissue-specific exons was 68 nucleotides (close to 23 
amino acids), and the average lengths of cassette and constitutive exons were 46 
and 54 nucleotides (15 and 18 amino acids, respectively). The fraction of exons 
with a predicted binding peptide or PTM site could be influenced by the length of 
tested exons. Therefore, I investigated if the difference in exon lengths affected 
the results which indicated enrichment for functional sites in the tissue-specific 
exons.
I filtered out shorter exons from the sets of cassette and constitutive 
exons in order to compose tests sets with the average length of exons of 68 
nucleotides. I compared the fractions of exons with predicted binding peptides 
and PTM sites in these two test sets with the one in the set of tissue-specific 
exons. I found that the set of tissue-specific exons still encoded a significantly 
higher fraction of PTM sites then the two test sets (Table 4.4). With regard to 
predicted binding peptides, I found that their fraction was significantly higher 
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among the tissue-specific exons when compared to constitutive exons, but the 
difference was not that dramatic when compared to cassette exons (Table 4.4). 
Cassette exons have a higher fraction of disordered regions, so in that sense, it is 
not surprising that disordered binding motifs are more frequently predicted in 
that set than in the set of constitutive exons. However, overall, the analysis of 
subsets with longer cassette and constitutive exons confirmed that the observed 
enrichment of tissue-specific exons with functional sites is independent of the 
exon length.
Table 4.4: Fractions of exons with either a predicted binding peptide or an 
annotated PTM site in the sets of tissue-specific exons and in the sets of 
cassette and constitutive exons that are filtered to have the same average 
length as tissue-specific exons. The column P-value shows the significance of 
the enrichment of tissue-specific exons with these functional sites compared to 
the two other sets as calculated by Chi-square test.
Analysis Set of exons
Fraction of exons 












4.3.5 Disordered residues encoded by tissue-specific exons are 
highly conserved
While the tissue-specific unstructured protein regions show apparently 
enrichment for binding motifs and PTM sites, it is known that unstructured 
proteins generally evolve faster than the structured ones (Brown et al., 2002). 
Hence, such peptide motifs could have occurred by chance. However, if they are 
functionally relevant then it is more likely that the unstructured regions and the 
predicted peptide motifs will be evolutionary conserved. Therefore, I 
investigated the similarity of exons from the three different sets with 
orthologous sequences in mouse. I compared the fractions of identical aligned 
nucleotides per exon in the three sets of exons and found that tissue-specific 
exons were significantly more conserved than cassette and constitutive exons 
(P<2.2x10-16 and P<2.2x10-16, respectively, Mann-Whitney test, Table 4.5).
I performed the same analysis for aligned disordered regions in the exons 
only. Again, I found that residues in disordered regions in tissue-specific exons 
were significantly more conserved than those in disordered regions of cassette 
and constitutive exons (P <2.2x10-16 and P <2.2x10-16, respectively, Mann-
Whitney test). The difference in the conservation of disordered regions was even 
more dramatic than the difference in the conservation of all residues in these 
three sets of exons (Table 4.5). The median value of conservation for residues in 
disordered segments was 0.90 in tissue-specific exons, 0.83 in cassette exons 
and 0.84 in constitutive exons (Figure 4.6).
Next, I looked at the conservation of predicted binding peptides only. 
Conservation of binding peptides was higher than the overall conservation of 
exons in all three sets, and it was the highest in the set of tissue-specific exons. 
Importantly, predicted binding residues were not only significantly more 
conserved in the tissue-specific exons when compared to cassette and 
constitutive exons (P<2.2x10-16 and P<2.2x10-16, respectively, Mann-Whitney 
test, Table 4.5), but were significantly more conserved then all other residues in 
the tissue-specific exons alone (P=6.3x10-6, Mann-Whitney test, Table 4.6). Thus, 
even though the binding function of these residues is only predicted, it is likely 
that they play an important role in these proteins. The median value of 
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conserved predicted binding peptides was 0.91 in tissue-specific exons, 0.86 in 
cassette exons and 0.86 in constitutive exons (Figure 4.6). 
For some residues, or whole exons, it was not possible to extract the 
orthologous mouse sequence and the reason for this is either that there is no 
orthologous sequence in mouse or that the two regions have evolved beyond 
recognition. If I take into account information about residues for which it was 
possible to extract the orthologous sequence, the observed high conservation of 
tissue-specific exons becomes even more prominent. Namely, I was able to 
extract the orthologous sequence for 98% of residues in tissue-specific exons, 
91% in cassette and 96% of residues in constitutive exons. Since disordered 
residues evolve in general faster, it is not surprising that on average less of them 
had a corresponding orthologous sequence: 98% of disordered residues in 
tissue-specific exons, 87% in cassette and 94% of residues in constitutive exons 
were aligned with their mouse orthologous sequence. Hence, this observation 
also confirms high conservation of the whole exons and in particular of the 
residues encoding disordered segments in the set of tissue-specific exons.
Taken together, the observed evolutionary conservation of tissue-specific 
exons likely reflects a functional constraint, which could have emerged due to
functionally important peptide motifs. 
158
Table 4.5: Conservation of exons in different sets, and of different elements 
in these exons. The number of exons encoding disordered segments and 
binding peptides for which orthologous mouse sequences were found is 
indicated in the column Nexons. The column headed Median shows the median 
value for the fractions of nucleotides in each exon that are identical to the 
aligned mouse nucleotides. The column P-value shows the significance of the 
difference in conservation between the set of tissue-specific exons and each of 
the two other sets as calculated by the Mann-Whitney test.
Set for analysis Set of exons Nexons Median P-value
Whole exons
Tissue-specific 1,404 0.89 N/A
Cassette 44,750 0.86 P<2.2 x10-16
Constitutive 143,811 0.87 P<2.2 x10-16
Disordered 
regions
Tissue-specific 883 0.90 N/A
Cassette 24,120 0.83 P<2.2 x10-16
Constitutive 68,719 0.84 P<2.2 x10-16
Binding 
peptides
Tissue-specific 630 0.91 N/A
Cassette 13,600 0.86 P<2.2 x10-16
Constitutive 37,708 0.86 P<2.2 x10-16
Table 4.6: Predicted binding peptide sites in Tissue-specific exons are 
significantly more conserved than other residues in these exons. The P-
value is calculated with the Mann-Whitney test. The number of exons that were 
applicable for the test is shown in the column Nexons. The column Median shows 














Figure 4.6: Residues in predicted disordered regions and peptide binding 
sites in the tissue-specific exons are highly conserved. (a) Conservation of 
predicted disordered residues in the three sets of exons, as calculated from 
residues aligned with mouse orthologus sequences. The median value for each 
set is shown as thick black line. Boxes enclose values between the first and third 
quartile. The interquartile range (IQR) is calculated by subtracting the first 
quartile from the third quartile and all values that lie more than 1.5x IQR lower 
than the first quartile or 1.5x higher than the third quartile are considered to be 
outliers and are not shown on these graphs. The smallest and the highest value 
that is not an outlier are connected with the dashed line. Disordered residues in 
tissue-specific exons were found to be significantly more conserved than those 
in cassette and constitutive exons (P <2.2x10-16 and P <2.2x10-16, respectively, 
Mann-Whitney test, details in Table S3) (b) Conservation of predicted binding 
peptides, as calculated from residues aligned with mouse orthologous 
sequences. Predicted binding peptides in tissue-specific exons were found to be 
significantly more conserved than those in cassette and constitutive exons (P 





4.3.6 Genes with tissue-specifically regulated exons have an important 
function in organism development and survival
If genes with tissue-specific isoforms tend to take part in different cellular 
pathways then mutations in these proteins are likely to have severe effects on 
the cellular and organism phenotype. I performed several analyses to see if this 
was the case. Firstly, I investigated whether genes from the MGI database (Bult 
et al., 2008), which are known to cause embryonic lethality in mice when 
mutated, were enriched with orthologues of human genes that have tissue-
specific isoforms. I indeed found that genes with the tissue-specific isoforms 
were overrepresented among the genes involved in embryonic lethality 
(P<1.2x10-8, Chi-square test, Table 4.7, Figure 4.7), which implied their 
potentially important role in the early stages of development.
Secondly, I investigated whether mutations in these genes could be 
related to cancer phenotype, since disruption of signalling pathways is a 
common initiator of the disease. Moreover, the study by Wang et al. that 
reported tissue-specific exons also included five different cancer cell lines, which 
increased the chances of detecting genes whose isoforms were potentially 
related to cancer. Indeed, I found that both Cancer Gene Census genes (Futreal et 
al., 2004) (genes that have been causally implicated in cancer) and genes from
the COSMIC database (Forbes et al., 2008) (genes found to be somatically 
mutated in different cancer cells) were enriched with genes that have tissue-
specific isoforms (P-values were  6.2x10-2 and 3.2x10-6 respectively, Chi-square 
test, Table 4.7, Figure 4.7). This suggested a possible connection between the 
genes with tissue-specific isoforms and cancer phenotype. 
Finally, I investigated whether the genes with tissue-specific isoforms 
were enriched in any particular cellular pathway since this could possibly imply 
their influence on the phenotype. I found that these genes were enriched with 
genes that belong to the PDZ pathway (Table 4.8), a pathway in which 
disordered residues are known to play an important role. Apart from the 
significant overrepresentation of genes from PDZ pathway, this analysis 
revealed another important link; clustering of genes with similar function 
showed overrepresentation of genes from the MAPK pathway (Table 4.8). A 
161
possible connection with disordered residues here is suggested by the following 
example from the literature. The MAPK kinase MEK exists in two gene copies, 
MEK1 and MEK2, which have essentially identical sequences but significantly 
different effects on the phenotype. I looked at the predicted disordered residues 
in these proteins and found that 54% of amino acids that differed between MEK1 
and MEK2 were predicted to be disordered, compared to only 1% of the 
identical residues. Therefore, it is possible that in this known example from the 
MAPK pathway disorder functions as a mediator of protein interactions in a
similar way in which I expect it acts in tissue-specific isoforms analysed here. 
Taken together, these results suggest that mutations in genes with tissue-
specific isoforms can have dramatic effects on the phenotype of an organism by 
influencing developmental and other crucial signalling pathways and that there 
is a possible link with disordered residues in the mechanism of its action. 
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Table 4.7: Genes that are associated with embryonic lethality and cancer 
phenotype are enriched in genes with tissue-specific isoforms. The Ntotal
column shows the number of genes that I successfully mapped to identifiers in 
the underlying disease gene databases. The N+ column shows the number of 
tissue-specific or all other genes in the databases that are also implicated in 
disease and N- those that are not annotated as such. Background genes in the 
case of the Mouse Genome Informatics (MGI) database are all human genes with 
mouse orthologues that have known phenotype effects. In the case of Consensus 
cancer genes and COSMIC genes, background genes are all human genes in the 
Ensembl 54 successfully mapped to human gene nomenclature identifiers. 
Background genes include Tissue-specific genes. P-values are for the Chi-Square 
tests.
Analysis Set of genes N+ N- Ntotal P-value
MGI
Tissue-specific 
genes 202 963 1,165
P<1.2 x10-8





genes 31 1,153 1,184
P<6.2 x10-2
All genes in the set 345 18,630 18,975
Cosmic
Tissue-specific 
genes 227 957 1,184
P<3.2 x10-6
All genes in the set 2,697 16,278 18,975
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Figure 4.7: Fraction of genes with tissue-specific isoforms that are among 
the disease causing genes compared to background human genes. This is an 
illustration of data from Table 4.7. Background genes are always composed of all 
human genes with the identifiers in the corresponding databases. (a) Fraction of 
tissue-specific genes (red column) and all genes in the MGI database (grey 
column) that cause embryonic lethality when mutated. (b) Fraction of tissue-
specific genes (red column) and all Ensembl genes with HGNC identifiers that 
are known to be involved in cancer development. (c) Fraction of tissue-specific 
genes (red column) and all Ensembl genes with HGNC identifiers that were 






Table 4.8: Pathways overrepresented among the genes with tissue-specific 
exons. The top results of a search for BIOCARTA pathways (www.biocarta.com)
that are overrepresented among the genes with tissue-specific exons are shown. 
Only the most significant individual pathway and cluster of pathways are 
included in the table. Lists of all terms that are reported to be enriched, but not 
with high significance are in Appendix C.2. The EASE P-values represent 
modified Fisher exact P-values (Hosack et al., 2003). The column ‘Benjamini’ 
shows P-values after applying the Benjamini correction for multiple tests.




Synaptic Proteins at the 
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4.3.7 Alternative isoforms of the gene p73
An example from the literature that illustrates the potential importance of 
alternative inclusion of exons that encode disordered protein segments is the 
one of the p73 gene. Gene p73 is a homologue of the p53 gene and its main 
function is tumour suppression. However, this gene encodes a number of splice 
variants (Figure 4.8) which have been shown to be expressed in a tissue-specific 
manner (Ishimoto et al., 2002). These different splice isoforms all share the same 
central DNA binding region and differ in the alternative inclusion of N- and C-
terminal exons (Bourdon, 2007). Functionally, the isoforms differ in their 
binding specificity, and the most striking of them is the ΔNp73 isoform which 
lacks the first three exons that encode the ‘transactivating region’ (Figure 4.8). 
Instead of acting as a tumour suppressor, the ΔNp73 isoform acts as an oncogene 
- possibly by competing with both p53 and other p73 isoforms for the DNA 
binding site (Ishimoto et al., 2002). When I predicted disordered regions
(Dosztanyi et al., 2005) in the main protein isoform TP73001, which includes 
also the terminal exons, I observed that the encoded protein had several
disordered segments and most importantly, that the N-terminal region encoded 
by the first three exons is predominantly disordered (Figure 4.8). Additionally, 
this region also contained two predicted binding peptides (not shown), as 
predicted by ANCHOR (Meszaros et al., 2009). Similarly to the p73 protein, it has 
been reported previously that the N-terminal region of the human p53 tumour 
suppressor protein contained large disordered segments (Bell et al., 2002; 
Dawson et al., 2003). The N-terminal part of the p53 protein has an important 
regulatory role (Chumakov, 2007), and so far, three different protein partners 
have been shown to bind to this region – binding peptides for these proteins 
were successfully predicted with ANCHOR (Meszaros et al., 2009). The example 
of the p73 gene clearly illustrates that the alternative inclusion of disordered 
protein segments can dramatically affect the function of a protein.
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Figure 4.8: p73 gene and its isoforms. Figures a and b are adapted from
(Bourdon, 2007), and show different splicing events that occur in the p73 gene. 
(a) The intron-exon structure of the gene is shown. Black boxes indicate 5’ and 3’ 
untranslated exon regions, and white boxes exon regions that encode protein 
sequences. There are two alternative transcription start sites: before the exon 1 
and before the exon 3’. (b) Protein segments encoded by different exons are 
shown. All splice isoforms apart from ΔN’p73 have the central DNA-binding 
domain, but differ in the segments encoded by the N- and C-terminal exons. The 
exon numbering in section (a) is transferred to section (b) of the figure. (c) 
Disordered regions (threshold is at 0.5 disorder tendency) in the longest Tap73 
(TP73-001) isoform, as predicted with the IUPred software.  This isoform 
includes the first three N-terminal exons that are missing in the ΔNp73 isoform 
and these are indicated with a grey square in the disorder prediction graph. The 
greatest part of the protein segment encoded by these first three exons is 





4.3.8 Tissue-specific splicing and protein domains 
The role of intrinsic disorder as a mediator of protein interactions is becoming 
increasingly recognized. However, the most studied and better-understood 
protein interactions are those mediated by protein domains of conserved 
sequence and defined structure. Therefore, I also investigated whether known 
protein domains, taken from the Pfam database (Finn et al., 2008), were affected 
by tissue-specific alternative splicing and if so, what was the predicted function 
of these domains. It was previously reported that alternative splicing tends to 
avoid protein domains more frequently than expected by chance (Kriventseva et 
al., 2003). I investigated if the same trend was present in tissue-specific and 
cassette exons, and found that indeed domains were avoided in both types of 
alternative-splicing events. Fractions of exons that overlapped with a predicted 
Pfam domain (Finn et al., 2008) were 43% and 42% in the sets of tissue-specific 
and cassette exons, respectively, compared to 54% of constitutive exons that 
overlapped a Pfam domain (P-value < 2.47x10-15 and P-value < 2.2x10-16 for 
tissue-specific and cassette sets of exons, respectively, Chi-square test). This 
confirmed that alternative splicing tends to avoid protein domains and is more 
likely to occur in protein regions without annotated domains.
Next, I looked at functional annotation of domains that were completely 
removed from proteins by tissue-specific alternative splicing. For this, I 
identified the cases where alternative splicing affected 90% or more of the 
domain, and exclusion of the tissue-specific exon removed all copies of the 
domain from a protein. I found that tissue-specific splicing affected 
predominantly DNA and protein binding domains (Table 4.9). However, this 
preference for binding domains was not statistically significant. Binding domains 
are in general common in the human genome, and the similar issue with 
recognizing the trends that affect these domains has been discussed previously 
with regard to DNA and protein binding domains in alternative splicing in 
general (Lareau et al., 2004; Resch et al., 2004). Nonetheless, specific binding 
domains are likely to play important roles in tissue-specific alternative splicing. 
An interesting example from Table 4.9 is discussed in Figure 4.9.
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Table 4.9: Pfam domains that are removed from the protein products of a
gene by tissue-specific alternative splicing. The column Ensembl ID indicates 
a transcript identifier to which the corresponding tissue-specific exon is 
mapped, Pfam ID shows the Pfam identifier of the domain that is removed from 




Ensembl ID Pfam ID Domain name
DNA/RNA binding
ENST00000313565 PF00096
Zinc finger, C2H2 
type
ENST00000235372 PF00096 Zinc finger, C2H2 
type
ENST00000374012 PF00096 Zinc finger, C2H2 
type








ENST00000380828 PF01754 A20-like zinc finger







ENST00000367580 PF07654 Immunoglobulin C1-
set domain








ENST00000397753 PF00651 BTB/POZ domain
ENST00000396852 PF02023 SCAN domain
ENST00000330501 PF02023 SCAN domain
ENST00000308874 PF07645 Calcium binding EGF 
domain
ENST00000372476 PF07974 EGF-like domain
ENST00000331782 PF07645 Calcium binding EGF domain
169
ENST00000379446 PF00018 SH3 domain
ENST00000216733 PF00018 SH3 domain
ENST00000219069 PF01352 KRAB box




ENST00000268605 PF00619 Caspase recruitment 
domain
ENST00000262320 PF00615
Regulator of G 
protein signaling 
domain
ENST00000345122 PF00071 Ras family
ENST00000345122 PF01846 FF domain
ENST00000355619 PF00646 F-box domain
ENST00000333602 PF00627 UBA/TS-N domain








ENST00000305631 PF00487 Fatty acid desaturase




ENST00000404535 PF01928 Trypsin inhibitor domain




ENST00000264381 PF00135 MutS domain V
ENST00000338660 PF00092 Carboxylesterase
ENST00000258613 PF00090 von Willebrand 
factor
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Figure 4.9: Example of a tissue-specific exon exclusion that removes the 
whole domain from a protein product. The ZNF397-202 isoform of Zinc finger 
protein 397 (ENST00000330501) encodes several DNA binding Zinc finger 
repeats and the protein interaction SCAN domain. Tissue-specific alternative 
splicing removes the exon that encodes the SCAN domain, thus possibly 
preventing the interactions that modulate action of this protein.
4.4 Discussion
4.4.1 Evolution and function of alternative splicing
Alternative splicing is considered to be a major source of functional diversity in 
animal proteins, particularly in mammals (Keren et al., 2010; Kondrashov and 
Koonin, 2003). Its major role is in increasing proteome diversity, but this 
mechanism also regulates transcript abundance through nonsense-mediated 
decay (Stamm et al., 2005). Data obtained by new sequencing technologies 
suggest that the degree of splicing  in human genes is much higher than 
previously anticipated, with more than 95% of multiexon genes undergoing 
alternative splicing (Pan et al., 2008). 
New alternative splice isoforms can be created by the insertion of new 
protein coding sequences that originated from noncoding sequences of introns
(Kondrashov and Koonin, 2003). However, as discussed in Chapter 3, alternative 
splicing can also play an important role after exon shuffling, in particular after 
gene fusion, ensuring that ancestral protein products are expressed together 
with new protein isoforms. Finally, new splice isoforms can emerge after 
transition of a constitutive exon to an alternative exon (Lev-Maor et al., 2007). 
Interestingly, it has been found that the origin of an exon can influence how 
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frequently it is spliced into an mRNA (Modrek and Lee, 2003), with old exons 
more frequently being constitutive than younger exons. 
Splicing can be regulated in a tissue- or developmental stage-specific 
manner. Such carefully regulated exons have been considered as a special class 
of exons in the previous studies as well, and specific regulation of an isoform was 
sometimes taken as support for its function (Lareau et al., 2004). In particular, 
tissue-specific exons were found to exhibit characteristics that can distinguish 
them from other types of exons. It was shown that tissue-specific exons tend to 
be highly conserved and modular – i.e. their length is often a multiple of three so 
inclusion or exclusion of these exons does not disrupt the translation of the rest 
of the protein (Xing and Lee, 2005). In this study, I observe that tissue-specific 
exons are enriched in functional disordered protein regions, which suggests that 
finely regulated expression of different splice isoforms of the same gene plays an 
important regulatory role. 
Previous analyses of alternative splice isoforms of the same gene 
demonstrated that alternative splicing can determine the intracellular 
localization of a protein, enzymatic activity and stability, but also the 
posttranslational modifications and binding properties of a protein – including 
the binding of small ligands, nucleic acids and other proteins (Stamm et al., 
2005). In line with this, it was suggested that alternative splicing bridges the gap 
between organism complexity and the number of genes in the organism not only 
by increasing the proteome size, but also by increasing the regulation and 
complexity of cellular networks (Lareau et al., 2004; Resch et al., 2004). Results 
from this study further emphasise the regulatory role of alternative splicing.
This study focused on alternatively spliced exons that encode functional 
residues which determine protein-protein interactions. However, alternative 
inclusion of other, even short, protein segments can have dramatic consequences 
for the overall protein function. A good illustration for this is the Piccollo protein 
(Garcia et al., 2004). This gene produces two protein isoforms that differ in nine 
residues. As a result of this, the shorter isoform has a stronger binding affinity 
for Ca2+, but is also incapable of undergoing Ca2+- dependent dimerization that 
normally occurs in a longer isoform. The structural study of this protein showed 
that this was a consequence of a large structural change induced by the omitted 
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short motif. Apart from causing a drastic change in protein structure, alternative 
splicing can also affect the connector region between the globular domains of a 
protein and in that way influences their orientation and recruitment of their 
binding partners. Additionally, splicing can also affect regions that determine
ligand binding, which was not covered in this study. Hence, design of this study 
covers only a fraction of alternative splice events that can have important
consequences for the overall protein function.
4.4.2 Unstructured functional residues direct isoform-specific 
networks
In this study, I observed a strong enrichment of tissue-specific exons in 
unstructured protein regions. Moreover, I also found that the disordered regions 
encoded by tissue-specific exons were likely to expose functional residues which 
determine binding interactions with other proteins. These binding interactions 
are determined by the exposed binding peptides and PTM sites. 
Tissue-specific exons are overall more conserved than other exons; this 
has been reported before and is also confirmed by the results from this study
(Xing and Lee, 2005) (Table 4.5). Interestingly, I observed that a large 
contribution to this high conservation of tissue-specific exons came from the 
exon regions that encode unstructured protein segments (Table 4.5). This can be 
explained either by the important function of the encoded disorder or by the 
conserved signals for exon splicing which overlap the residues that encode these 
disordered segments. However, predicted unstructured binding segments in 
tissue-specific exons are more conserved than predicted disordered regions, and 
are in fact more conserved than all other residues in these exons. Hence, this 
lends support to the claim that conserved disordered segments encoded by 
tissue-specific exons are indeed functional. Moreover, the high conservation of 
tissue-specific exons is likely to be also due to important binding motifs in these 
exons. Similarly, previous work has associated conserved disordered regions 
with DNA/RNA and protein binding functions (Chen et al., 2006). 
Protein posttranslational modifications have emerged as a common 
regulatory switch in cell signalling networks. Moreover, it has been reported that 
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PTMs in general and protein phosphorylation in particular, tend to occur more 
frequently within intrinsically disordered protein regions than in ordered ones
(Iakoucheva et al., 2004). Because of the flexibility of disorder regions, exposed 
PTM sites can easily, and specifically, interact with modifying enzymes. Hence, 
this also allows the introduced modifications to be readily reversible (Fuxreiter 
et al., 2007). Such modes of interactions are of significant benefit in regulation,
signaling and network organization (Dunker et al., 2005). Hence, disordered 
regions are believed to be hot spots for regulation by posttranslational 
modification (Dyson and Wright, 2005). Here, I observe a strong correlation 
between the fraction of disorder and a fraction of PTM sites encoded by exons 
(Figure 4.5). Significant overrepresentation of PTM sites in tissue-specific exons 
provides further support for the role of these exons in cellular networks and the 
functional significance of disorder encoded by tissue-specific exons. 
This study suggests an important interplay of finely regulated tissue-
specific alternative splicing and disordered protein segments in cell signalling 
pathways. By this means, unstructured binding motifs can act as a mode of 
switching interaction partners and contributing to the re-wiring of signalling 
pathways. This implies an important role played by tissue-specific protein 
isoforms in specific protein interactions and consequentially their role in 
signalling and regulatory pathways. When the data for it become available, it will 
be interesting to see if alternative splicing specific for developmental and 
differentiation stages uses the same strategy as tissue-specific splicing. It has 
already been suggested that alternative splicing could determine the binding 
partners of proteins and consequentially direct cellular interaction networks
(Resch et al., 2004; Stamm et al., 2005; Yura et al., 2006). This study confirms 
that this indeed is the case with tissue-specific exons and additionally, it explains 
the dominant mechanism for this. By exposing functional disordered segments, 
alternative splicing has an opportunity to re-wire signalling pathways 
dynamically at the post-transcritional level (illustrated in Figure 4.11). 
Furthermore, by splicing in these regions, protein functional diversity can be 
achieved without compromising stability. Therefore, through alternative splicing 
of disordered regions, which act as mediators for interactions, protein networks 
can change depending on the context – e.g. tissue.
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Figure 4.11: Illustration of the predicted effect of tissue-specific alternative 
splicing of functional disordered residues. Tissue-specific splicing and 
differential inclusion of exons frequently results in differential presence of a 
protein segment with specific binding motifs. Binding motifs are shown as blue 
(constitutively present) and red (tissue-specifically present) circles on proteins 
(wavy lines). The consequence of this is tissue-specific rewiring of protein 
networks. In the depicted network, proteins are shown as circles and 
connections with proteins that the protein shown above (a coloured circle in the 
network) directly interacts with are presented with continuous lines. Absence of 
a specific binding motif results in a loss of connection to one or more branches of 
a protein network.
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4.4.3 Examples for the role of disordered protein segments in signal 
transduction
The role of disordered protein segments in mediating protein regulatory 
function is becoming increasingly appreciated. Another aspect of protein 
interactions that seems to be well explained by structural malleability of 
unstructured segments is the phenomenon of “moonlighting”, e.g. the ability of 
the same protein to have distinct binding partners and hence distinct functions 
(Tompa et al., 2005). The advantage of using disordered protein regions for 
mediating interactions lies in the fact that the same unstructured region can 
have overlapping interaction surfaces and can adopt different conformations 
after binding (Tompa, 2005). By this means, a protein can exert distinct 
functional effects, depending on the available binding partner. An example from 
the literature for the importance of tissue-specific splicing that I have described 
here is the p73 gene. This gene is a homologue of the p53 tumour suppressor 
gene and hence it is not unexpected that disordered regions would play an 
important role in its function. Namely, it is known that the N terminal region of 
the p53 protein plays an important regulatory role and is able to bind several 
protein partners (Chumakov, 2007), among which MDM2 (Kussie et al., 1996),
RPA 70N (Bochkareva et al., 2005) and RNA polymerase II (Di Lello et al., 2006). 
Interestingly, this region has been reported to be completely disordered
(Dawson et al., 2003) and spectrometric studies of the p53 protein showed that 
this protein was partially unstructured over its whole length (Bell et al., 2002). It 
was suggested that this could be an explanation for why it can interact with a 
multitude of protein partners.
Even though the assignment of genes to pathways they belong to is fairly 
incomplete (Wu et al., 2010), there is enough annotation of the genes with 
tissue-specific isoforms to observe here that there are pathways which are 
repeatedly connected with these genes. Genes with tissue-specific isoforms are 
significantly enriched in genes that are involved in the PDZ pathway (Table 4.8). 
Proteins with the PDZ domain are scaffold proteins that play an important role 
in signal transduction; in particular they help to anchor transmembrane proteins 
to the cytoskeleton and hold together signalling complexes (Ranganathan and 
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Ross, 1997). The PDZ proteins also play a crucial role in the organization of 
synaptic protein composition and structure. The PDZ domain has several modes 
of interaction (Figure 4.12a), but is specialized in binding short unstructured 
peptide motifs at the extreme C-termini of protein partners (Kim and Sheng, 
2004; Nourry et al., 2003). An illustration for this is the interaction of the 
membrane-embedded voltage-activated potassium channel (Kv) with the PDZ 
containing scaffold protein PSD-95 (Magidovich et al., 2007). This interaction is 
mediated by the C-terminal segment of the Kv channel and is essential for the 
proper assembly and functioning of the synapse. Experiments involving C-
terminal chains with different flexibility and length clearly demonstrated that 
intrinsic disorder in this segment modulates its interaction with the PDZ protein 
partner (Magidovich et al., 2007). The interaction, described as a “fishing rod 
mechanism”, is illustrated in Figure 4.12b. This experimental evidence highlights 
the importance of intrinsically disordered protein segments in complex 
processes of synapse assembly, maintenance and function. The ability of PDZ 
proteins to bind short extreme C-terminal sequences of their interaction 
partners offers an easy way for PDZ proteins to interact with target proteins 
without disrupting the overall structure and function of their protein partners, 
which are often membrane receptors bound to ligands (Hung 2002). Because of 
this, the PDZ proteins have a widespread role in synaptic signalling, in both the 
presynaptic and postsynaptic terminus. The role of protein disorder in the PDZ 
pathway is well established, and this study suggests that genes in this pathway 
can utilize tissue-specific expression of protein segments, which are likely to be
disordered, as an extra mode of regulation. This is particularly interesting 
because the connection with alternative splicing suggests that some of the 
interactions in the pathway could be involving disordered regions present only 
in certain gene isoforms.
Genes with tissue-specific isoforms are enriched in genes from the PDZ 
pathway but are also reported to include genes from several pathways related to 
MAPK signalling (Table 4.8). As discussed in the introduction, this central 
signalling pathway can activate numerous cellular processes and represents a 
good hypothetical target for modulation of protein function through alternative 
inclusion of disordered binding residues. However, the role of functional 
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disordered residues has not been connected with this pathway so far. 
Nonetheless, the example of the MEK kinase shows disorder could be utilized in 
this pathway to direct specific signalling. The MEK kinase exists in two gene 
copies: MEK1 and MEK2. Sequences of their protein products are highly similar 
and their kinase domains essentially identical; they were initially even 
considered to be functionally redundant (Shaul and Seger, 2007). However, the 
proteins do differ in their N-termini and in the proline-rich inserts (residues 
phosphorylated by MAPK kinase kinases). As a result, each protein forms 
signalling complexes with different protein partners (Shaul and Seger, 2007). 
This has such strong implications that knockout of MEK1 causes an embryonic 
lethality in MEK1-/- mice whereas MEK2-/- mice are viable and fertile (Shaul and 
Seger, 2007). The analysis of the MEK1 and 2 protein sequences showed that 
their N-terminal regions are indeed unstructured (section 4.3.6).
Taken together, these examples illustrate the specific cases where protein 
disorder plays an important role and where finely regulated alternative splicing 
differentially exposes peptide motifs, which can be bound by other proteins, as a 
means to re-wire protein networks.
     
Figure 4.12: PDZ domain proteins play an important role in the targeting of 
proteins to specific membrane compartments and their assembly into 
supramolecular complexes. a) PDZ domains participate in at least four 
different classes of interaction: recognition of C-terminal motifs in peptides, 
recognition of internal motifs in peptides, PDZ-PDZ dimerization, and 
recognition of lipids. b) Interaction of a voltage-gated K+ channel with a PSD-95 
scaffold protein is an example of a fishing rod mechanism by which PDZ proteins 
interact with the unstructured C-termini of their protein partners. The moon-
shape represent the PDZ domains of the PSD-95 protein. Figure (a) is adapted 
from (Nourry et al., 2003) and figure (b) from (Magidovich et al., 2007).
(a) (b)
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4.4.4 Genes with tissue-specific isoforms and disease development
As discussed above, genes with tissue-specific isoforms are likely to play an 
important role in carefully regulated signalling pathways. Therefore, one can 
expect that mutations in these proteins are likely to have long-range 
consequences. In agreement with this, the set of tissue-specific genes is enriched 
with genes that were reported to cause embryonic lethality when mutated and 
are implicated in cancer development. Higher abundance of disordered regions 
among the cancer associated proteins has been suggested previously; 79% of 
human proteins associated with cancer have been classified as intrinsically 
unstructured, compared to 47% of all eukaryotic proteins in UniProtKB/Swiss-
Prot (Iakoucheva et al., 2002). With regard to alternative splicing and cancer, it 
is known that mutations that affect splicing can have causal roles in cancer 
initiation and progression (Wang et al., 2002) and alternative splicing is in 
general frequently disrupted in cancer, though presumably mostly as a 
consequence of the overall instability in cancer cells (Venables, 2004). This study 
suggests a possible connection between the two and a role of isoforms with 
specific binding peptides in the pathways involved in cancer development. 
The majority of protein domains, which are encoded by tissue-specific 
exons has a function related to binding (Table 4.9), emphasising that splicing can 
determine protein binding partners not only through alternative inclusion of 
unstructured binding motifs, but also by other means. RNA-binding proteins, 
which are essential for the production of alternative splice isoforms, could 
possibly work together with transcription factors in defining tissue-identity. The 
role of RNA-binding splicing factors in modulating the function of signalling 
proteins could be a part of the explanation for why these proteins are implicated 
in diseases that are connected with specific signalling pathways - both genetic 
disorders and cancer (Lukong et al., 2008).
By inclusion of disordered regions, functional capability of a single 
protein can expand depending on the context, space and time. When this process 
is related to disease development, it is an attractive target for drug application -
especially if a drug, such as for example an antibody, can be made specific for
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one isoform and not interfere with the function of other isoforms. However, in 
order to be able to interfere with this process, it is necessary first to understand 
it. More comprehensive studies of splicing and genomic architecture in an 
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An organism’s phenotype is primarily determined by the proteins its genome 
encodes. A crucial biological question is how protein repertoires have expanded 
in more complex organisms and how regulation of more complex proteomes is 
achieved. In my thesis, I addressed this problem by studying two means for the 
increase of proteome size: creation of novel proteins during evolution and 
alternative inclusion of functional modules in different isoforms of the same 
gene. My approach here was to look at the architecture of functional elements in 
proteins, investigate mechanisms that include or exclude these elements from 
the proteins, and consequences this has for the overall protein function.
In the first part of the thesis, I used animal gene phylogenies to 
investigate trends that shaped the evolution of protein domain architectures. 
Protein domains form the basic unit of protein functional and structural 
complexity. Furthermore, proteins with novel domain combinations had a major 
role in evolutionary innovation. Thus, formation of novel proteins through 
domain shuffling is a crucial aspect of animal evolution. The results of my study 
confirmed previous observations that changes in protein domain composition 
occur preferentially at the protein termini. Additionally, the study suggested that 
the same trend was present after both inferred gains and losses of single copy 
domains. Since different mechanisms can underlie insertions and deletions of 
single copy domains, it is possible that the observed pattern is not only shaped 
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by the acting mechanisms, but also by the selective pressure which strongly 
disfavors changes in the middle of proteins. Changes in the middle are more 
likely to disrupt the ancestral protein structure and hence only a small fraction of 
these are expected to get fixed in a population. A bias for the changes to occur at 
the termini is not as strong for duplications and deletions of domains in repeats. 
Nevertheless, different mechanisms and evolutionary forces can contribute to 
the evolution of domain repeats. The design of this study allowed me to 
distinguish changes in domain architecture that followed gene duplication from 
those that occurred after speciation. Interestingly, the same positional pattern of 
changes was observed for both types of events. Hence, this implies that changes 
in an individual protein are modeled similarly after both types of evolutionary 
events. However, the frequency of changes was two times higher after gene 
duplications, which indicated that the pressure to preserve the ancestral domain 
composition is relieved after a gene is present in two copies.
Even though the position of a domain gain or loss in a protein can 
discriminate between certain mechanisms that cause the changes, it cannot 
clearly specify the underlying mechanism. In the second part of this thesis, I 
focused on the investigation of the evidence for the mechanisms that were 
driving emergence of more complex domain architectures during evolution of 
animal gene families. In prokaryotes, new domains are predominantly acquired 
through fusions of adjacent genes. However, the relative contributions of the 
different molecular mechanisms that cause domain gains in animals were
unknown. A crucial step here was to obtain a set of high confidence domain 
gains, and to relate these gains to the changes in the gene structures. For this, I 
again relied on the phylogenetic data that described the evolution of animal gene 
families. Results of this study showed that the major mechanism for gains of new 
domains in metazoan proteins was gene fusion through joining of exons from 
adjacent genes, possibly mediated by non-allelic homologous recombination. 
Two other mechanisms that were previously suggested to have an important 
role in the evolution of metazoans - retroposition and insertion of exons into 
ancestral introns through intronic recombination - appear to be only minor 
contributors to overall domain gains. Interestingly, the results of this study also 
suggested exon extensions through inclusion of previously non-coding regions as 
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an important mechanism for addition of disordered segments to proteins. In the 
case of confident domain gains, I observed that gene duplication preceded 
domain gain in at least 80% of the gain events. The interplay of gene duplication 
and domain gain demonstrates an important mechanism for fast 
neofunctionalisation of genes. Interestingly, the gained domains are frequently 
involved in protein interactions. Hence, this illustrates a fundamental connection 
between the evolution of proteome diversity and regulation of more complex 
cellular networks.
In addition to evolutionary changes in the architectures of protein 
functional elements, novel protein products can also be created through 
alternative inclusion of exons from the same gene. By this means, the gene’s 
function can adapt to different cellular contexts. In the final part of this thesis, I 
investigated how finely regulated alternative inclusion of tissue-specific exons
modifies protein function. I observed a strong trend for tissue-specific exons to 
encode the segments enriched in intrinsically disordered regions. I found that 
these alternatively spliced protein segments were also significantly enriched in 
binding peptides and post-translationally modified sites. Functional relevance of 
the observed phenomenon was further indicated by significant evolutionary 
conservation of the tissue-specific disordered regions and predicted binding
peptides. By alternatively splicing functional disordered segments, an individual 
gene can achieve functional versatility without compromising the structural 
stability of its protein products. In addition, different protein isoforms of the 
same gene can be used in different cellular networks. This could also be one of 
the mechanisms for the regulation of tissue-specific signalling pathways. It is a 
frequent phenomenon that the same gene takes part in cellular pathways that 
have different, sometimes even opposing, outcomes. Intriguingly, mechanisms 
that ensure the specificity of the transmitted signals are still unclear. This
research suggests that it is possible that finely regulated alternative splicing of 
functional disordered protein segments can assist in attaining this specificity.
Since the mechanisms for regulation of signalling specificity are frequently 
disrupted in cancer and other diseases, it is important to understand the 
contribution of this process in the regulation of signalling cascades. In 
conclusion, extension of proteins with novel interaction domains and alternative 
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inclusion of disordered binding segments demonstrate two different effective 
means for the increase of proteome size and a level of proteome regulation.
The work in this thesis emphasises the impact that inclusion or exclusion 
of protein functional elements has on its role in an organism. Both changes on 
the gene level and changes on the transcript level can modify the architecture of 
functional elements in the final protein product. Improved characterization and 
coverage of proteins with these elements – protein domains, binding peptides 
and post-translationally modified sites – can help in better understanding of the 
effect that these changes can have on protein function, and in understanding how 
this drives protein evolution and adaptation to different tissues and cellular 
contexts. Additionally, I expect that application of new technologies for 
sequencing not just genomes, but also transcriptomes in different organisms and 
tissues will improve our understanding of the areas that I address in this thesis. 
Identifying transcripts that are specific for an organism or a tissue is a good 
starting point for describing proteins that define tissues, or organism 
phenotypes, and can provide more complete datasets for similar studies.
A problem that I find particularly interesting is the effect of a change in 
the number of short repeated domains, since these are crucial for cellular 
interactions. A change in the number of domains in a repeat can change protein’s 
affinity for the binding partners and hence affect the whole cellular interaction 
network. To adequately address this issue, it would be first necessary to have 
high quality domain annotations. One means to increase the quality of these 
annotations is to lower the threshold for assignment of repeated domains - in 
particular after the first domain from a repeat has already been assigned to a 
protein, and in order to avoid false assignments - to require that a short repeated 
domain, when annotated, is present in a protein with its whole length. Finally, to 
better understand how a change in the number of domains in a repeat, or the 
presence or absence of other functional elements in proteins, influences protein 
functions, it would be valuable to have good quality functional annotations for 
different protein homologues and isoforms of the same gene. Relating a certain 
type of a change in the architecture of protein functional elements to the overall
change in protein function would allow us to better understand the 




Table Appendix A.1: Possible false positive Pfam assignments in the 
TreeFam proteins. A list of Pfam domains that only a single gene in a gene 
family is annotated with, and that are not predicted with a high E-value nor cover 
a high fraction of a domain model.
TreeFam 
family
Pfam domain Domain name
Fraction of a 
model covered
E-value
TF101021 PF01154 HMG_CoA_synt_N 0.14 0.0011
TF101181 PF01576 Myosin_tail_1 0.08 0.00018
TF101220 PF00621 RhoGEF 0.26 2.60E-05
TF102023 PF08092 Toxin_22 0.3 0.0081
TF105126 PF08609 Fes1 0.17 0.00086
TF105285 PF00021 UPAR_LY6 0.15 0.00022
TF105388 PF00580 UvrD-helicase 0.08 0.00011
TF105664 PF07602 DUF1565 0.07 1.30E-05
TF105993 PF08624 CRC_subunit 0.25 0.0001
TF106336 PF05693 Glycogen_syn 0.07 0.0004
TF106337 PF03488 Ins_beta 0.27 1.30E-05
TF300142 PF01370 Epimerase 0.27 0.00018
TF300253 PF00125 Histone 0.28 0.0002
TF300491 PF00128 Alpha-amylase 0.16 0.00017
TF300506 PF08001 CMV_US 0.12 0.00031
TF300523 PF02689 Herpes_Helicase 0.04 3.00E-05
TF300533 PF02672 CP12 0.21 5.30E-05
TF300647 PF08764 Coagulase 0.05 0.02
TF300805 PF05585 DUF1758 0.06 0.00043
TF312998 PF00398 RrnaAD 0.13 0.00046
TF313187 PF02790 COX2_TM 0.2 0.017
TF313234 PF01757 Acyl_transf_3 0.28 2.10E-05
TF313377 PF07732 Cu-oxidase_3 0.27 0.017
TF313568 PF08634 Pet127 0.05 0.0052
TF313594 PF08443 RimK 0.19 5.00E-05
TF313654 PF02932 Neur_chan_memb 0.14 4.10E-05
TF313802 PF06807 Clp1 0.1 0.0013
TF313930 PF04258 Peptidase_A22B 0.08 1.70E-05
TF313947 PF01271 Granin 0.07 0.011
TF314126 PF05904 DUF863 0.02 3.50E-05
TF314165 PF00136 DNA_pol_B 0.09 4.50E-05
TF314440 PF08529 NusA_N 0.18 0.00091
TF314441 PF06127 DUF962 0.01 6.80E-05
TF314495 PF08401 DUF1738 0.15 0.0001
TF314521 PF00650 CRAL_TRIO 0.15 0.0054
TF314774 PF01595 DUF21 0.13 2.10E-05
TF315186 PF06282 DUF1036 0.18 3.60E-05
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TF315189 PF00851 Peptidase_C6 0.05 0.00029
TF315227 PF05511 ATP-synt_F6 0.29 5.10E-05
TF315263 PF00600 Flu_NS1 0.12 0.0098
TF315272 PF08320 PIG-X 0.08 0.00088
TF315302 PF08637 NCA2 0.08 0.0026
TF315363 PF00636 Ribonuclease_3 0.14 0.00011
TF315367 PF02752 Arrestin_C 0.26 1.90E-05
TF315472 PF01546 Peptidase_M20 0.29 0.00044
TF315592 PF00775 Dioxygenase_C 0.01 0.0011
TF315712 PF03564 DUF1759 0.26 3.10E-05
TF315897 PF01537 Herpes_glycop_D 0.11 2.40E-05
TF316533 PF07462 MSP1_C 0.04 0.00028
TF316780 PF03238 ESAG1 0.06 0.0053
TF316929 PF02932 Neur_chan_memb 0.13 0.00026
TF317006 PF06650 DUF1162 0.12 1.90E-05
TF317757 PF02093 Gag_p30 0.15 0.0043
TF317925 PF00878 CIMR 0.12 0.00022
TF318379 PF01030 Recep_L_domain 0.26 4.90E-05
TF318668 PF00001 7tm_1 0.01 2.80E-05
TF318706 PF08719 DUF1768 0.15 1.20E-05
TF319588 PF00650 CRAL_TRIO 0.15 0.0054
TF319633 PF07714 Pkinase_Tyr 0.01 2.20E-05
TF319951 PF01461 7tm_4 0.18 7.00E-05
TF321275 PF02682 AHS1 0.08 0.00019
TF321359 PF00106 adh_short 0.29 0.00044
TF321457 PF00443 UCH 0.25 1.20E-05
TF321796 PF05473 Herpes_UL45 0.17 2.00E-05
TF322230 PF02752 Arrestin_C 0.26 1.90E-05
TF323518 PF07933 DUF1681 0.13 0.00012
TF323731 PF00650 CRAL_TRIO 0.17 0.002
TF323819 PF01237 Oxysterol_BP 0.18 0.00014
TF323965 PF00094 VWD 0.15 9.60E-05
TF323987 PF00147 Fibrinogen_C 0.16 0.00011
TF324336 PF08389 Xpo1 0.26 2.50E-05
TF324755 PF09409 PUB 0.26 0.00067
TF324880 PF00261 Tropomyosin 0.07 0.00018
TF325457 PF03052 Adeno_52K 0.16 0.001
TF325523 PF08583 UPF0287 0.21 0.00053
TF326264 PF00168 C2 0.23 0.00015
TF326378 PF02355 SecD_SecF 0.14 0.00029
TF326897 PF00122 E1-E2_ATPase 0.23 2.20E-05
TF328040 PF01613 Flavin_Reduct 0.14 0.00012
TF329290 PF07933 DUF1681 0.13 0.001
TF329430 PF00168 C2 0.25 8.10E-05
TF329606 PF00447 HSF_DNA-bind 0.22 1.30E-05
TF329606 PF01579 DUF19 0.12 0.021
TF329710 PF02250 Orthopox_35kD 0.12 0.00046
TF330156 PF07732 Cu-oxidase_3 0.27 2.90E-05
TF330183 PF05806 Noggin 0.08 4.60E-05
TF330319 PF03401 Bug 0.18 0.00035
TF330845 PF00012 HSP70 0.11 0.00038
TF331115 PF00555 Endotoxin_M 0.29 0.0033
TF331158 PF05642 Sporozoite_P67 0.04 7.20E-05
TF331282 PF00386 C1q 0.26 9.10E-05
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TF331344 PF00822 PMP22_Claudin 0.12 2.90E-05
TF331400 PF02790 COX2_TM 0.21 0.0077
TF331842 PF01429 MBD 0.25 0.00033
TF332204 PF05253 UPF0224 0.19 2.60E-05
TF332241 PF00059 Lectin_C 0.29 2.00E-05
TF332364 PF02373 JmjC 0.27 2.60E-05
TF332426 PF07798 DUF1640 0.24 1.80E-05
TF332497 PF08124 Lyase_8_N 0.06 0.0006
TF332538 PF05579 Peptidase_S32 0.05 7.90E-05
TF332659 PF08562 Crisp 0.21 0.0011
TF332845 PF04266 ASCH 0.18 0.00011
TF333186 PF09451 ATG27 0.09 5.20E-05
TF333434 PF00836 Stathmin 0.24 0.0017
TF333463 PF00081 Sod_Fe_N 0.21 0.00082
TF333601 PF03255 ACCA 0.2 0.001
TF335097 PF01271 Granin 0.05 0.0082
TF335573 PF02622 DUF179 0.12 0.0003
TF335835 PF01068 DNA_ligase_A_M 0.24 0.00025
TF338389 PF02825 WWE 0.3 0.0016
TF338479 PF00100 Zona_pellucida 0.23 0.0003
TF339541 PF06039 Mqo 0.05 0.00014
TF339848 PF01579 DUF19 0.15 0.012
TF340612 PF03154 Atrophin-1 0.04 0.00079
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Figure Appendix B.1: Distribution of the percentages of identity between 
the inferred gained domain and the most similar sequence in the same 
gene family that does not have that domain assigned. The set of domain gains 
that is shown in the graph was filtered to include only internal gains and gains 
that have a descendant with the gained domain in at least one genome of a better 
quality. Two sequences in the same gene family are aligned either because of the 
shared ancestry, or because multiple alignment algorithms (MUSCLE in this case, 
http://www.drive5.com/muscle) over-align similar regions in proteins, even 
when they are not evolutionarily related. Both of these instances are likely to be 
present in the regions where inferred gained domains are aligned to sequences 
of other proteins in the same gene family. The peak at 0.16 could be explained 
with addition of values from these two scenarios. 
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Table Appendix B.2: High confidence domain gain events. Information 








TF340491 PF02518 ENST00000275580 Primates
TF331377 PF04680 ENST00000290291 Primates
TF352220 PF05033,PF00856 ENST00000307483 Primates
TF331083 CL0074 ENST00000338965 Primates
TF342157 PF04698 ENST00000354668 Primates
TF328297 CL0219,PF02023 ENST00000357581 Primates
TF340395 CL0159 ENST00000359050 Primates
TF314793 PF00271,CL0008 ENST00000370424 Primates
TF351422 PF10409 ENST00000381866 Primates
TF105356 CL0023 ENST00000194097 Mammals
TF335271 CL0041 ENST00000254691 Mammals
TF328011 PF02023 ENST00000259883 Mammals
TF337552 PF00096 ENST00000262637 Mammals
TF328424 PF05386 ENST00000262715 Mammals
TF337951 PF00147 ENST00000301455 Mammals
TF300253 PF03002 ENST00000320498 Mammals
TF350810 PF01352 ENST00000338637 Mammals
TF338854 PF01352 ENST00000344099 Mammals
TF331962 PF00612 ENST00000366709 Mammals
TF338165 PF04711 ENST00000367990 Mammals
TF336000 PF08065 ENST00000368654 Mammals
TF330114 CL0175 ENST00000373330 Mammals
TF333425 PF04593 ENST00000388827 Mammals
TF325887 PF10522 ENST00000394516 Mammals
TF105660 PF08062 ENST00000399466 Mammals
TF330855 PF03523 ENST00000262101 Mammals
TF334740 CL0006,PF00621 ENST00000296794 Mammals
TF329807 PF06049 ENST00000367797 Mammals
TF324004 PF02008 ENST00000373644 Mammals
TF317779 PF09307 ENST00000009530 Vertebrates
TF326567 CL0003 ENST00000046794 Vertebrates
TF325130 PF00023 ENST00000160373 Vertebrates
TF106374 CL0172 ENST00000199447 Vertebrates
TF105392 CL0159,PF03160 ENST00000200181 Vertebrates
TF325426 PF00632 ENST00000206595 Vertebrates
TF319848 PF01033 ENST00000229003 Vertebrates
TF106352 PF00023 ENST00000230792 Vertebrates
TF313285 PF01759,PF01821 ENST00000245907 Vertebrates
TF329176 CL0081 ENST00000249910 Vertebrates
TF330078 PF10393 ENST00000255132 Vertebrates
TF320327 PF04812 ENST00000257555 Vertebrates
TF320327 PF04813 ENST00000257555 Vertebrates
TF330114 PF05485 ENST00000260045 Vertebrates
TF331062 CL0072 ENST00000260283 Vertebrates
TF313938 CL0154 ENST00000260983 Vertebrates
TF316484 PF01463,CL0022,PF01822 ENST00000262304 Vertebrates
TF316148 PF03815 ENST00000262424 Vertebrates
TF312824 PF00612 ENST00000262457 Vertebrates
TF316113 CL0003 ENST00000262878 Vertebrates
TF317402 CL0159 ENST00000263798 Vertebrates
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TF317511 PF00017 ENST00000263915 Vertebrates
TF331945 PF07525 ENST00000264607 Vertebrates
TF316876 PF00093 ENST00000264895 Vertebrates
TF316876 PF03160 ENST00000264895 Vertebrates
TF324610 PF02732 ENST00000267430 Vertebrates
TF351678 PF01392 ENST00000273857 Vertebrates
TF314731 PF10565 ENST00000279593 Vertebrates
TF313240 PF10606 ENST00000282753 Vertebrates
TF316380 CL0011 ENST00000283296 Vertebrates
TF316380 PF01390 ENST00000283296 Vertebrates
TF351678 CL0202 ENST00000284885 Vertebrates
TF329158 CL0023 ENST00000285928 Vertebrates
TF314232 PF00569,CL0220 ENST00000288642 Vertebrates
TF316484 PF02010 ENST00000289672 Vertebrates
TF332664 PF07776 ENST00000289816 Vertebrates
TF313285 CL0005 ENST00000291440 Vertebrates
TF336193 PF01342,PF03172 ENST00000291582 Vertebrates
TF323966 CL0214 ENST00000294383 Vertebrates
TF317402 PF01403 ENST00000296474 Vertebrates
TF329295 CL0124 ENST00000296498 Vertebrates
TF329059 CL0001 ENST00000296575 Vertebrates
TF331157 CL0041 ENST00000297350 Vertebrates
TF312852 CL0219 ENST00000298139 Vertebrates
TF323475 CL0003 ENST00000298229 Vertebrates
TF323480 CL0005 ENST00000302495 Vertebrates
TF331319 PF01822,CL0164 ENST00000303746 Vertebrates
TF106506 PF00023 ENST00000303941 Vertebrates
TF106401 PF00249 ENST00000310806 Vertebrates
TF327329 PF00051,PF09396 ENST00000311907 Vertebrates
TF314204 PF02816 ENST00000313478 Vertebrates
TF324155 PF00023 ENST00000313581 Vertebrates
TF315996 CL0006 ENST00000314276 Vertebrates
TF316105 CL0188 ENST00000317133 Vertebrates
TF317614 PF06959 ENST00000317905 Vertebrates
TF315956 PF05485 ENST00000321679 Vertebrates
TF317659 PF01391 ENST00000322313 Vertebrates
TF329915 PF00040 ENST00000323926 Vertebrates
TF106510 PF02161 ENST00000325455 Vertebrates
TF313103 PF07941 ENST00000328224 Vertebrates
TF318980 PF02165 ENST00000332351 Vertebrates
TF333138 PF01391 ENST00000333570 Vertebrates
TF329287 PF00642 ENST00000333834 Vertebrates
TF317921 PF00023 ENST00000340022 Vertebrates
TF316214 PF04621 ENST00000343495 Vertebrates
TF105669 PF00458 ENST00000344102 Vertebrates
TF318080 CL0016 ENST00000344204 Vertebrates
TF315606 CL0041 ENST00000344227 Vertebrates
TF329345 CL0010 ENST00000344936 Vertebrates
TF321873 CL0056 ENST00000355044 Vertebrates
TF326161 PF01284 ENST00000355237 Vertebrates
TF300189 PF10574 ENST00000357484 Vertebrates
TF330032 PF01033 ENST00000357639 Vertebrates
TF300851 PF00642 ENST00000357720 Vertebrates
TF328589 PF09303 ENST00000358316 Vertebrates
TF323607 PF06462 ENST00000359520 Vertebrates
TF323475 PF00017 ENST00000359570 Vertebrates
TF315592 PF01392 ENST00000360986 Vertebrates
TF331681 PF00057 ENST00000361205 Vertebrates
TF326495 PF06663 ENST00000367213 Vertebrates
TF315841 PF02205 ENST00000367288 Vertebrates
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TF334159 PF05177 ENST00000367856 Vertebrates
TF315806 CL0123 ENST00000368474 Vertebrates
TF314133 CL0003 ENST00000369075 Vertebrates
TF329606 PF03509 ENST00000369235 Vertebrates
TF316297 PF06839 ENST00000369466 Vertebrates
TF316833 PF06484 ENST00000371130 Vertebrates
TF313103 PF03521 ENST00000371741 Vertebrates
TF101106 PF10487 ENST00000372577 Vertebrates
TF331727 PF05604 ENST00000372970 Vertebrates
TF312900 CL0202 ENST00000373187 Vertebrates
TF330498 CL0154 ENST00000373209 Vertebrates
TF330345 CL0011 ENST00000373401 Vertebrates
TF320194 CL0196 ENST00000373638 Vertebrates
TF300648 CL0172 ENST00000375663 Vertebrates
TF300648 PF00043 ENST00000375663 Vertebrates
TF313965 PF00084 ENST00000377034 Vertebrates
TF331310 CL0033 ENST00000377674 Vertebrates
TF106001 PF02344,PF01056 ENST00000377970 Vertebrates
TF313698 PF03700 ENST00000380285 Vertebrates
TF315592 CL0202 ENST00000380605 Vertebrates
TF324293 CL0154 ENST00000380868 Vertebrates
TF316876 CL0056 ENST00000380881 Vertebrates
TF332820 PF08365 ENST00000381389 Vertebrates
TF329720 CL0084,PF00533 ENST00000381989 Vertebrates
TF323983 CL0179 ENST00000383733 Vertebrates
TF105391 CL0128 ENST00000389202 Vertebrates
TF317067 CL0266 ENST00000389247 Vertebrates
TF316056 PF09004 ENST00000389568 Vertebrates
TF318198 CL0188 ENST00000389821 Vertebrates
TF106341 PF00010 ENST00000389936 Vertebrates
TF330156 PF03815 ENST00000392504 Vertebrates
TF331707 CL0219,PF09091 ENST00000392723 Vertebrates
TF331055 CL0010 ENST00000393398 Vertebrates
TF336041 CL0001 ENST00000394980 Vertebrates
TF337303 PF00435 ENST00000395209 Vertebrates
TF314963 CL0208 ENST00000396197 Vertebrates
TF317532 CL0011 ENST00000396906 Vertebrates
TF317402 PF01833,PF01437 ENST00000397752 Vertebrates
TF106276 PF08959 ENST00000398892 Vertebrates
TF331207 PF00014 ENST00000399429 Vertebrates
TF106451 PF07452 ENST00000204604 Bilateralia
TF314081 CL0033 ENST00000215739 Bilateralia
TF313754 PF00805 ENST00000221200 Bilateralia
TF331485 PF00988,CL0014 ENST00000233072 Bilateralia
TF323999 PF00773 ENST00000252889 Bilateralia
TF323502 PF02185 ENST00000254260 Bilateralia
TF324918 PF00057,CL0186 ENST00000260197 Bilateralia
TF313551 PF08912 ENST00000261535 Bilateralia
TF313326 CL0190 ENST00000261875 Bilateralia
TF323159 CL0020 ENST00000263635 Bilateralia
TF351276 CL0072 ENST00000264042 Bilateralia
TF354308 CL0221 ENST00000278279 Bilateralia
TF315363 PF00611 ENST00000281092 Bilateralia
TF324744 PF00642 ENST00000295373 Bilateralia
TF315892 CL0010 ENST00000295713 Bilateralia
TF318935 PF02218 ENST00000301843 Bilateralia
TF315897 PF03765 ENST00000306726 Bilateralia
TF323280 PF00630 ENST00000323468 Bilateralia
TF318014 PF00412 ENST00000336180 Bilateralia
TF101179 PF09465 ENST00000338179 Bilateralia
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TF315363 CL0266 ENST00000348343 Bilateralia
TF323999 PF07145 ENST00000358691 Bilateralia
TF323312 PF00641 ENST00000359653 Bilateralia
TF324164 CL0223 ENST00000369443 Bilateralia
TF326321 PF01424,CL0196 ENST00000371527 Bilateralia
TF324293 CL0266,PF00621 ENST00000380868 Bilateralia
TF323674 PF02825 ENST00000389044 Bilateralia
TF314351 CL0126 ENST00000061240 AllAnimals
TF330032 CL0263 ENST00000075322 AllAnimals
TF329240 CL0200 ENST00000202017 AllAnimals
TF313988 PF04707 ENST00000251170 AllAnimals
TF314316 PF01463,CL0022 ENST00000252804 AllAnimals
TF335359 PF06009 ENST00000252999 AllAnimals
TF314796 CL0041 ENST00000261600 AllAnimals
TF317296 CL0266 ENST00000261752 AllAnimals
TF320906 PF00787 ENST00000262211 AllAnimals
TF313191 PF08403 ENST00000262461 AllAnimals
TF105399 PF06466 ENST00000263754 AllAnimals
TF313184 PF00595 ENST00000264431 AllAnimals
TF323502 CL0031 ENST00000265562 AllAnimals
TF317067 CL0006 ENST00000268676 AllAnimals
TF314219 PF02809 ENST00000289528 AllAnimals
TF102004 CL0072 ENST00000295797 AllAnimals
TF314470 CL0186 ENST00000298125 AllAnimals
TF316118 PF00439 ENST00000302054 AllAnimals
TF314638 CL0183 ENST00000310298 AllAnimals
TF300359 CL0220 ENST00000310454 AllAnimals
TF312822 CL0271 ENST00000311630 AllAnimals
TF105056 CL0137 ENST00000313698 AllAnimals
TF314677 PF09141 ENST00000314888 AllAnimals
TF314748 CL0154 ENST00000324068 AllAnimals
TF319230 PF00023 ENST00000332509 AllAnimals
TF106173 PF02148 ENST00000334136 AllAnimals
TF312960 CL0010 ENST00000338257 AllAnimals
TF313629 CL0266 ENST00000339416 AllAnimals
TF316643 PF00373 ENST00000340930 AllAnimals
TF318080 CL0011 ENST00000344204 AllAnimals
TF316643 PF03623 ENST00000346049 AllAnimals
TF105282 PF08070 ENST00000348049 AllAnimals
TF314159 PF06311 ENST00000355058 AllAnimals
TF106448 CL0114 ENST00000357008 AllAnimals
TF106151 CL0196 ENST00000358896 AllAnimals
TF313758 PF00880 ENST00000359988 AllAnimals
TF351123 CL0159 ENST00000360304 AllAnimals
TF323658 PF00397 ENST00000361125 AllAnimals
TF105224 CL0186 ENST00000361961 AllAnimals
TF314076 CL0186 ENST00000367097 AllAnimals
TF354311 CL0221 ENST00000367122 AllAnimals
TF300807 PF02225 ENST00000367512 AllAnimals
TF320809 CL0010 ENST00000369405 AllAnimals
TF314566 PF09162 ENST00000372788 AllAnimals
TF317034 PF00620 ENST00000373026 AllAnimals
TF314897 PF01585 ENST00000373451 AllAnimals
TF323767 CL0003 ENST00000373886 AllAnimals
TF319104 PF00880 ENST00000377187 AllAnimals
TF323577 PF00784 ENST00000377307 AllAnimals
TF314263 CL0016 ENST00000378168 AllAnimals
TF324293 CL0010 ENST00000380868 AllAnimals
TF300785 PF07533 ENST00000382194 AllAnimals
TF102004 CL0266 ENST00000392038 AllAnimals
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TF314028 PF00355 ENST00000399167 AllAnimals





































































































            
Figure Appendix B.3: Distribution of high confidence domain gain events 
according to the position of domain insertion and number of exons gained 
according to three different classification methods. (a) Method 1 was used 
for classification of high confidence domain gain events in Chapter 3. (b) Method 
2 classifies a domain gain as an exon extension if there are at least 20 amino 
acids towards either of the exon borders and at least 30% of these are identical 
to a sequence in the alignment that does not contain the gained domain. (c) 
Method 3 classifies a domain gain as exon extension if there are at least 15 amino 
acids towards either of the exon borders and at least 25% of these are identical 
to a sequence in the alignment that does not contain the gained domain. Methods 
2 and 3 classify each domain gain as a gain at the termini if towards the termini 
there are at least 80% unaligned residues or there are less than 10% identical 
residues in any of the sequences without the gained domain. There were seven 
and six domain gain events with ambiguous positions obtained by Methods 2 and 





Table Appendix B.4: Domains that are gained by insertion of new 
exons(s) into the introns of ancestral genes. Phases of introns that 
surround the exons coding for the gained domains are shown for each 
gain event. In two cases (marked with * next to domain name) introns 
surrounding domains did not have symmetrical phases, however 
additional exons appeared to have been gained together with the one(s) 
coding for these domains and phases of introns surrounding all inserted 
exons were symmetrical. It is also noted whether the gained domain(s) 
is/are coded by single or multiple new exons. 





Is single exon 
coding for the 
gained domain
TF336041 CL0001 1 1 Yes
TF335097 PF00530 1 1 Yes
TF331962 PF00612* 1 1 Yes
TF313965 PF00084 1 1 Yes
TF351678 CL0202 1 1 No
TF330156 PF03815 1 1 No
TF329915 PF00040 1 1 No
TF325130 PF00023 1 1 No
TF324293 CL0010 1 1 No
TF323674 PF06701 1 1 No
TF321873 CL0056 1 1 No
TF318080 CL0011 1 1 No
TF317532 CL0011 1 1 No
TF317402 CL0159 1 1 No
TF316484 PF02140 1 1 No
TF316380 CL0011 1 1 No
TF315592 PF01392 1 1 No
TF315592 CL0202 1 1 No
TF313537 CL0164 1 1 No
TF105391 CL0128 1 1 No
TF331319 PF01822,CL0164 1 1 No
TF324293 CL0266,PF00621 1 1 No
TF314677 PF09141 0 0 No
TF314133 CL0003 0 0 No
TF314081 CL0033* 0 0 No
TF313551 PF08912 0 0 No
TF300785 PF07533 0 0 No
TF106435 PF00748 0 0 No
TF325887 PF10522 0 1 Yes
TF324610 PF02732 0 1 Yes
TF323999 PF00773 1 2 Yes
TF322044 PF00628 0 1 Yes
TF315892 CL0010 1 2 Yes
TF354311 CL0221 2 1 No
TF350794 PF01352 0 2 No
TF335359 PF06009 1 0 No
TF331062 CL0072 2 1 No
TF329158 CL0023 2 1 No
TF319848 PF01033 1 2 No
TF319230 PF00023 2 1 No
TF317921 PF00023 2 0 No
TF317614 PF06959 0 2 No
TF316118 PF00439 0 1 No
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TF314638 CL0183 2 0 No
TF313938 CL0154 0 2 No
TF313629 CL0266 0 1 No
TF312900 CL0202 1 0 No
TF106448 CL0114 0 1 No
TF327329 PF00051,PF09396 1 2 No
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Appendix C
Table Appendix C.1: Predicted binding sites and annotated PTM sites in the 
set of tissue-specific exons compared to the sets of cassette and 
constitutive exons. Column headed ‘N+’ shows the number of exons with the 
examined characteristic, ‘N-‘of those without it, and column headed ‘Fraction+‘ 
shows a fraction of exons with the examined characteristic. PTM sites were taken 
from the UniProtKB/Swiss-Prot database. The P-value shows the results of the 
comparison with the set of Tissue-specific exons, and is obtained with the Chi-
square test.
Analysis Set of exons N+ N- Ntotal Fraction+ P-value
ANCHOR
Tissue-specific 410 1,016 1,426 0.288 N/A
Cassette 8,821 40,203 49,024 0.180 P<2.2x10-16
Constitutive 27,374 122,564 149,938 0.183 P<2.2x10-16
PTM sites
Tissue-specific 119 798 917 0.130 N/A
Cassette 1,521 20,272 21,793 0.070 P=9.9x10-12
Constitutive 7,671 85,360 93,031 0.082 P=3.2x10-7
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Table Appendix C.2: All BioCarta pathways, and clusters of BioCarta 
pathways that a set of genes with tissue-specific isoforms is enriched in. 
EASE P-values represent modified Fisher exact P-values. Column ‘Benjamini’ 





















Multi-step Regulation of Transcription by Pitx2
0.09 0.90
p35alzheimersPathway:
Deregulation of CDK5 in Alzheimers Disease
0.08 0.90
BiopeptidesPathway:
Bioactive Peptide Induced Signaling Pathway
0.06 0.92
VegfPathway:
VEGF, Hypoxia, and Angiogenesis
0.08 0.92
Her2Pathway:
Role of ERBB2 in Signal Transduction and Oncology
0.05 0.93
CaCaMPathway:




Endocytotic role of NDK, Phosphins and Dynamin
0.04 0.94
At1rPathway:
Angiotensin II mediated activation of JNK Pathway 
via Pyk2 dependent signaling
0.04 0.97
RhoPathway:













p38 MAPK Signaling Pathway 
0.26 0.98
ErkPathway:




Angiotensin II mediated activation of JNK Pathway 
via Pyk2 dependent signaling
0.04 0.97
BiopeptidesPathway:






Links between Pyk2 and Map Kinases
0.11 0.91
Fcer1Pathway:






Erk and PI-3 Kinase Are Necessary for Collagen 






Signaling of Hepatocyte Growth Factor Receptor
0.69 1.00
TcrPathway:
T Cell Receptor Signaling Pathway
0.82 1.00
